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ABSTRACT 
The aim of this project was to generate a new type of therapeutic delivery 
system and immunogenic vector, based on calixarenes, that is able to not only deliver 
immunogenic peptide but also act as a potential cancer vaccine. The introduction 
presents calixarenes derivatives in the context of supramolecular chemistry. Their 
properties on the nanoscale allow them to be potential adjuvants for cancer 
immunotherapeutics. 
The synthetic study of these materials presented in Chapter II compares traditional 
synthetic protocols and a new greener approach utilising microwave irradiation. Initial 
studies in this area concentrate on alkyl-footed derivatives of both the resorcin[4]arene 
and pyrogallol[4]arene macrocycles but have also been expanded to the previously 
problematic aromatic derivatives. This microwave method has been optimised to 
produce the rccc diastereoisomer for both the alkyl and aromatic derivatives, showing 
that the nature of the substituent on the pendant chains does not have a great effect on 
the conformation using this green protocol. The solution and solid state studies of these 
new aromatic pyrogallol[4]arene macrocycles, in the rccc cone conformation, have been 
investigated and demonstrate their future potential application in hydrogen storage.  
The synthesis of polar analogues, described in Chapter III, was achieved by 
functionalising the pendant chains with polar groups, including amines, alcohols and 
carboxylic acids. The importance of the solvent in the crystallisation process is 
highlighted by single crystal X-ray diffraction study, showing that it can act as 
templating agent or guest. 
Access to polar footed calixarenes has enabled the project to investigate their potential 
to link bioactive therapeutics including amino acids and peptides, towards nano-vectors 
exposed in Chapter IV. The traditional synthesis in solution was challenging due to 
purification issues, and only succeeded in the attachment of three trialanines. The 
method was therefore tuned towards solid phase synthesis, which opened up to the new 
development of Merrifield resin functionalised with calixarenes. 
As the macrocycle will be considered for immunisation in the future, the lead 
macrocycle from this study have been screened for potential downstream biological 
applications. Preliminary studies, including haemolytic properties and cytotoxicity 
studies did not show any toxicity at the workable concentrations. 
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CHAPTER I: INTRODUCTION 
A. SUPRAMOLECULAR CHEMISTRY 
Since the early age of scientific discovery, scientists have tried to understand the 
bigger picture behind a given phenomena. The role of chemists is not only focussed on 
the understanding of the formation of chemical bonds but also on the interactions of 
those molecules with their surroundings. This could be considered as the foundations of 
supramolecular chemistry, also known as the chemistry beyond the molecule. The field 
of supramolecular chemistry, was further refined when molecules were designed to 
achieved the highest interactions or recognition with other entities.subodh1 Originating 
from the study of host-guest recognition, it has now opened up into self-assembly and 
self-organisation of macrocycles; moving from the molecular scale to the nanometre 
scale.2  
As described by one of the pioneer of supramolecular chemistry, Nobel Prize 
winner Jean-Marie Lehn:  
 
“Beyond molecular chemistry, supramolecular chemistry aims at constructing 
highly complex, functional chemical systems from components held together by 
intermolecular forces”.3 
 
Research is moving one step closer towards constitutional dynamic chemistry 
and adaptive chemistry. The supramolecular chemistry field is now interdisciplinary and 
so wide that it cannot be restricted to one specific area;4-5 however, the essence of the 
subject still relies on the various interactions occurring at the molecular level. 
1. SUPRAMOLECULAR INTERACTIONS 
Although of different natures and different strengths, supramolecular 
interactions always comprise one important feature, they are non-covalent and are based 
on dipole interactions.  
Ion-ion interactions, Figure 1, are a result of the attraction of a cation towards an 
anion. The strength of this ionic bond is comparable to that of a covalent bond, but 
without the overlapping molecular orbitals.  
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Figure 1: Crystal lattice based on ion-ion interactions in sodium chloride. 
In heteroatomic covalent bonds, the electronegativity of an atom may differ from 
the one it is bound to, resulting in a partial displacement of the electron density from 
one atom to another, creating polarity between the atoms that in turn forms a dipole. In 
the presence of ions, dipoles can form coordinate bonds (Figure 2a) which are the basis 
of many inorganic complexes, e.g. in cis-platin. Dipoles can also interact with other 
dipoles, by aligning with one another in different manners, either perpendicularly or in 
parallel, as shown in Figure 2b and 2c respectively. 
 
 
Figure 2: (a) Ion-dipole coordinate bond between sodium and water (b) perpendicular dipole-
dipole interaction and (c) parallel dipole-dipole interaction between two carbonyls. 
Hydrogen bonding is one of the most significant non-covalent interactions, 
mainly due to its involvement in the recognition and the stability of DNA, wherein two 
complimentary oligonucleotides come together to form a double helix held together by 
hydrogen bonding. One hydrogen attached to a strong electronegative atom (usually 
oxygen or nitrogen) called the donor (D) binds to another electronegative atom that 
generally has a lone pair called the acceptor (A) and is often referred to as D-H...A 
(Figure 3).  
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Figure 3: Hydrogen bonding between (a) a donor and an acceptor, (b) two carboxylic groups, (c) 
and two complementary DNA bases (guanine and cytosine) (Hydrogen bonding interactions are 
represented by dashed lines) 
As seen in Figure 3, hydrogen bonds can have different geometries, i.e. linear (Figure 
3a), bent (Figure 3b) or bifurcated (c). Depending on the electronegativity of the donor 
and acceptor, hydrogen bonds can vary in length and strength, as shown in Table 1. 
 
 Strong Medium  Weak 
Bond energy (kJ.mol-1) 60-120 16-60 <12 
H...A Bond length (Å) 1.2-1.5  1.5-2.2 2.2-3.2 
D...A Bond length (Å) 2.2-2.5 2.5-3.2  3.2-4.0 
Bond Angle (°) 175-180  130-180  90-150 
NMR shift downfield (ppm) 14-22 <14  
Example Proton sponge 
HF-complex 
Strong acid/base 
Acids 
Alcohols 
Biological molecules 
D-H... π bond 
C-H…H bond 
 
Table 1: Hydrogen bond characteristics 6 
Solvents, especially polar ones, also interact with molecules via electrostatic 
interactions. This process is known as the solvation effect and can interfere with other 
chemical binding and recognition. If carefully considered, solvents can also play an 
integral role in self-assembly by becoming incorporated into the supramolecular 
structure. When water is involved into this process, it is known as the hydrophobic 
effect. As shown in Figure 4, the hydrated guest is included into the solvated host 
resulting in a hydrated host-guest complex. This effect can lead to the exclusion of non-
polar entities from aqueous solution.7 
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Figure 4: Hydrophobic effect on host -guest complexation 
In aromatic compounds, the electron rich π system has no permanent dipole 
moment itself, but a partial negative charge is hosted above and below the plane of the 
aromatic ring (Figure 5a). This enables the system to interact with ions and most 
interestingly with itself. This π -π interaction can take two forms, face-to-face (Figure 
5b) or edge-to-face (Figure 5c). This is also seen in nature for example in DNA 
stacking.  
 
 
Figure 5: (a) π-system in benzene; π-π interactions (b) face-to-face (c) edge-to-face 
2. MACROMOLECULES 
A macrocycle is a cyclic molecule, usually constituted of a minimum of nine atoms 
arranged in a ring with several binding sites.8 The most commonly used classes of 
macromolecules are crown and lariat ethers, cryptands and heterocryptans, hemi-, 
crypta- and full spherands, heterocrowns, curcubiturils, catenanes, rotaxanes, 
cyclotriveratrylenes (CTV) and calixarenes.9 These macrocyclic compounds are 
inherent players in supramolecular chemistry; they are built to offer the optimal design 
for many guests, by exploiting intra- and intermolecular interactions. 
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a) Calixarenes  
Calixarenes are a three dimensional class of macrocycles which are known to 
adopt cup-like motifs. They are known to bind to cations as well as other molecular 
guests in solution.10 They can also undergo self-assembly with themselves to form 
inclusion capsules and cages on the nanometre scale and therefore contribute to a wide 
array of supramolecular chemistry research. 
In 1872, Adolph von Bayer was in search of a new type of dyes. He mixed 
formaldehyde and phenol together and heated them up into a new material, which had 
exceptional properties, but was not fully characterised. A few years later, using a similar 
method, Leo Baekeland developed a polyphenolic resin called Bakelite. These new 
applications drove scientists to probe the synthesis of this new material in more detail.11 
This first synthetic plastic became the material of choice for building heat resistant 
appliances such as radios or kitchenware. 
Although the first calixarene structure was characterised by Cornforth in 1955,12 
research into their potential properties and applications only kick-started twenty years 
later, when Gutsche turned his attention to this class of molecules and formally named 
them calixarenes. This name originates from their shape representing a Greek bowl, 
named a calyce (Figure 6b).13 
Made from the controlled condensation of tert-butylphenol and formaldehyde 
under basic conditions, their synthesis has not changed much since their first discovery. 
Greener approaches such as the use of microwave induced condensation is one of the 
rare modifications to the procedure.14 The cyclic oligomers formed during the 
condensation can be seen to have an increasing number of monomer units (n), varying 
from four to ten as shown in Figure 6. The size of the ring can be controlled by the 
temperature of reaction used in the cyclisation. The nature and size of the cation of the 
base used also play a pivotal role in ring size formation.15 
 
Figure 6: (a) tert-Butylcalix[n]arene (n= 4 to 10) and (b) tert-butylcalix[4]arene cyclic oligomer 
in cone conformation 
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Many calixarene derivatives are available today; the tetramers being the most 
commonly studied are used in a wide range of applications such as electrochemical and 
optical sensors, as well as chiral recognition devices and have been established as 
scaffolds for protein surface recognition.10, 16-18 In this work, only calixarenes relevant 
to biological systems or with demonstrated potential for biopharmaceutical applications 
will be further considered.19  
The nature and therefore the properties of the calixarenes are dependent on their 
pendant chains, as well as their aromatic starting material. Generally made from 
phenols; they can be composed of aromatic heterocycles or phenol derivatives such as 
resorcinol and pyrogallol (Figure 7).20  
 
b) Resorcinarenes and pyrogallolarenes 
Calixarenes containing hydroxyl groups, derived from the 1,3-di-
hydroxybenzene and 1,2,3-tri-hydroxybenzene are commonly referred to as 
resorcinarene and pyrogallolarene respectively (Figure 7). It should be noted that 
pyrogallolarenes taxonomy varies and other terms such as pyrogallol[4]arene, 
pyrogallolcalix[4]arene, calix[4]pyrogallolarene, 5,11,17,23-
tetrahydroxyresorc[4]arene, often replace the IUPAC name: 2,8,14,20-
tetraalkylpentacyclo[19.3.1.13,7.19,13.115,19]octacosa-1(28),3,-
5,7(25),9,11,13(26),15,17,19(27),21,23-dodecaene-4,5,6,10,11,12,16,17,18,22,23,24-
dodecol. 
 
 
Figure 7: Calixarenes: (a) tert-butylcalix[4]arene (b) resorcin[4]arene (c) pyrogallol[4]arene  
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The addition of extra hydroxyl groups to the calixarenes macrocyclic ring 
enables more intermolecular interactions due to their greater accessibility to hydrogen 
bonding. This subsequently plays an essential role in the self-assembly of these 
monomers to form carcerants,21-22 cavitands23-24 and capsules.25 It also improves their 
host-guest complexes wherein the hydrophobic pocket, formed by the benzene rings of 
the macrocycle, also contains a hydrophilic rim made up of the hydroxyl groups (Figure 
8). 
 
 
Figure 8: (a) Pyrogallol[4]arene structure (b) View of the upper rim of the monomers, doted lines 
represent the intramolecular hydrogen-bonding (c) side view of the hydrophobic pocket 
Several interesting properties of resorcin[4]arene and pyrogallol[4]arene have been 
exploited in various applications such as metal complexing agents,26-28 sensors,29-30 
water soluble traps,31-33 phase transfer extraction of heavy metals34 or hydrocarbon gas35 
and novel stationary phases for chromatography.36-38  
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(1) Stereoisomers 
The thermodynamic tetramer products exist as a number of different stereoisomers, 
depending on the orientation of the pendant chains on the methine bridge, in either axial 
of equatorial position and the overall shape of the macrocycle (Figure 9).39  
 
Figure 9: Main isomers of the pyrogallol[4]arene tetramer 
Generally, the all cis (i.e. all side chains are cis to one another) conformer rccc; 
the cone (or crown) shaped tetramer, precipitates during the course of the reaction 
because of its low solubility in acidic aqueous media and drives the reaction 
thermodynamically. The other most common form is the kinetic diastereoisomer rctt 
chair conformation. The polarity and solubility of the compound in the reaction solvent 
is one of the driving forces towards the formation of the calixarenes. By precipitating 
out of solution, the equilibrium is thermodynamically displaced towards the formation 
of the desired product. The cone rccc conformation is highly stable due to four 
intramolecular hydrogen bonds, which are not accessible in the other all cis chair, 
saddle and boat conformations.  
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The formation of other isomers is driven by the choice of pendant chain, largely 
due to steric hindrance, but can also be altered by the presence of an electron-
withdrawing group in the α-position of the phenolic residue of resorcinol. This has 
previously been demonstrated to interfere with the cyclisation process.21  
Reaction time is also reported to play an important role in both conformation 
and configuration, wherein the ratio of C4v (cone) to C2v (boat) isomeric products are 
time dependent; longer reaction time favours the C4v product.40 In a similar manner, the 
rctt isomer forms faster than the rccc, but it is isomerised back to the more stable rccc 
through reversible protoalkylation/protodealkylation under the synthetic conditions. 
Barriers of ring inversion are low enough to allow conformational equilibrations to 
occur rapidly at ordinary working temperature. Thus in configurational assignments, 
conformations can formally be ignored.21 The ratio of C4v to C2v is dependant on the 
electronic character of the pendant chain, as for example with electron withdrawing 
groups like nitrile only rctt is detected. Only one rare example of 2,8,14,20-tert-butyl-
pyrogallol[4]arene exhibits a unusual rcct conformation, whereby three chains are down 
and only one is up.41 
The host-guest chemistry that drives the vast majority of research and 
applications of these materials relies on the formation of the rccc cone conformer that is 
also preferred in the design of larger assemblies. This cone, crown or cup can be 
functionalised on the upper rim i.e. the wider top of the cup or the lower rim i.e. the 
narrow bottom part of the cup. Examples of their possible applications as host include a 
variety of macrocycles. Phosphorylated resorcinarenes, undecylcalix[4]resorcinarene 
and other calixarenes were used as neutral ionophores to compose the liquid membrane 
electrodes in cation exchange HPLC, for the screening of β-adrenergic and β-blocking 
chiral drugs.42 Stationary phase based on calixarenes and resorcinarenes have been 
prepared for reverse phase HPLC (RP-HPLC), their selectivity seems to be higher 
towards steroids than their C18 equivalents, showing the application of host guest 
chemistry.43 Pyrogallol[4]arene can be used to complex as dopamine sensors at the air-
water interface of phospholipids monolayers.30 
 
(2) Synthesis 
Despite the rapid emergence and utilisation of these materials, the original 
synthesis remained relatively unchanged for over a hundred and thirty years.44  
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It is based on the cyclocondensation of resorcinol or pyrogallol with an aldehyde under 
acidic conditions for up to seven days at reflux (Scheme 1).40 The first synthesis based 
on the condensation of pyrogallol and aldehyde as a modification of the Hoegberg 
synthesis, was reported in 1990.45  
 
 
Scheme 1: Synthesis of resorcinarene (H) or pyrogallolarene (OH) with alkyl (R) or aryl (Ar) 
chains 
The studies of resorcin[4]arene formation and conformation were followed by 
Weinelt who suggested a potential mechanism via the formation of an acetal, 46 the 
latter can be used as a starting material as well.47  
NMR and HPLC studies have been used to show that during the polymerisation 
process (Figure 10), larger oligomers with n=5 and n=6 i.e. a pentamer and a hexamer, 
are produced in the first two hours of reaction but are isomerised at different rates to 
completely obtain the tetramer after six hours.47 
 
 
Figure 10: Polymerization leading to the resorcin[4]arene 
  26 
The tetramer can also be obtained by fragment condensation of aldehydes with 
two dimers (obtained by changing the molecular ratio of resorcinol and aldehyde from 
4:4 to 2:1). This approach facilitates the introduction of diverse pendant chains onto the 
same monomer in an alternate manner.48  
More recently a novel approach led to the formation of resorcin[4]arene 
octaisopropyl ether, also referred as “resorcin[4]arene parent”, by treatment of 2,4-
diisopropoxybenzyl alcohol with chlorotrimethylsilane (Scheme 2). Although these 
compounds have a main aromatic core they have no pendant chain and require a 
deprotection step to reach the hydroxyl derivative.49 
 
 
Scheme 2: Synthesis of resorcin[4]arene parent 
Resorcin[4]arene octamethyl ether tetraesters can also be obtained by the 
reaction of 2,4-dimethoxycinnamates with etheral boron trifluoride (BF3.OEt2) as a 
Lewis acid catalyst (Scheme 3).50 This synthetic apparoach results in three 
conformational states, the 1,2-alternate (rccc), the 1,3-alternate (rccc) and flattened cone 
(rccc). Their ratio depends on the nature of the ester as well as the reaction conditions. 
 
 
Scheme 3: Synthesis of resorcin[4]arenes octamethyl ether tetraester 
Octamethoxyresorcin[4]arene derivatives, in the crown conformation, can be 
synthesised by a Friedel-Crafts type condensation, with a dimethoxybenzene and a 
variety of Lewis acid. 51 The catalyst leading to the highest yields and the conformation 
selectivity using this strategy is tin (IV) chloride in chloroform. 
  27 
Methoxypyrogallol[4]arene can also be formed in the presence of tin(IV) chloride with 
trimethoxybenzene and trioxane.52 Brönsted acid catalysis also plays an essential role in 
the selective formation of the rctt chair stereoisomer of octa-O-alkyl-
resorcin[4]arenes.39 
Although calix[4]arenes require a base catalysed condensation, resorcin[4]arenes 
and pyrogallol[4]arenes are commonly synthesised via acid catalysis; however, the 
exception to the rule is for nitroresorcin[4]arene, that can not be obtained by the usual 
acidic cyclocondensation. Instead, it is synthesised by using sodium hydroxide as a 
basic catalyst.53 
Research towards greener synthetic approaches has resulted in novel methods 
emerging over the last ten years. The first to be reported was the solvent-free method, 
wherein equimolar amount of dihydroxybenzene and an aldehyde are ground together 
with a catalytic amount of p-toluenesulfonic acid (pTSA) resulting in aryl-
resorcin[4]arenes and alkyl-pyrogallol[4]arenes. 54-55 Interestingly, the calixarenes self-
assemble into a capsule.  
Advances in microwave-assisted technologies allowed other green methods to 
yield to calixarenes. Brönsted acid catalyst, the Keggin-type tungstophosphoric acid 
(TPA) combined with microwave irradiation have been shown to synthesise 
resorcin[4]arenes.56 This work was later developed to include the pyrogallol[4]arene 
macrocycles by Yan et al.57 Microwave-assisted synthesis can also be employed to 
further functionalise the upper rim of the calixarenes as shown by the alkylation of tetra-
p-hydroxyphenyl-pyrogallol[4]arene.58 
(3) Self-assembly 
Calixarenes are able to form capsule and cage like architectures. This can be 
achieved via covalent linking as Cram and Warmuth have demonstrated,59 or 
introducing more versatility by utilising non-covalent interactions. Examples include 
dimeric capsules also known as “tennis balls” or “soft balls”.60  
The unique combination of pyrogallol[4]arene’s shape and hydrogen bonding 
potential leads to multitudes of possible hydrogen bonding networks creating capsules 
and layers that can expand into three dimensional frameworks (Figure 11).61 The 
hydrogen bonds can be replaced by partial or complete inclusion of metal coordination 
bonds. Their self-assembly in both solid state and liquid state has been extensively 
studied by the use of X-ray crystallography and diffusion NMR techniques. 62-63 
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Figure 11: Self-assembly into (a) layer (b) dimeric capsule (c) hexameric capsule 
(a) In layer-like Assemblies 
Packing control is achieved by tuning the environement, usually via the solvent 
selection, the nature of the pendant chain or a relevant guest that can act as a templating 
agent.64 Polar protic solvents such as alcohol or DMSO, take part in the hydrogen 
bonding network and often lead to the formation of layer-like assemblies.65 The addition 
of 4,4-bipyridine molecules to the pyrogallol[4]arene leads to an hydrogen bonded 
extended cavity (Figure 12).66 
 
Figure 12: Extended cavity (a) Hydrogen-bonding interaction, (b) space filling view 66 
The nature of the pendant chain also plays a role in the self-assembly of the 
calixarene. When long alkyl chains are present (C15 H31), the amphiphilic properties 
take precedence over the hydrogen bonding capacity of the macrocyles, leading to the 
formation of vesicles in solution.67 Additionally, at the air-water interface, 
pyrogallol[4]arenes with alkylated branched side chains have the ability to self-
assemble into cogged hydrogen bonded nanotubes (Figure 13).68 The presence of other 
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organic compounds such as pyrene, can lead to the formation of organic nanotubes in 
the solid state. Their stability in solution remains to be fully understood.69 
 
 
Figure 13:Nanotubes (a) Cogged hydrogen bonded and (b) pyrene mediated 
Water soluble aminoamide substituted lipophilic resorcinarene are also seen to 
form micro-tubes, that can be observed by electron microscopy.70 These tubular 
properties have been further exploited by capping gold nanoparticles with the calixarene 
to form bifunctional microtubes (Figure 14).71  
 
 
Figure 14: Resorcinarene hydrazine: (a) molecular structure, (b-d) TEM images of microtubes 
cross sections 71 
(b) In capsules 
The formation of a large hexameric capsule, was first observed with six C-
methyl-resorcinarenes and eight water molecules, self-assembling through sixty 
hydrogen bonds into a sphere with an interior volume of ca 1375 Å3, when grown from 
a water/nitrobenzene mixture.72 C-tetra-isobutyl-resorcin[4]arene has also been 
observed to form analogous capsules when crystallised from acetonitrile.73  
The addition of extra hydroxyl groups at the upper rim, achieved by substituting 
resorcinol for pyrogallol leads to the formation of the hexamer with a reinforced 
hydrogen bonding network. Pyrogallol[4]arenes are able to form supramolecular 
nanometre-sized host capsules (Figure 15). Constructed from six pyrogallol[4]arene 
macrocyclic cavitands, these self-assemble via seventy-two hydrogen bonding 
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interactions into globular capsules, with an internal volume of ca. 1300 Å3.74 The first 
example of this capsule was isolated from methanol and acetonitrile.75 
 
 
Figure 15: Pyrogallol[4]arene hexamer, hydrogen bond (yellow) and internal volume (green) 
C-Alkylhydroxycalixarenes tend to form hexameric capsules in the solid state 
when grown from acetonitrile, aqueous acetonitrile, ethyl acetate, chloroform and rarely 
benzene and methanol. The formation of the hexameric capsule is now well understood 
and has been reported using various techniques such as NMR76 and mass spectrometry77 
moreover the controlled assembly-disassembly was investigated using spinning disk 
processing.78 Consequently, scientists started the extensive study of the self-assembly 
properties of the pyrogallol[4]arene and compared them to the resorcin[4]arene. 
The ability of the macrocycles to form hexameric capsules in solution has been 
extensively studied using diffusion NMR.79 As the diffusion coefficients for both 
undecyl-pyrogallol[4]arene and undecyl-resorcin[4]arene are similar, it is assumed that 
both capsule are analogous in solution. It was also showed that the pyrogallol[4]arene 
capsules are more stable than the resorcinarene ones in solution, as they required more 
polar molecules such as DMSO or methanol to break the hydrogen network, therefore 
demonstrating that four extra hydroxyl groups per macrocycle make a significant 
difference.80 As resorcin[4]arene requires the presence of water or alcohol to complete 
the hydrogen bonding network they are much less stable than the pyrogallol[4]arene 
capsules. 
 
 
 
2.5 nm 
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The influence of water in the crystallisation of C-alkyl-pyrogallol[4]arenes 
(propyl to octyl) in acetonitrile was explored in the absence of any guests. It was 
confirmed that water can interfere with the formation of the hexamer and that the chain 
length play an important role as longer chains favour the self-assembly at the upper 
rim.81  
Following this work, other capsules from longer alkyl chains have also been 
obtained for butyl to octyl, the chain length control (CnH2n+1, n = 3 to 11) over the nano-
capsule packing has been shown to have a dramatic effect on the extended packing 
(Figure 16). The inter-capsule separations decrease from n = 4 (ca. 22.5 Å) to the lowest 
when n = 6 (19.1 Å ) and increase nearly linearly to 23 Å when n = 11.82 The most 
favourable inter-capsule hydrogen bonding is observed in the solid state when n = 6.83  
 
Figure 16: Effect of the chain length on the packing82 
The interactions of the side chains of the hexamers lead to different packing in 
the solid state, the lipophilic chains partially interpenetrate (C5H11 and C7H15) or can 
assemble into nano-rods (C6H13).83 The effect within the chain can be reflected on the 
organisation of the structure in the solid state: as the number of carbon atoms in the side 
chain increases, the intermolecular interactions become more sizable, as viewed by 
Transmission Electron Microscopy (TEM).84 It results in larger spherical aggregates 
(Figure 17) with a diameter of ca 80 nm, made of hexameric pyrogallol[4]arene capsule 
with cross-section of about 4 nm.85 
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Figure 17: TEM image of the spherical aggregates and its theoretical representation 85 
The encapsulation properties of the resorcinarenes alone and in the presence of 
various guests have been reviewed in some detail.86-89 The hexameric containers have 
different encapsulation properties, whilst pyrogallol[4]arene has only been 
demonstrated to encapsulate neutral tertiary alkylamines, resorcinarene can 
accommodate both the amines and the respective ammonium salts, showing that such a 
system could be used as a potential molecular pH switch.90 Even in really apolar solvent 
such as alkanes, pyrogallol[4]arenes retain the ability to not only self-assemble into 
hexamers but also to encapsulate the hydrocarbons. In this case, 40 to 50% of the capule 
internal volume is occupied by the guest, which is within the limit of the 55% rule.91 
The encapsulation properties extend to the encapsulation of the solvent such as 
chloroform and benzene.92 
The hexameric capsule can also be composed of mixed macrocycles containing 
both resorcinol and pyrogallol, showing a molecular “self-sorting”.93 The self-assembly 
was then shown to proceed by self-recognition as the mixture of two macrocycles of 
different type resulted in no instantaneous formation of heterohexamers but an 
equilibrium towards heterohexamers is attained after a week.94 
 
(c) Metallo-capsules 
Inspired by the coordination properties of phenols and catechols, the ability of 
the hydroxyl groups to coordinate to metal and metal hydrides was exploited to form 
metallo-hydroxycalixarenes complexes. Advancement into supramolecular design was 
achieved when the hydrogen network was substituted by metals, forming metallo-
supramolecular capsules either dimeric (zinc) or hexameric capsules (copper and 
gallium), 95-96 Even though the loss of four intramolecular hydrogen bonds can increase 
the flexibility of the cone monomer,97 the complexes keep similar size and volume to 
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their hydrogen-bonded homologues. Comprehensive reviews on metallo-supramolecular 
capsules and mixed metal-organic nanocapsules demonstrate the advances in this 
field.26, 98 These capsules are readily prepared by dissolving hydroxycalixarenes in a 
methanolic solution of the metal nitrate, and crystallising the resulting solid from an 
appropriate solvent. 
The rapid self-assembly of a copper nanocapsule was described as a possible 
cause for the formation of discrete metal-organic assemblies (Figure 18).99 Six C-
propan-3-ol-pyrogallol[4]arenes coordinate to twenty-four Cu(II) to form an hexameric 
capsule with an internal volume of ca 1200 Å3.100 The synthetic ion channel based on 
copper sealed C-undecyl-pyrogallol[4]arene capsule keeps its shape, even in 
phospholipids bi-layers.101  
 
 
Figure 18: Example of metal-organic capsules.96 
The substitution of copper by gallium leads to the formation of a “rugby ball” 
with an estimated internal volume of 1150 Å3. These hexamers encapsulate six to seven 
acetonitrile molecules or twelve metal ions (Ga3+) and four coordinated water 
molecules.62 The characterisation of the latter was obtained by X-ray crystallography 
and matrix-assisted laser desorption/ionization mass spectrometry (MALDI-TOF 
MS).95, 100 Other pyrogallol[4]arenes were considered as potential ion transporters when 
caesium and silver were found to move to the interior of metal (Ga (III)) organic 
capsules.96 Capsules containing multiple metals, i.e. gallium (III) and copper (II), are 
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obtained by exploiting the capacity of a metal (gallium) to replace other metal sites 
(copper) trapped in the preformed capsule.102  
The metal coordination seems to have an important effect as it can generate a 
conformational change with the calixarenes.103 The deformation of the capsule shape is 
explained by the incorporation of structural water molecules in gates to the interior of 
the assembly with gallium whereas for copper insertion, water is not involved and 
afford a near spherical nanocapsule.96, 100 
C-Chlorobutanyl- and C-hexyl-pyrogallol[4]arene form ionic dimeric capsules 
when mixed with caesium chloride in head-to-head and one offset manner 
respectively.104 Dimeric zinc capsule entrapping methyl-pyridine was obtained from C-
propyl-pyrogallol[4]arene and [Zn(NO3)2(3-methylpyridine)3] in methanol and DMSO, 
which was coordinated to the zinc centres (Figure 19a).105 Pyridine can easily replace 
the DMSO molecules, forming a Pelton wheel (Figure 19b). 95-96  
 
 
Figure 19: Examples of dimeric metal-organic capsule106 
When zinc is replaced by paramagnetic metals like nickel and cobalt, the 
complex retained their magnetic properties.106 Metallopyrogallol[4]arenes’ potential as 
an ion carrier, by forming large stable conductance pores, has been investigated using 
conductance studies, when in the bi-layer form or metal (Cu) capsule. The metal-
calixarenes capsules are able to reversibly switch over a wide range of potentials.107  
 
(d) Traceable capsules 
Pyrogallol is known to have chemiluminescence properties, when cyclised into a 
water soluble tetramer, with sulphonated pendant chains. The chemiluminescence 
intensity is 1.3 times greater than the pyrogallol monomers.108 The colorimetric values 
of resorcinarenes and some boronic derivatives have been considered for the visual 
investigation of saccharides binding.109-111 
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Following this work, fluorescent chiral resorcinarenes, with tetraarylboronate feet have 
been used for the chiral recognition of amino acids, especially for lysine.112 Exploiting 
the advantages of both self-assembly and encapsulation, fluorescent capsules have been 
described, using two approaches either the encapsulation of a fluorophore or the 
covalent attachment of fluorescent entities. Functionalised pyrogallol[4]arene with 
fluorophores (one donor and one acceptor) on their pendant chains have been assessed 
for their ability to self-assemble into a hexameric capsule (Figure 20) by fluorescence 
resonance energy transfer (FRET).113-114 This work not only proved that 
pyrogallol[4]arene capsules have a slower monomer exchange than resorcinarenes one, 
it also confirmed water was not required for the self-assembly to occur. This 
demonstrated that pyrogallol[4]arenes which are less sensitive to concentration of 
mixing, are much more stable than the resorcinarene in polar media and the macrocycles 
have the ability of self-sorting.115  
 
Figure 20: Hexameric capsule containing pyrene and perylene 116 
 
The encapsulation of pyrene butyric acid (PBA) by C-hexyl-pyrogallol[4]arene 
was used to investigate the internal chemical environment of the capsule. Absorption 
and fluorescence emission results showed that the two encapsulated PBA are kept apart 
by more than 7 Å (Figure 21)116. Similar results were obtained for the hydroxyl 
derivative pyrene butanol.117  
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When large fluorescent molecules such as benzo[α]pyrene (B[α]P) and pentacene were 
trapped by the assembly, it was assumed that only one of those large molecules can 
occupy the capsule at a time due to size restriction.118  
 
 
Figure 21: Encapsulated PBA molecules (orange and space filled) in the hexamer119 
A fluorescent molecule with an in-built quencher, 1-(9-anthryl)-3-(4-
dimethylaniline) propane (ADMA) has been encapsulated within the hexamer. The X-
ray structure of the exo-capsule was presented showing the intercalation of the 
fluorophore within the pendant chains.119 When ADMA is encapsulated in both hexyl-
pyrogallol[4]arene (acetonitrile and ethyl acetate) and decyl-pyrogallol[4]arene (ethyl 
acetate) hexamers, it resides in both the exo-capsule within the pendant chain (Figure 
22) and the endo-capsule (inside the hexamer), it had an enhanced fluorescence 
emission intensity compared to the free ADMA.120 
 
 
Figure 22: ADMA (spacefilled) intercalated into the pendant chains (yellow)119 
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3. PYROGALLOLARENE AND RESORCINARENE DERIVATIVES 
Although much research has been performed on the resorcinarene derivatives 
and their extended cavitands, less has been achieved on the pyrogallol[4]arene. 
Although they have similar structures and only differ by the number of hydroxyl groups 
available for hydrogen bonding. By reviewing the latest research on the resorcinarenes, 
it is possible to understand their behaviour and properties which could be extrapolated 
to pyrogallol[4]arenes. 
a) Modification of the upper rim 
Resorcinarenes are a well-studied class of molecules that have received much 
interest in recent years, mainly as carcerants or cavitands. Cram and co-workers have 
made an enormous contribution to this class of macrocycles, by developing novel 
synthesis to extend their cavity that can accommodate bigger guests.21, 121 Gibb has also 
created a new range of “deep-cavity” cavitands, by extending the upper rim of 
resorcinarenes.122  
The resorcin[4]arene upper rim is modified by bridging the phenol hydroxyl 
groups at position 1 and 3, leading to cavitands that can be easily functionalised at the 
lower rim. This enforced cavity induces a synthetic viability with rigidity, but removes 
the ability to self-assemble via hydrogen bonding. The basic cavitand is made from a 
simple methylene bridge, (R1=H in Figure 23) or extended with other aromatic rings, 
such as resorcinol (R1=C6H3(OH)2) which is available for further substitution.123  
 
 
Figure 23: Ethylene bridged cavitand 
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Other aromatics such as pyrazine, quinoxaline (Figure 24) and benzimidazole 
can be directly bound to resorcinol to form switchable cavitands whereby the upper rim 
can be transformed from a deep cavity to a flat extended surface.24, 124 
 
 
Figure 24: Quinoxaline bridged cavitand 
The first readily accessible preparation of the bridged cavitands containing 
pendant chains with sensitive functionality such as alcohols was achieved using 
ethylene ditosylate, as well as bromochloromethane, and silicon bridging using 
trimethylsilyl chloride. The resulting cavitands were typically synthesised over one to 
two days under mild temperatures (40 - 60 ºC) in a 10 to 80% yield. 125 
Amino acid derivatives, as well as small peptides, were attached on the upper 
rim of the cavitands in order to obtain a model synthesis for de novo proteins, using the 
rigid macrocycle as a scaffold. This was achieved by transformation of phenols and 
thiophenols on the 2-position of the upper rim of the cavitands with halo-acetylated 
peptides (Figure 25). This methodology was also applied to the cyclotriveratrylene 
(CTV) macrocycle and their ability to hydrogen bond was measured by IR and NMR 
spectroscopy.126  
A series of di- and tri-peptides have been attached onto the upper rim of the 
cavitands via a 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and 
hydroxybenzotriazole (EDC/HOBt) coupling, affording a stable inclusion complex with 
acetonitrile in chloroform solution. To date, it is one of the rare peptide-cavitand based 
on resorcinarenes.127  
 
  39 
 
Figure 25: Peptido-cavitands (a) precursors, (b) its schematic view  
In the study towards water soluble cavitands, a series of methylene bridged 
resorcin[4]arenes containing hydroxyls and phosphates at their lower rims with 
bromoethyl and thiomethyl on their upper rim have been investigated.  
The introduction of a bromine at the phenolic 2-position was achieved by 
bromination of resorcin[4]arenes using N-bromosuccinimide, and subsequent 
transformation led to a thiol using thiourea.125 These new materials can be further 
functionalised and used as building blocks for aqueous supramolecular chemistry.128 
 
 
Scheme 4: Bromination of resorcin[4]arene129 
Commonly, methyl-resorcinol derivatives are obtained from the commercially 
available 2-methyl-1,3-di-hydroxybenzene. Cram et al. speculated that cyclic tetramers 
could not be obtained from any aldehyde with either 2-nitroresorcinol, 2-
bromoresorcinol or 2-carboxyresorcinol, due to the deactivation of the resorcinol 
nucleus towards electrophilic substitution; both with respect to forming cyclic 
oligomers and equilibrating them once formed. Instead, the cyclic macrocycle must be 
preformed and then functionalised.21 A number of resorcinarenes have been transformed 
in this respect by replacement of the hydrogen in the 2-position of resorcinol by 
different functional groups, examples include the aminoethyl, sulfomethyl, alkoxy, 
acyloxy and bromethyl. The attachment of an oxidising agent such as 
(b) (a) 
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(2,2,6,6,tetramethylpiperidine-1-yl)oxyl (TEMPO), or a more biologically relevant 
group such as L-proline have been utilised in this manner.130-138 These last 
transformations were either achieved on the unprotected resorcinarene or on the 
protected macrocycle, i.e. the transformation of octa-O-methyl resorc[4]arene.139 Other 
derivatives such as hydrazinocarbonyl-methyl-resorcinarenes and pyrogallolarenes were 
synthesised for their unique inclusion properties with promising binding ability for 
metal extraction.140  
b) Modification of the pendant chains 
The nature of the calixarenes is highly dependent on their pendant chains. These 
chains have been reported to play an essential role in the structural conformation, 
solubility and self-assembly of the macrocycle.  
(1) Apolar derivatives 
Alkyl derivatives are by far the most studied due to their ease of formation and 
their high solubilities in organic solvents. In early work, Cram synthesised a library of 
aliphatic and aromatic resorcinarenes as building blocks for cavitands in order to 
understand the limitation of the condensation to the tetramers and the investigation into 
the various symmetries.21 Most of the aromatic pyrogallol[4]arene reported in the 
literature are in the rctt chair conformation (Figure 26), which although it is the kinetic 
product, is found to be the predominant isomer observed with aromatic pendant 
chains.141-142 Various substituted phenyl-pyrogallol[4]arene macrocycles (cyano, bromo, 
chloro, fluoro) have been synthesised in the rctt conformation via the acidic 
condensation of the respective aldehyde with pyrogallol under reflux for one day. Many 
of these have been crystallised in DMSO and studied in the solid state. 143 The effect of 
the aromatic substituent at the four position has been assessed in some details.  
The steric and electronic properties of the aromatic substituent on the pendant chains are 
reported to play a role in the host ability to bind the guest. The strength of the hydrogen 
bonding can also be increased via the fluorine substituent.144 
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Figure 26: Example of the rctt chair diastereoisomer 
 
A series of aromatic pyrogallol[4]arenes (C6H5, p-C6H4CH3, p-C6H4OCH3, p-
C6H4Cl, o-C6H4OCOCH3 and p-C6H4OCOCH3) were synthesised as the rctt isomers by 
microwave irradiation in 2-ethoxy-ethanol. These were further acetylated or alkylated at 
the upper rim via the use of acetic anhydride or benzyl bromide.57 Microwave-assisted 
synthesis was employed to alkylate tetra-p-hydroxyphenyl-pyrogallol[4]arene in the rctt 
chair conformation with comparable results compared to the conventional heating 
methods.58 A series of acylated phenyl and ferrocenyl pyrogallol[4]arenes were 
synthesised using a microwave protocol showing the rctt  and the rccc conformations 
respectively.145 
(2) Polar derivatives 
In order to develop calixarenes that can be further functionalised at the lower 
rim, functional groups such as amino, carboxylic acid and thiols have been attached at 
the pendant chains. However, their synthetic precursors must be first prepared. The 
table below represents all the documented derivatives of this class of functionalised 
macrocycles (Table 2), as seen in Scheme 5, R is the function on the 2-position of the 
dihydroxybenzene and R’ the pendant chain.  
 
Scheme 5: Synthesis of resorcin[4]arene (H) or pyrogallol[4]arene (OH) with alkyl (R) or aryl (Ar) 
chains 
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Synthesis via Cycle (R) Chain (R’) 
Ald Other 
Ref. 
H (CH2)2SO3-   146 
OH (CH2)4Cl   147 
OH (CH2)8Br   147 
H (CH2)4OH   21, 
125
 
H (CH2)3OH   125 
Br (CH2)4OH   125 
Br (CH2)3OH   125 
H p-C6H5Br   21 
H p-C6H5NO2   21 
H (CH2)5Cl   21 
H, CH3 MeC(O)N(CH3)CH2,CH2NH2,CH2N(CH3)PO(EtO)2, 
CH2NHCH3, CH2NHC(O)NHPh 
 
 
148
 
H (CH2)3NHBoc   149 
H, OMe CN, CH2OH, CH2Br, CH2N3, CH2NHAc, CH2NH2 
CH2COOH and dipeptides 
 
 
150-
153
 
H (CH2)10SH   154 
Table 2: Documented polar footed derivatives aldehyde (ald.) is ticked when the derivatives are 
synthesised from the aldehyde or its acetal. 
Highly water soluble tetraethylsulfonate derivatives of 2-methyl-resorcinarenes 
have been used as an additives in capillary electrophoresis.146 The resorcinarene 
derivatives were bound to hydroxyproline groups via a Mannich condensation and 
evaluated as a chiral NMR solvating agent.138 Chiral phase-transfer catalysts derived 
from cinchona alkaloids were prepared for the enantioselective synthesis of α-amino 
acids with good results.155  
The first tetrasulfonate derivative (R=(CH2)2SO3Na) of resorcin[4]arene provide 
the host with the ability in water to interact with guests such as hydrophobic 
monosaccharides and nucleosides.156 Sulfonato-footed resorcin[4]arene containing L-
proline moieties have found application as chiral NMR shift reagent for aromatic guest 
in water.157 
Gibb synthesised hydroxyl derivatives of resorcin[4]arene as precursors to 
hydroxyl cavitands, using dihydropyran and dihydrofuran as masked aldehydes.125 The 
monofunctionalised alcohol resorcinarene was synthesised by monoepoxidation of an 
alkene and then attached to a polymer in an eleven steps synthesis.158 
Monofunctionalised resorcinarenes can also be synthesised in low yield, in a single step, 
by reacting three equivalents of one alkylaldehyde, with one equivalent of the 
functionalised aldehyde, such as 3,4-dihydro-2H-pyran, with four equivalents of 
resorcinol.159 
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Phosphate derivatives of methylene-bridged resorcin[4]arenes are accessed by 
phosphorylation of the hydroxyl feet with di-tert-butyl-N,N-diethylphosphoramidite 
(DDP) followed by oxidation with hydrogen peroxide and subsequent removal of the 
tert-butyl group with trifluoroacetic acid (TFA).128 These phosphorylated 
resorcin[4]arenes synthesis can be simplified by reacting resorcinol with phosphorylated 
acetals.148  
Four cavitands modified at the lower rim with cyano and pyridyl functional 
groups (Figure 27), have been coordinated to transition metals such as Ni(II), Ag(II) and 
Pd(II). They have been obtained by acetylation of hydroxyl-footed cavitands with 
isonicotinoyl chloride hydrochloride; this can only be done on the cavitands as the 
presence of the free phenols will interfere with the reaction. 160 Halogenated derivatives 
have been obtained and crystallised both in a bi-layer structure and hexamer analogous 
to those reported for the alkyl pyrogallol[4]arenes.147 However, this study is limited to 
solid state studies.  
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Figure 27: Modified cavitands 
Boc protected amine footed extended cavitands were developed, in order to 
engineer water soluble cavitands that can mimic receptors by modification of C-
hydroxybutyl resorcin[4]arene.149 It was a lengthy process of six steps, (Scheme 6) 
which involved several protection and deprotection steps with an overall yield of 31%. 
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The cavitands were then used as hosts in NMR spectroscopy binding studies with many 
water-soluble amines as guests.161-162 
 
 
Scheme 6 : Synthesis of the amino footed cavitand 
The same cavitands were immobilised, by their pendant chains, onto a polymer 
base via isocyanate linkage to understand the ability of self-recognition and the 
formation of inclusion complexes on supports. The hydroxyl footed derivative was 
attached via formation of tetrahydropyranyl ethers.163 Amino and nitrile calixarenes 
were immobilised on a polymeric backbone to evaluate the ability of chromium 
extraction with promising results.164 The reaction of N-functionalised acetals, such as 
phthalimidoacetal derivatives with resorcinol and methyl-resorcinol, lead to 
resorcin[4]arenes which can be hydrolysed with hydrazine hydrate in a basic solution to 
the corresponding amine (Figure 28).148  
 
 
Figure 28 N-Functionalised resorcin[4]arene 
Only the halogenated salt dimers are obtained by mixing equimolar quantities of 
resorcinol and methyl resorcinol with N-methylaminoacetaldehyde. The free amine 
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could not be isolated due to the ionisation of the hydroxyl groups in alkaline media and 
the formation of soluble phenolates. The dimer was then reacted with formaldehyde 
using the acidic aqueous mixture to form a tetramer (Scheme 7). Linear oligomers 
linking two pendant chains were also obtained by addition of diisocyanate.165 This 
approach demonstates potential to control the formation of difunctionalised calixarenes.  
 
Scheme 7: Synthesis of methylresorcin[4]arene with two N-methylaminomethyl pendant chains 
Using a different approach, a resorcin[4]arene octamethyl ether tetrabromide 
was obtained from a tetraalkyl derivative and transformed to a tetraamine via the 
tetraazide as the reduction from the tetracyanide was not a viable route.152 
Tetrathiol footed resorcinarene derivatives with various functionalities on the 
upper rim, obtained by anti-Markovnikov addition of a thiol to the terminal double bond 
of an alkenyl pendant chain,166 were investigated as a self-assembled monolayer 
absorbed on gold.167 Their selective guest-host associations with lactones were 
investigated.154 In similar work the interaction of self-assembled monolayers (SAMs) of 
thiocalixarenes on gold films with bovine serum albumin (BSA) was investigated by 
surface plasmon resonance (SPR).168 A series of mono functionalised thio-derivatives at 
the lower rim were prepared by convenient differential protection or derivatisation of 
the upper and lower rims.169 Thiol footed resorcinarene derivatives have also been 
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employed as a building block for a novel stationary phase bearing polar head groups in 
reversed phase HPLC.36 
(3) Biologically relevant derivatives 
(a) Calixarenes 
Peptidocalixarenes have received little attention compared to other substituted 
calixarenes, although they have interesting molecular recognition properties.170 N-linked 
dipeptides have been attached onto protected calixarenes (Figure 29a) via the acid 
chloride derivatives,171 and used to assess their ability to bind various amino acids.172 C-
linked dipeptides were described later and were found to have better interactions with 
anion interactions than their N-linked derivatives. Alanine was attached on the upper 
rim of calix[4]arenes and their ability to self-associate into a dimer was assessed.173  
A class of calixarene based hydrogen bonding receptors was obtained by linking 
amino acids, peptides and sugar moieties to calixarenes.174-175 Ungaro’s group have 
concentrated on the synthesis of N,C-linked peptide-calix[4]arenes as “pseudo-peptides” 
and the study of their conformational self-assembly and molecular inclusion 
properties.176 New linear and cyclic N,C-linked peptido-calix[4]arenes were produced 
by condensing calix[4]arene based amino acids during the step-wise elongation 
sequence of a peptide using solid phase microwave synthesis based on 
fluorenylmethyloxycarbonyl (Fmoc) chemistry (Figure 29).177 
 
Figure 29: (a) Amino-carboxylic acid calix[4]arene, (b) cyclic peptide calix[4]arene (c) protected 
di-C,N-trialanyl calix[4]arene 
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Using the upper rim to add functionality impedes the cavitands’ ability to self-
assemble into globular structures and therefore only their inclusion properties can be 
exploited. Interestingly, only two of the four hydroxyls on the bottom rim were 
protected in order to functionalise the upper rim. As they disclosed in the study, the two 
hydroxyl groups played an important role to reduce the conformational flexibility 
through hydrogen bonding. By comparing the role of the phenols for calix[4]arene and 
pyrogallol[4]arene, it be can assumed that the 2-position of the pyrogallol, that is not 
involved in the intramolecular hydrogen bonding, may still interfere with the 
functionalisation. 
 
(b) Resorcin[4]arenes 
In the nineties, Botta et al. discovered a novel route to protected resorcinarenes 
with ester functionalised pendant chains. The tetramerization of 2,4-
dimethoxycinnamates with a Lewis acid, BF3.OEt2, resulted in the 1,2-alternate, the 1,3-
alternate and the flattened- cone conformers.178 The reaction was then optimised for an 
increased selectively to the flattened cone (60%) and an 1,2-alternate chair (40%) 
conformations.50 Studies were extended to the formation of a resorcinarene lower rim 
“basket” (Figure 30).150, 179  
 
 
Figure 30: Lower rim basket (a) with polymethylene bridge, 179 (b) diaminocyclohexane chiral 
bridge.150  
Chirality was introduced by functionalisation of the pendant chain with D- and 
L-valine.180 The enantioselectivity of binding of the amido[4]resorcorcinarene cavity 
was assessed with a range of amino acids.181-182 The host-guest binding is highly 
dependent on the conformation of the macrocycle.183 The flattened cone favours the 
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enantioselective allosteric effect.184 The selectivity in the gas phase allows the 
separation of three classes of amino acids.185 Their complexes with aromatic amino 
esters are stable in both gas phase and solution and have the potential to show a receptor 
ability for amphetamine186,187 The side chains can interact with various metals including 
iron and copper.151-152 They also complex with nitrosium and vinca alkaloids. 153, 188 
In 2007, the formation of peptidoresorcinarenes (Figure 31), by conjugation of 
the acid chloride derivatives with peptides, showed that recognition also occurs on a 
larger scale.189 The macrocycles are capable of recognising the homologous dipeptides 
(valine-leucine) as guests both in solution and in the gas phase. They are also reported 
to be resistant to chromatographic purification but not to heating.190 
The gas phase enantioselective reactions in non-covalent ion-molecule 
complexation have recently been investigated.191 Their potential to form adducts with 
ethanolamine neurotransmitters showed potential.192 
 
 
Figure 31: Peptide footed methoxyresorcinarene190 
In all reported cases of lower rim amino functionalised resorcinarenes, the upper 
rim is protected via an ether. However, there has been no reported attempt to deprotect 
the upper rim to free the phenolic hydroxyls. If this was achieved the macrocycle could 
act as a host by exploiting its hydrogen bonding potential for amino acid. It is also 
noticeable that the lower rim can be functionalised on each of its four feet, which means 
that the steric hindrance should not play an important role in the attachment of peptides, 
although a protection step may be required.  
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In the only example of a peptide attached on one foot of the unprotected 
resorcinarene, an small anti-inflammatory peptide was attached onto a pegylated chain 
of a resorcinarene and immobilised on glass in attempt to generate an bioactive anti-
inflammatory model.193 The monofunctionalised precursor of this macrocycles was 
obtained after protection of the upper rim by hydroboration/oxidation of the 
monoalkene, or radical addition of a mercapto derivative (Figure 32).169 
 
It would be interesting to see how the presence of extra hydroxyl on the upper 
rim would interfere with the recognition and therefore similar work should be 
considered, applied to the synthesis of new class of molecules: the peptide footed 
pyrogallol[4]arenes.  
 
 
Figure 32: Pegylated (a) precursor (b) peptido-resorcin[4]arene.193 
(a) (b) 
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B. FROM SUPRAMOLECULAR TO NANOMEDICINE 
Exploiting the ability of pyrogallol[4]arene to self-assemble into nanocapsules, 
with twenty-four pendant chains assuring multi-functionality, they will be considered as 
nanovectors for cancer immunotherapy. 
1. NANOTECHNOLOGY AND NANOMEDICINE 
a) Nanotechnology 
Nanotechnology, which has bloomed in the last twenty years, is defined as the 
knowledge of technical operation (technology) in the nanometre-scale (10-9 m) and 
encompasses anything from 0.1 to 100 nanometres.  
Although often represented as reduced sized apparatus or robot able to solve 
problems, this theoretical view needs to be demonstrated. Nanotechnology now has 
many definitions and may be the seed of some scientific arguments,194 but the appeal 
towards nanotechnology remains thanks to its interdisciplinary nature and its purposes. 
Realising their potential, European governments and funding bodies are looking to 
invest more in nanotechnology related projects in the future years.195 
The range of applications is wide and nanomaterials are already components of 
some everyday products. Nanomaterials are used in energy production as fuel catalysts 
and photochemical devices for solar thin-films. Titanium dioxide and zinc oxide 
nanoparticles are used in sunscreen and anti-wrinkle cosmetics. Nanopore properties are 
exploited by fabric manufacturers to render the materials stain or perspiration resistant. 
Nanocomposites are introduced into car parts to make them lighter, cheaper and with 
higher resistivity, in the same way that carbon nanotubes are used in tennis rackets.196-
198
  
Nanomaterials can be designed by the top-down approach, whereby nanometre 
scale components are obtained by reduction of larger materials, using micro- or nano- 
fabrication methods. While the bottom-up approach is the synthesis of nanostructures 
and nanomaterials by means of nanochemistry, using supramolecular and biomimetic 
systems.8 
Scientists are now able to engineer molecules to achieve their goals by 
controlling matter on the molecular or atomic scale. Thanks to the development of 
different analytical technologies including X-ray crystallography, TEM, SEM, atomic 
force microscopy (AFM) and two-photons to microscopy techniques, it is now possible 
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to visualise and analyze matter on the nano-meter scale, which was not possible a few 
years ago mainly due to the lack of computing tools.  
b) Nanomedicine  
Most biological pathways, such as DNA pairing and antibody or receptor 
recognition also occur at the nanoscale, (Figure 33) and therefore nanomaterials have 
the ability to interact on the cellular level, highlighting the possibility of a new type of 
treatment based on nanomedicine.  
 
 
Figure 33: Nanoscale and biological systems 
Richard P. Feynman, Nobel physicist in 1965, was one of the visionaries of 
nanomedicine. He described his view on the future of medicine in a lecture in 1959.199 
Over fifty years later, nanomedicine is an innovative science that uses new technology 
and engineered nanomaterials to selectively treat diseases. The latest researches in 
nanomedicine focus on imaging, diagnosis and treatments of disease including cancer, 
infections, inflammations, metabolic and autoimmune disease but also tissue 
engineering and regeneration.200-201 
In this field, the nanomaterials taxonomy is broad “nanopharmaceuticals”, 
“nanoparticles”, “nanocapsules”, “nanospheres”, “nanovector”, “microcapsules”, 
“microspheres”, “colloidal carriers” and “lattices”. Nevertheless, they all describe any 
materials in the nanometre scale with biological purposes. 
A review on recent progress for the rational design of therapeutically active polymer 
based nanoparticles retraced the latest development in nanomedicine. The main events 
in the advancement of nanomedicine are summarised in the following timeline (Figure 
34).202-203 
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Figure 34: Timeline of the main discoveries in nanomedicine, (adapted from214-215) 
Although great breakthroughs have been achieved in nanomedicine, their 
applications in diagnosis seems to surpass those in therapeutics, maybe due to the safety 
concerns that still remain to be addressed.204  
Sanhai summarised them into seven challenges to overcome:205 
- determination of the distribution of the nanoparticulate carriers in the body 
following systemic administration through any route 
- understanding of mass transport across compartmental boundaries in the body; 
- development of radiolabelled nanoparticles; 
- prediction of risk and benefits; 
- establishment of standards or reference materials; 
- development of new mathematical and computer models; 
- realisation of an analytical toolkit for nanopharmaceutical manufacturing. 
As a result, approval by the food and drug administration (FDA) and its British 
equivalent, the medicines and healthcare products regulatory agency (MHRA) can be 
challenging. Generally due to the novelty of those nanopharmaceuticals that can play an 
important role in the drug formulation. So far, the FDA approved nanomaterials that 
dominate the research of drug delivery are based on liposomes and a polyether, 
polyethyleneglycol (PEG).215 
The multiple pathways involved in the processing of the nanoparticles are still 
insufficiently understood, due to the novelty and the multifunctionality of those 
materials. Some work still remains to be completed to obtain homogeneous distribution 
of the drug, with a high drug loading that must retain in the carrier until destination, and 
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the release of the drugs must be controlled.204 Their routes of excretion certainly differ 
from the free drugs and are still not fully defined. In addition, more in vivo studies are 
needed to reinforce the studies performed in in vitro cell lines.  
An appreciation of the behaviour of the biomaterials within the body is essential; 
it depends on the size, shape, surface and the cytotoxicity of the nanoparticles.  
The biological barriers encountered by any pharmaceutical exist at different levels. 
Some organs act as a natural filter and only let through particles under a certain size. 
The spleen only tolerates particles from 200-250 nm, whilst the liver excludes particles 
over 150 nm and particles under 5 nm are removed by extravasation or renal clearance.  
(a) (b)
(c)
(d)
 
Figure 35: Endocytosic pathways: (a) Phagocytocis (b) macropinocytosis (c) caveolar endocytosis 
(d) chlatrin mediated endocytosis 202 
At the cellular level, the first barrier is the mononuclear phagocyte system 
(MPS) or reticuloendothelial system, which eliminates particles from 100-200 nm. 
Endocytosis is one of the key process for the nanoparticles internalization at the cellular 
level.206 It can be sub-divided into four main categories: phagocytosis, clathrin-
mediated endocytosis, caveolar-mediated endocytosis and pinocytosis (Figure 35). 
Phagocytosis generally happens first, in phagocytes, and it is size-independent. 
Clathrin-mediated endocytosis, which is the main route of cellular entry is usually 
involved in the uptake of essential nutrients in mammalian cells and is receptor 
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dependent. Caveolae are a membrane type of lipid raft that can induce endocytosis. 
Pinocytosis is the only non-specific internalization that is used for the transport of 
extracellular fluids to the cell. By understanding the endocytosis pathways receptor 
mediated targeting can be considered, being either passive for particle under 100 nm by 
the size dependent take-up by the MPS, or active by using specific ligands. 
c) Nanomedicine and cancer 
Nanotechnology is involved with both cancer detection in a search for high 
throughput devices and cancer therapy with the aim to find suitable vectors. It could 
potentially overcome the problems of drug resistance at the tumour and cellular level by 
improving the cell penetration, as well as reducing its toxicity and increasing the 
biodistribution, biotransformation and the clearance of anticancer drugs.200, 207 Tumour 
capillaries rarely exceed 300 nm, meaning that the nanoparticles can accumulated in 
tumours, which can be enhanced by the permeation and retention effect (EPR) found in 
the tumour environment.208 
The applications of nanoparticles in cancer therapy started to emerge from 1979 and 
has expanded since.209 To date, from the eighty-eight clinical trials that are assessing 
nanoparticles, seventy-one are involved with cancer treatments.210 From the various 
types of nanotechnologies involved in cancer therapeutics, the most prominent and most 
widely studied are nanoshells, carbon nanotubes, dendrimers, quantum dots, 
superparamagnetic nanoparticles and liposomes as summarised in Table 3.211-213  
Independently of their nature, they all utilise encapsulation, conjugation (either 
covalent or non-covalent) and adsorption of modalities such as drugs, peptide, protein, 
DNA, RNA, antibodies, ligands and stealth molecules (Figure 36). Their main asset is 
their multifunctionality, which enables them to achieve the recognition and location of 
the tumour, as well as visualisation and imaging. Release of the therapeutic can be 
triggered by the use of external factor (e.g. hyperthermia, MRI or light), enzymes or a 
change in the microenvironment, like the acidity around the tumour, or reductive 
environment in the cytosol (using disulfide bridges).  
Nanoparticle drug delivery is thought to improve the therapeutic response to 
anticancer drugs.214-215 An interesting example is Doxorubicin, which is a 
chemotherapeutic agent with many side effects. These adverse effects were reduced by 
a change in the formulation, by incorporating the drugs into pegylated liposomes and 
non-pegylated liposomes. 
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Nanoparticles’ 
class 
Size 
(nm) 
Material Used with Detection Therapies 
Quantum dots 1-10 CdSe, CdTe, 
InP, InA 
Ab, siRNA 
Peptides, 
PEG 
Tumour  
cell 
labelling 
 
Superpara-
magnetic 
nanoparticles 
SPIOs 
10 
<50 
Fe3O4 Dextran 
PEG 
peptides 
Contrast  
Agent 
 for MRI 
Thermal 
ablation  
therapy 
Dendrimers <5  
<1000 
Polymer (C/N) 
or sugar 
Fluorescein 
Gd 
Tracer Drug  
delivery 
Carbon  
nanotubes 
1-2  Carbon DNA 
siRNA 
 Transport 
DNA 
thermal  
Nanobeads 
Polymeric 
nanosphere 
40-50 Polymer  Antigen 
coated, 
Enzyme, 
drugs 
 Delivery 
system 
Liposomes 90-
150 
Lipid bi-layer Drug, RNA, 
DNA, PEG 
 Delivery 
system 
Nanoshells 120  
 
SiO2 core 
coated with 
Au shell 
Ab-PEG 
complex 
 Thermal 
ablation 
therapy 
Table 3 Nanoparticles involved in cancer therapies and detection 
 
Figure 36: Nanocarriers for cancer detection and therapy216 
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Stealth nanoparticles are made to be unperceivable by the macrophages and are 
less likely to be excreted. They almost always contain PEG that reduces the uptake by 
the RES and the MPS and is known to accumulate into tumours.208 The efficacy of the 
treatment can be improved by the use of a nanoparticle, by reducing the toxicity using 
liposomes and micelles, controlling biodistribution (PEGylated nanoparticles) and 
improving intracellular penetration (PEGylated liposome and micelle). Pegylated 
entities are covalently bound to polyethylene glycol, which has excellent water-soluble 
properties and low toxicity. The presence of PEG prevents the absorption by opsonin 
(binding molecule in phagocytosis) by repulsion of plasma protein due to its hydrophilic 
properties and results in the non-clearance by the macrophages. 
 Increase in selective delivery of the drugs to cancerous cells can be achieved by 
using active targeting molecules for instance via the use of folate-binding protein or 
RDG. The αvβ3-integrin receptors are over expressed on the tumour surface for this cell 
penetrating peptide. 
2. TOWARDS CANCER DETECTION AND THERAPY 
a) Cancer Overview 
According to the World Health Organisation (WHO), cancer is a leading cause 
of mortality (13%) in the world. In most of the developed countries, it is the 2nd cause of 
mortality after heart disease. According to Cancer Research UK, a third of the 
population will develop some form of cancer during their lifetime. Due to its high 
incidence, one of the main priorities in pharmaceutical research is the quest for the 
ultimate cure for cancer. Unfortunately, as cancer can spread in every organ, so far there 
is no universal therapy.  
Over two hundred distinct cancer types exist as tumours can be found within 
various organs. The most frequent tumour sites are the lung and bronchus (ca 30%), 
prostate (10%) and breast (15%), followed by colon and rectum (10%) and skin (4%).217  
Cancer is a very complex disease caused by the dysfunction of ones’ own cells 
and is connected with modification of many biological pathways such as gene 
regulation, signalling and cell metabolism. Although it is recognised to be induced by 
various external factors such as carcinogenic substances, inflammations or viruses, it is 
still not fully explained by the somatic mutation theory (SMT) or the tissue organisation 
field theory (TOFT).218  
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Cancer is defined as an abnormal growth of cells caused by multiple changes in 
gene expression.219 The accumulation of new cells results in a new solid growth: a 
tumour that can be benign or malignant. Benign tumours usually stay encapsulated and 
remain localised; as they grow by extension, they alter normal tissue functions by 
pushing them aside. On the other hand, malignant tumours invade and destroy 
surrounding tissues by metastases. As metastatic cells lose the ability to adhere. They 
gain invasive properties and an increased capacity to migrate from the primary tumour 
site to other organs, to grow new mass or tumours through the lymphatic and blood 
vessels, hence they are also called haematological malignancies.201, 220 If those cells 
reach organs that are highly regenerative such as the liver, spreading of the disease can 
be aggravated.  
The alterations in the cell physiology and morphology involved in the malignant 
growths were classified by Weinberg221 as the tumour cell’s ability to: 
• have self-sufficiency in growth signals; 
• be insensitive to growth inhibitory (antigrowth) signals; 
• evade programmed cell death (apoptosis); 
• have limitless replicative potential; 
• sustain angiogenesis (growth of new blood vessels); 
• invade tissues and metastasise. 
All the above pathways are tuned to avoid the tumour cell death and the ability 
of tumour cells to evade the immunosurveillance, they also contribute to their survival 
in the body.222 Although, the immune system is able to detect some tumours, they 
develop the aptitude to escape the immune surveillance through the production of 
soluble immunosuppressive factors and the recruitment of immune cells.223 
b) Detection  
Cancer symptoms are cancer type specific and therefore not always obvious 
enough to detect. The best chances for cancer remission are usually favoured by its 
early detection, even before the symptoms have started and most importantly before 
cells start to metastasise. Frequent check ups and routine tests are usually the first stages 
of detection, especially for prostate and breast cancer. 
The most appropriate non-invasive technique to assess the presence of tumour 
are imaging techniques that give morphological, structural metabolic and functional 
information. The most commonly used is X-ray based in the form of computed 
  58 
tomography (CT). In addition techniques such as ultrasonography, scintigraphy 
(radiodiagnosis) and magnetic resonance imaging (MRI) are also widely used.224 
Imaging is not only used for detection but also for screening, biopsy guidance for 
detection, staging, prognosis, therapy planning, guidance and response, recurrence and 
palliation.225  
If a tumour is found, a biopsy is performed by fine needle aspiration (FNA) or 
core needle biopsy (BPA) to take a sample of the lesion. It is then analysed by 
biochemical tests to assess the stage and the aggressiveness of the tumour. The main 
techniques used are immunohistochemistry to measure the protein expression using 
labelled antibodies and fluorescence in situ hybridisation (FISH) to measure the genetic 
changes.  
c) Therapies 
Even though many treatments, either curative or palliative, are available for 
cancer patients, they are often associated with considerable side effects, mainly due to 
their non-specificity caused by the challenge of differentiating cancerous cells from 
normal cells. The choice of treatment depends on the location of the tumour, its stage 
and aggressiveness; and is generally used post-surgery when the bulk tumours is 
accessible for removal. Targeted therapies such as immunotherapy, hormone therapy 
and angiogenesis inhibitors are treatments that are used alone or in combination with the 
most widely used chemo- and radio-therapy. 
Radiotherapy: is used in 50% of the cancer treatments, it employs radiation 
(usually from X-ray) targeting DNA inside cancerous cells, thus reducing their 
replicating power. There are two types of internal radiotherapy; brachytherapy (solid 
source close to tumour) and radioisotope therapy (radioactive substances are injected). 
Due to its harshness, it comes with both immediate and long-lasting side effects. 
Chemotherapy: is the use of drug molecules that affect cell division, in the form 
of alkylating agents similar to mustard gas and can act as inhibitors, anti-metabolite 
treatments or topoisomerase inhibitors that inhibit the enzyme that unwinds DNA. 226-227 
Chemotherapy usually target fast replicating cells, but unfortunately hair follicle, skin 
and the cells lining the gastrointestinal tract are the fastest growing cells of the body and 
are often damaged. The research in chemotherapy is mainly focussing now on 
improving the treatment by using alternative administration routes and pharmaceutical 
formulations adjusting both the pharmacokinetics and the pharmacodynamics by using 
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liposomal and polymeric drug carrier systems.228  
Anti-angiogenic therapeutics are designed to inhibit the growth of new blood 
vessels (angiogenesis) around the tumour. These are usually highly vascularised with 
blood vessels creating a nutrient supplying networks, in an organ-like manner. 
Commonly they target the inhibition of the vascular endothelial growth factor (VEGF) 
by the means of human antibodies or drugs and have mild side-effects. 
Immunotherapy: exploits the ability of the body’s own immune system to fight 
against various pathogens, especially to respond to tumour specific antigens in order to 
reduce the growth and produce a long-term immune memory, which may reduce 
relapse. Its basis will be outlined in more details below.  
3. CANCER IMMUNOTHERAPY 
a) Cancer vaccine 
Cancer immunotherapy can have different aspects; immunoprotective or 
preventive in the case of cancers that are known to express viral-antigens. One of the 
most common examples is the cervical cancer vaccine that has been used in the 
prevention of infection by the human papilloma virus (HPV) in teenage girls. 
Immunotherapy can also be active, whereby the immune system could potentially be 
trained to recognise cancerous cell markers, therefore making it able to unlock the 
cascade of event to attack them. The concept of cancer immunotherapy stems from the 
proposed function of the immune system, called immuno-surveillance, to protect 
growing tumours. It appears that the immune system is able to control the tumour 
development until it undergoes enough mutations to be able to escape the immune 
system check points.229 
Research is now concentrating on finding new biomarkers that could not only be 
used in cancer diagnosis, but will help to target the therapy towards the most suitable 
treatment and assess the outcome of the therapy. One of the difficulties in oncology 
research is to find specific markers, which have altered expression in tumours compared 
to healthy cells. Fortunately, novel techniques such as proteomics and micro arrays have 
shown promise for their identifications. Cancer biomarkers include mutant genes, RNA, 
proteins, lipids carbohydrates and small metabolites. The mutant genes are separated 
into two categories, oncogenes which are responsible for mutations leading to cell 
proliferation and tumour suppressor genes that are inhibit cell proliferation.230  
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When over expressed they encode for products called tumour associated antigens or 
tumour specific antigens, that can be both used as targets in cancer immunotherapy.231 
The recent emergence of many newly discovered tumour associated antigens, 
thanks to new techniques such as proteomics, is reflected in the number of late stage 
clinical trials.232 Cell-based and protein based vaccines are the most commonly used, 
followed by DNA, virus, antibodies, carbohydrate and mRNA.233 Each of the vaccine 
types has its advantages and drawbacks, but in the research of cancer therapeutics field, 
drug candidates have offered more candidates than cancer vaccines in the last twenty 
years.234 Unfortunately many only show weak immune response thought to be caused 
by the low expression of those over-expressed antigens and the close similarities 
between cancer and normal cells. The weak or moderate immune response is also due to 
the inhibition of the high avidity T cells that are suppressed in the thymus. The T cells 
remaining are only the T reg that do not have the same efficacy in the long term. 
b) Immune system 
Immunity is separated into two components that are linked; innate immunity and 
adaptive immunity. Innate immunity is a non specific response that constitutes the first 
line of defence against pathogens whereas adaptive immunity is specific and varies 
depending on the pathogen.  
Dendritic cells (DCs) are a key player in the immune system as they are at the 
interface of the innate and the adaptive immunity (Figure 37). Naïve, immature 
dendritic cells engulf and process antigens leading to their maturation, recognised by the 
presence of cell surface markers (e.g. CD40, CD80 and CD86) and an increased 
production of IL-12, an interleukin that recruits and stimulates other lymphocytes. Also 
referred to as professional antigen presenting cells (APCs), once matured, they are able 
to transport, process and present antigen fragments to specific lymphocytes (B and T) 
that mediate adaptive immunity. 
Major histocompatibility complex (MHC), also known as the human leucocytes 
antigen system (HLA) in humans, genetically encodes for the MHC molecules that are 
responsible for the presentation of the antigenic peptides. The MHC molecules are 
separated in two classes, depending on their structure and their resulting peptide binding 
clefts.235 Dendritic cells present endogenously processed antigens, as eight to ten amino 
acid long peptides, via MHC class I to the CD8+ cytotoxic T lymphocytes (CTL) which 
are then able to recognise and lyse tumour cells. Exogenous antigens, as 13 to 18 amino 
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acids long peptides, are presented on MHC class II molecules to the CD4+ T helper 
cells.236 In humans, DCs are the only cells in the body that constitutively express HLA 
Class II,237 which is an important target for tumour immunology.238 
 
Figure 37: Interaction between DCs and lymphocytes236 
By involving DCs in the vaccine design, the active therapy can rapidly generate 
an effective response against a tumour antigen, by activating CTLs and simultaneously 
generating an immune memory through the B lymphocytes activated by T helper 
cells.239 The immune system would therefore be able to recognise recurrent tumours and 
prevent relapses. Many studies have used different vaccination modalities to generate an 
immune response in dendritic cells, using different pathogens such as peptides, viruses, 
bacteria, DNA and proteins, that can be part of the vaccine formulation administrated in 
vivo. Dendritic cells can also be stimulated ex vivo when harvested, matured with 
specific antigens and then reintroduced to the body.240 More than 150 clinical trials in 
phase I/II for cancer treatment, mainly melanoma, using or targeting DCs have been 
reported so far. Although showing some results, they are not clinically consistent 
enough to be used in a later phase trial.241  
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c) Peptide vaccine 
Oncogenes or products they encode for, such as proteins and their truncated 
versions, peptides, such as previously identified in-house novel immunogenic HLA-
DR1 and HLA-DR4 restricted class I/II peptides derived from tyrosinase and p53, are 
usually over expressed by tumour cells and could be targeted.242 Compared with cellular 
vaccines, peptide vaccines have the advantage of being similar to existing vaccine 
approaches used for decades in immunization programs against infectious agents.233 The 
use of peptides as a vaccine modality is increasing due to their availability and the ease 
with which they can be manufactured at low cost, but it also introduces some 
challenges. 
Synthetic peptide based vaccines can exhibit low immunogenicity, thought to be 
caused by their rapid biodegradation, the presence of cryptic T cells epitope, the low 
stability of the MHC-peptide complex or simply their overly high purity (aseptic and 
endotoxin-free).243 In addition, APC’s preferentially present endogenously synthesised 
tumour peptides rather than exogenously (or synthetic) derived peptides.244 This can be 
overcome by using recombinant viruses that encode for the epitope. The peptide can be 
released within the cell by introducing a multi-epitope spacer, such as small peptides 
AAA and NKLR, which contain three trypsin-like cleavage site associated with the 
proteosome.245  The choice of the spacer may have its importance as for example using 
arginine rich peptides can help to cross the cell membrane barrier or aid the 
endocytosis.246 The low immunogenicity of highly purified or synthetic antigens, can 
also be increased by the choice of an appropriate adjuvant in the vaccine formulation.243 
d) Vaccine adjuvant 
A vaccine adjuvant is defined as any component co-administered with vaccines 
antigens or strategy that improves the adaptive immune response or that stimulates the 
innate immune system to induce desired effectors or mediators. In vivo, adjuvant effects 
can be divided into delivery and immune potentiation based on their mechanism of 
action.247 Individual adjuvants have often more than one mechanism or more than one 
characteristic. Adjuvant or delivery systems have the ability to stimulate humoral, 
cellular and mucosal immune responses and induce not only innate but also memory 
immune responses. This was illustrated by Glaxo Smith and Kline’s research for the 
melanoma vaccine MAGE-3, that has seen significant improvement by transforming 
their adjuvant mix.233 Many treatments have been improved by adding some immune 
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stimulatory molecules and nine successful formulations with varied approaches (e.g. 
Oncophage, BiovaxID, Melacrine, CreaVaxRCC, Hypercell, OncoVax, dSlim/Midge, 
CimaVax EGF, Provenge) are now on the market. Vaccines based on mixtures of 
tumour peptides with strong adjuvants like Toll-Like Receptor (TLR) agonists can be 
potent inducers of the immune response.229 
Today the most common licensed vaccine adjuvants for humans, throughout the 
world are salt based, i.e. aluminium hydroxide, aluminium phosphate and calcium 
phosphate. Oil-in-water emulsion like the incomplete freund adjuvant (IFA) are only 
used in animal models but MF59, a similar nano-sized adjuvant composed of 
nanodroplets (< 250 nm) with strong immunogenicity, was approved for human use 
outside the USA. Other potential adjuvants are products of bacteria like 
lipopolysaccharides (LPS) and their synthetic derivatives (liposomes), which are also 
widely used. 
 
e) Nanomaterials as cancer vaccines adjuvants 
 
Figure 38: DC interactions with nano-sized materials. Targeting receptors with (a) Antibodies (i.e 
anti-CD11c) or (b) danger signal, internalization through (c) phagocytosis or (d) receptor 
mediated endocytosis. (e) Release of the internalised antigen in the cell. 248 
(c) 
(a) (b) 
(d) 
(e) 
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Novel nanoparticle based delivery systems or vaccine adjuvants considered for 
cancer immunotherapy usually target dendritic cells to deliver the antigen,249 as they 
have the ability to interact with biomaterials (Figure 38).248 Their interaction on the 
especially on the nano-meter scale is achieved; either by binding them to receptors that 
then trigger internalization through endocytosis (e.g. mannose-grafted particles) or by 
controlling their size. They can also simply be internalised by macropinocytosis (using 
nanoparticles in the size range of macromolecules) or phagocytosis (using 
microparticles) without specific recognition.  
A number of nanoparticle based vaccine adjuvants and delivery systems are still 
under investigations but are not yet approved by the FDA or MHRA as seen in Table 4. 
Although many are showing good promise, they have not always reached the market as 
their toxicity is still not well understood.250 
Adjuvant type Application 
Viral vectored vaccines Non replicating virus containing genetic material 
Virus-like particles and 
virosomes 
Like viral vector without genetic material 
Immunostimulating 
complexes (ISCOM) 
ca 40 nm cage-like particles composed of protein antigen, 
cholesterol, phospholipids and saponin adjuvant Quil A 
Monophosphyryl lipid A MPL®an immunostimulating TLR-4 receptor antagonist 
composed of detoxified LPS 
Calcium phosphates 
nanoparticles 
made of a mixture of calcium chloride, sodium phosphate 
and sodium citrate 
Polymeric nanoparticles biocompatible and biodegradable approved for use in 
human use in vaccine 
Non-degradable 
nanoparticles 
from gold, latex, silica or polystyrene 
Liposome phospholipids bi-layer shell with aqueous core, 
encapsulation in the core or buried in the non-viral lipid bi-
layer or absorbed on the surface 
Table 4: Example of nano-based adjuvant 
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C. AIMS AND OBJECTIVES 
Immunotherapy is an appealing treatment for cancer as it can induce a long 
lasting protection against the reoccurrence of tumour cells. Unfortunately, it has many 
drawbacks including targeted delivery. When using immunogenic peptides, derived 
from oncogenic proteins, such as p53, it often requires the need of an adjuvant that can 
be engineered to increase its potency and selectivity. This can be achieved by the 
attachment of target molecules for specific receptors or by size modification, as 
dendritic cells, professional antigen have shown to favour the processing of 
nanoparticles. This programme of work aims to investigate the potential of nano-
scaffolds, based on multi-functional calixarene macrocycles, as vectors systems for 
immunogenic peptides towards the formulation of a peptide based cancer vaccine using 
the p53 model, as represented in Figure 39. 
The first objective investigates the synthesis and full characterisation of a library 
of molecular building blocks that demonstrate potential to self-assemble into nanometre 
scale scaffolds to anchor immunogenic peptides. The molecular building blocks are to 
be based upon resorcin[4]arene and pyrogallol[4]arene macrocycles with accessible 
terminal groups, including primary alcohols, amines and carboxylic acids to covalently 
attached peptides. The self-assembly of these molecular building blocks into 
supramolecular nanometre scale scaffolds will be investigated in both the solid-state and 
solution, using X-ray crystallography, electron microscopy, dynamic light scattering 
and multinuclear one and two dimensional NMR techniques including pulse filled 
diffusion.  
To demonstrate the potential of downstream implementation of this technology 
and to investigate high throughput screening of these molecular building blocks, the 
rapid synthesis of these materials, via microwave irradiation and polymer bound 
supports, will be investigated towards the high throughput synthesis of novel materials 
in high yield with minimal purification requirements. Lead molecular building blocks 
will be investigated for toxicity and inertness in vitro. This work involves heamolytic 
properties on red blood cells and their effect on dendritic cells. The latter will be 
assessed by studying the effect of varying concentration of the lead macrocycle on the 
viability and proliferation of the cells.  
Known immunogenic peptides based on the p53 model will be synthesised 
alone, with bio-cleavable linkers, such as tri-alanine linker, and fluorescently labelled. 
Synthetic methods to attach these peptides to the bioavailable mol
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will be investigated; these methods include traditional peptide coupling reactions and 
combined polymer support microwave irradiation techniques. The potential of nano-
scaffolds as peptide pro-drug systems for model peptides will be investigated both in 
vitro and in vivo, using a p53 mouse model, and compared to the model peptides on 
their own and combined with a traditional adjuvant IFA.  
 
 
 
Figure 39: Representation of the optimal calixarene based nanovector. 
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CHAPTER II: APOLAR FOOTED CALIXARENES 
Although pyrogallol[4]arenes are well studied, their synthesis has remained 
unchanged for the last hundred and thirty years. The use of greener techniques, such as 
a solvent-free method54-55 and the new microwave-assisted synthesis described 
herein,251 allow not only the rapid synthesis of this class of macrocycle but also ensure 
the formation of the rccc cone conformation that is needed to form higher self-
assemblies such as hexameric capsules.74 The aliphatic derivatives being the most 
studied of all, their investigation provides a good basis for the optimisation of the 
greener synthesis.252 In order to demonstrate that this selective control over the 
stereoisomer formation of both the resorcin[4]arene and pyrogallol[4]arene 
conformation have been maintained, aromatic as well as heterocyclic compounds, 
inherently known to form the rctt chair conformation, were also investigated.  
A. MICROWAVE SYNTHESIS 
From the modified conventional domestic microwave oven to specific 
microwave reactors, microwave energy is now widely used as a greener tool for organic 
synthesis.253 Exploiting the electromagnetic irradiation between IR and radiofrequency, 
within a frequency range of 0.3 to 300 GHz,254 microwave-assisted organic synthesis 
(MAOS), adapted from conventional microwave has been used since the 1970s.253 
Based on the same principle, domestic microwaves are multi-modal which means that 
the waves are produced in multiple directions whereas chemistry specific microwaves 
are mono-modal. The wave is directed onto the reaction vessel, creating a constant wave 
independent of the stirring, which may interfere. Any material with a dielectric constant 
is able to absorb the energy and convert it to heat. It is controversially thought that the 
microwave also has its own effect, mainly due to the fast heating profile that cannot be 
reproduced by using conventional heating.254 The monitoring of the temperature inside 
the reaction mixture can be done using infrared sensors (external, -40 to 400 °C) or a 
fibre optic probe (internal, 0 to 330 °C). The reactions can also be done under controlled 
pressure in a sealed vessel or at atmospheric pressure (open-vessel).  
Two synthetic chemistry microwaves are dominating the market, the Biotage 
Initiator™ 60 and CEM Discover-SP™ instruments, their main differences rely on their 
waveguides, which are rectangular and circular respectively, and the CEM also allows 
open vessel reactions whereas controlled pressure is necessary in the Biotage system. 
Microwave irradiation has emerged as a versatile tool for organic synthesis using its 
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ability to reach high temperatures rapidly via electromagnetic waves and has found 
applications in a wide range of reactions.255 The synthesis of calixarene macrocycles is 
no exception and is a considerable improvement from the traditional synthesis that can 
take up to five days.256 Calixarene derivatives have only been reported to be synthesised 
in microwaves in the last four years, Brönsted acid39 and tungstophosphoric acid, 
Keggin type can be combined with microwave irradiation to synthesise 
resorcin[4]arenes.56 This work was later developed to include the pyrogallol[4]arene 
macrocycles.57 However, in all cases when highly hindered substituted aldehydes such 
as aryl or tolyl are used, like in the conventional heating method, the favoured 
diastereoisomer is rctt chair conformation. 
 
B. ALIPHATIC 
In order to ensure the conformation of the macrocycles, the following method 
has been tuned to produce the rccc stereoisomer, as the major product, independently of 
the pendant chain length or steric hindrance; thereby, substantially increasing the 
accessibility to a wider range of diverse macrocycles via greener technologies. 
Additionally, by controlling the reaction conditions, the work-up procedure was reduced 
to a simple filtration.251 The general procedure consisted of premixing equimolar 
quantities of resorcinol or pyrogallol with an aldehyde in an acidic reaction medium. 
The reaction vessel was sealed and subjected to microwave irradiation for five minutes 
at a constant temperature of 100 °C using a CEM Discover-SP™. Upon cooling, the 
rccc product crystallised from solution, whereupon it can be collected by filtration as 
the pure product. 
 
Scheme 8: Synthesis of resorcin[4]arene (R = H) or pyrogallol[4]arene (R = OH) with alkyl (R’) 
or aryl (Ar) chains 
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1. CONFORMATIONAL STUDIES 
The rapid synthesis of the macrocycles using this microwave technique has 
enabled the exploration and the study of the effects of the varying reaction conditions on 
the formation of the different stereoisomers. These studies were conducted, on the well-
studied, C-butyl-pyrogallol[4]arene as a model synthesis.17-18 The effects of changing 
reaction conditions including time, temperature, solvent and acid catalyst were assessed 
and are summarised in Table 5.  
Time 
(min) T( °C) Solvent 
Yield 
(%) 
rccc 
a
 
(%) 
 Time 
(min) T( °C) Solvent 
Yield 
(%) 
rccc 
a
 
(%) 
1 Oligomer b  40 Oligomer b 
2 57 77  60 Oligomer b 
3 65 79  80 77 85 
4 60 80  120 Decomposed b 
5 73 83  
5 
140 
EtOH 
Decomposed b 
6 76 86  MeOH 56 66 
7 79 86  nPrOH 40 88 
8 66 83  nBuOH 76 96 
9 72 86  EtOAc 25 96 
10 
100 EtOH 
70 86  
5 100 
H2O 56 4 
Table 5: Conformational study of the microwave-assisted synthesis of C-butyl-pyrogallol[4]arene    
a Stereoisomer yields based on 1H NMR integration. b Product was not isolated.  
To assess the stereoisomeric control caused by the varying synthetic parameters, 
the crude product of the reaction was isolated via precipitation with water. The 1H NMR 
spectrum of the precipitate, in d6-DMSO, displayed one triplet with a chemical shift 
around 4.10 ppm, as highlighted in Figure 40. The satellite triplets around 4.10 ppm can 
be attributed to the unreacted aldehyde or the oligomer. The main difference in the 
aromatic region (6.5 – 7.5 ppm) is indicative of the presence of both stereoisomers. 
When in the rccc cone isomer; only one singlet is present at 6.85 ppm, whereas when in 
the rctt chair isomer, two singlets are present in the aromatic region at 6.85 ppm and 
6.77 ppm (2 ArHhorizontal and 2 ArHplanar). The relative percentages of both stereoisomers 
present in the crude product were assessed by 1H NMR integration techniques. 
Integration of the characteristic singlet for the pyrogallol aromatic proton at 6.85 ppm, 
was normalised to 1, and the integrations of the characteristic triplets of the rctt 
conformation were measured. In all cases, the rccc product was observed to be the 
predominant configuration. There was no evidence of the rcct isomer in any of the 
crude products. 
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Following the reaction over time revealed the exposure time did not influence 
significantly influence the formation of the rctt isomer, as it remained constant after six 
minutes. This is illustrated in Figure 40, that shows the time-lapsed 1H NMR spectra 
overlay.  
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Figure 40:Effect of reaction time on the overall 1H NMR spectrum of C-butyl-pyrogallol[4]arene 
However, higher yields were obtained with increased reaction times, Figure 41 
illustrates the relationship between time and yield, before two minutes only the linear 
oligomers are present and therefore yields and percentage of rccc could not be 
calculated. There is no linear relationship between time and yield over ten minutes. The 
overall formation of the rccc stereoisomer appears favoured with prolonged exposure to 
microwave irradiation, from 57% after two minutes irradiation to a higher yield of 70% 
after six minutes. 
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Figure 41: Overall yield (crude) and rccc stereoisomer yield depending on microwave irradiation 
time (min) 
As shown in the characteristic region of the 1H NMR spectrum (Figure 42), the 
macrocyclic product was only observed when the temperature was allowed to increase 
above 60 °C. Below these temperatures (i.e. 40 °C), only linear oligomers were isolated 
as waxy compounds that have several aromatic peaks between 6 and 6.5 ppm. As the 
temperature increases, the relative percentage yield of the rccc stereoisomer remained 
constant. However, when the temperature was further increased to 120 °C and above, 
the compound starts to decompose, maybe due to ring opening, back into the non-
cyclised oligomer, this can be seen by the similarity of the 1H NMR spectra for 40 °C 
and 140 °C. 
 
Figure 42: Effect of temperature on the characteristic region of the 1H NMR spectrum of C-butyl-
pyrogallol[4]arene 
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As the formation of the conformers is reported to be an equilibrium,44 it can be 
displaced by selecting the reaction media that precipitates as the desired product (Figure 
43). In order to change the reaction media, several solvents were considered. Ethyl 
acetate and acetonitrile are well known to favour the formation of the hexameric 
capsule; however, the latter could not be used in this study as it was found to form the 
ammonium salt in presence of strong acid such as hydrochloric acid. 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
MeOH EtOH nPrOH nBuOH EtOAc H2O
Reaction solvent
% rccc  Yield (%)
 
Figure 43:Overall yield (white) and % rccc (red) depending on the solvent system 
As seen in Figure 44, the formation of the macrocycle is reported to proceed via 
the acetal form of the aldehyde in situ,47 which subsequently reacts with the phenol, 
therefore a selection of alcohols were considered. Switching the solvent from ethanol to 
water resulted in a negligible isolated yield. This is due to the equilibrium of this 
condensation reaction being driven to the left, thereby preventing the reaction from 
going to completion. In contrast, the insolubility of the rccc isomer in ethanol drives the 
equilibrium towards the product. Remarkably, when ethyl acetate was used as the 
solvent system the rccc isomer crystallises out of the reaction media on cooling as the 
nanometre scale hexameric assembly but with a low yield.82 The steric bulkiness of the 
acetal function was thought to play a predominant role in influencing the formation of 
one conformation over the other. As the length of the alcohol chain was increased from 
methyl to butyl, the yield of the rccc macrocycle was increased. Hence, by increasing 
the bulkiness of the acetal, the possibilities to interchange conformations were lowered. 
The lowest yield, obtained from propanol, may be due to a solubility issue more than its 
steric hindrance. The disappearance of the rctt isomers in the crude product is clearly 
visible in the overlay of the 1H NMR spectra, (Figure 45) especially around 7.2 ppm. 
H2O 
  73 
 
Figure 44: Proposed acetal mechanism 
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Figure 45: Effect of the solvent on the overall 1H NMR spectrum 
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The solid state molecular structure obtained from slow diffusion of water into a 
solution of C-butyl-pyrogallol[4]arene in DMSO, shows that the solvent coordinates to 
the upper rim hydroxyl groups of the pyrogallol (Figure 46). The cone conformation of 
pyrogallol[4]arene is maintained by four intramolecular hydrogen bonds from 2.762 Å 
(O3…O4) to 2.817 Å (O6…O7). However, in the presence of strong polar solvent such as 
DMSO, the eight remaining phenolic groups are strongly hydrogen bonded to DMSO 
molecules that is reflected by the shortening of the hydrogen bond lengths from 2.711 Å 
(O2…O14) to 2.635 Å (O7…O16). From this X-ray study, it was deduced that this 
hydrogen bonding interaction could disturb the pre-organisation of the cone rccc 
stereoisomer during the condensation reaction. DMSO was therefore introduced to the 
reaction solvent (ethanol) to reduce the possibilities of intramolecular hydrogen bonding 
in the tetramer leading to the formation of the rctt stereoisomer. Surprisingly, the 
addition of DMSO had no significant effect on the overall yield or stereoisomer ratio, 
suggesting that the hydrogen bonding capability of the solvent has little effect on the 
macrocycle formation. 
 
Figure 46: Molecular projection of the C-butyl-pyrogallol[4]arene DMSO clathrate: (a) top view 
of two rccc  symmetrical cone configured macrocycles, hydrogen bonded together via two DMSO 
bridges, (b) 3 DMSO clathrate, hydrogens have been omitted for clarity 
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Substitution of the acid catalyst from hydrochloric acid to acetic acid, in the 
absence of any additional solvent, prevented the reaction from proceeding to the desired 
product. However, when pTSA was used as the acid catalyst in ethanol, over 70% of the 
rctt product was isolated. The addition of acetic and formic acid to a 25% hydrochloric 
ethanolic solution, to change the acidity and solubility, resulted in lower overall yields, 
whilst retaining the rccc conformation as the predominant stereoisomer. 
 To facilitate both the recycling of the catalyst and towards developing a flow 
reactor, a switch from homogeneous to heterogeneous conditions was investigated. 
Preliminary experiments involving solid acidic zeolites, including K10-montmorillonite, 
silicates (HMFI, HFAU), sodium mordenite (Na-MOR) as well as aluminium oxide 
were attempted. However, yields were far from comparable to the homogeneous acid 
conditions. These foulings may be caused by the heterogenous character of the catalysts. 
In addition, the pores sizes may restrict the access to the catalyst leading to the 
formation of the macrocycle or clogging the zeolites rendering them inactive, this could 
be potentially overcome by the use of ultrasound incorporated into the reactor design. 
2. SYNTHESIS 
 Using this greener synthesis tuned to predominantly yield the rccc stereoisomer, 
a series of pyrogallol[4]arenes 1-4 and resorcinarenes 5-8, with increasing pendant 
chain lengths were chosen as representative samples. All reactions were conducted on a 
gram scale and the products were characterised using 1H and 13C NMR techniques and 
MALDI-TOF mass spectrometry. In order to isolate any potential rctt isomer, distilled 
water was added to the reaction medium and the precipitate was subsequently collected 
and characterised. Potentially, any unreacted starting materials and solvent can then be 
readily recycled.  
Yields and NMR chemical shifts for macrocycles 1-8 were consistent with the 
literature values compared to the isolated stereoisomers synthesised using traditional 
techniques.82-83 There is no linear relationship between the increase of chain lengths and 
the overall yields; however, it is noticeable that they are usually higher for 
resorcin[4]arene than pyrogallol[4]arenes. It can be assumed that the presence of the 
extra hydroxyl group on pyrogallol may have an interfering role in the stabilisation of 
the aromatic ring during the cyclisation. Crystalline materials isolated from the crude 
reaction media were further investigated by single crystal X-ray analysis. In all cases, 
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the molecular structure was that of the rccc isomer as a solvated clathrate, with 
crystallographic measurements and their unit cells consistent with literature values.44 
 R R' %Y m/z 
[M+Na]+ 
 R R' %Y m/z 
[M+Na]+ 
1 OH (CH2)CH(CH3)2 85 799 5 H (CH2)CH(CH3)2 90 735 
2 OH (CH2)2CH3 61 743 6 H (CH2)2CH3 96 679 
3 OH (CH2)3CH3 62 799 7 H (CH2)3CH3 67 735 
4 OH (CH2)4CH3 68 855 8 H (CH2)4CH3 84 791 
Table 6: Microwave-assisted synthesis of calixarene macrocycles 
  
C. AROMATIC  
Aromatic resorcinarene macrocycles have received much interest in the last 
years, due to their ability to extract cations such as caesium, strontium,257 lead, 
chromium258 and lanthanum.259-261 They have been investigated for their ability to 
extract other aromatics from water solution262 Alt’shuler et al. used a different approach 
to form hydrated polymers,263 and investigated their ability to react with quaternary 
ammonium264 and to form cationite.265 Phenyl-pyrogallol[4]arenes derivatives were 
considered as alternative compounds for lithography.266 Their ability to form star-
shaped initiators for radical polymerisation is another one of their potential uses.267-268 
Aromatic resorcinarenes have the ability to interact with biologically relevant 
compounds such as amino acids269 and proteins.270 Only a few exhibit the rccc 
conformation, like the seven resorcinarenes derivatives that were synthesised as high 
resolution resistant materials for supercritical CO2 processing, which appeared to be all 
in the rccc isomers.271 In most applications, the interactions with guest and the 
extraction power is driven by the all cis conformations. However, in 2001, the original 
greener method showed that it is complex to predict the isomeric ratio that will be 
obtained during the reaction.54 Although the same reaction conditions were applied to 
for each aromatic aldehyde, Scheme 9,  the reactions led to different rccc: rctt isomer 
ratios of 2:1 for the o-OH, p-O(CH2)3CH3, p-(CH2)4Br and p-NO2 but 95:5 for the p-
O(CH2)7CH3.  
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Scheme 9:Solvent-free synthesis of aromatic resorcin[4]arenes54 
It is reported that the rctt isomer can be converted to the rccc by complexation 
with pentacoordinated zinc(II), even when bulky group such as benzyl and naphthyl are 
used.103 The main drawback to this method is the presence of the metal that will reduce 
the coordination potential of the calixarenes. As it is not always easy to separate the 
different isomers, the selective control of the conformations is therefore needed. 
Hoegberg reported the first synthesis of aromatic resorcinarene in the rccc 
conformation.256 He stated that the stereoselectivity is a result of a combination of three 
main factors: the conformational control via the non-bonded interactions within the 
intermediate, the reversibility of the C-C bond formation and the difference of solubility 
of the two macrocycles. The rccc is the thermodynamic product whereas the rctt is the 
kinetic product; therefore, time is thought to play an important role. An extensive study, 
which included a wide variety of aromatic substituted resorcinarenes, confirmed 
previous findings. They also drew attention to the character of the aldehyde, that may 
have a steric effect as well as an electron withdrawing effect i.e. a strong electron 
withdrawing effect lead mainly to the rctt isomer.21 Using this traditional synthesis 
many aromatic derivatives have been synthesised all in the rctt.257 The choice of the 
catalyst is essential, when using lanthanide salts of p-toluenesulfonic acid as the acidic 
catalyst seems to favour the rctt diastereoisomer.260 Whereas, a new synthesis of the 
resorcinarene derivatives by the condensation of an aldehyde and a 
methoxyhydroxybenzene with another Lewis acid, BF3.OEt2, only lead to the C4v 
conformer where all substituents are in the cis position.272 Using another Lewis acid 
such as tin tetrachloride also led to the rccc isomers of octamethoxyresorcin[4]arenes in 
a 85% yield.51  
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1. SYNTHESIS 
The selective control of the conformation was attempted, using the method that 
was optimised for the alkyl derivatives and aromatic footed macrocyles 9-16 were 
isolated. Usually the presence of a bulky group such as a benzene ring, leads to the 
formation of another diastereoisomer, the rctt, to sterically accommodate the subsituent, 
but as explained previously, the bulkiness is not the only factor. Methods developed by 
others with a different solvent such as ethoxyethanol using microwave irradiation for 
only two minutes was showed to favour the kinetic product rctt.57 Interestingly all 
derivatives synthesised by Han et al. were also in the rctt conformation except for the 
ferrocenyl derivative that was exclusively in the rccc.145 Those results led to the 
assumption that similar behaviour would be observed, however, the utilisation of our in-
house method, when followed by a recrystallisation of the crude product from 
methanol-acetonitrile 1:1, showed that mainly the rccc isomers were present.  
N R R' Yield 
(%) 
m/z 
[M+Na]+ 
N R R' Yield 
(%) 
m/z 
[M+Na]+ 
9 OH C6H5 66 879 13 H C6H5 72 805 
10 OH o-tolyl 30 935 14 H o-tolyl 44 848 
11 OH m-tolyl 94 935 15 H m-tolyl 96 848 
12 OH p-tolyl 87 935 16 H p-tolyl 94 848 
Table 7: Microwave-assisted synthesis of aromatic calixarene macrocycles 
The 1H NMR data and the crystal data obtained for a series of aromatic 
resorcinarenes and pyrogallolarenes showed that the all cis were obtained as the 
predominant isomers. Although not in the cone conformation due to steric hindrance as 
well as its reduced flexibility, if the rccc isomer is formed with aromatic substituents it 
is usually in the pinched cone (boat) conformation.273 This conformation is rarely 
obtained as such even when microwave irradiation has been employed in the past. These 
macrocycles containing bulky pendant chains may offer interesting features such as 
novel inclusion complexes and new carcerands.  
In addition to the mechanism of the reaction, proposed by Weinelt,46 it can be 
assumed that the electrophilic cyclisation is achieved by a relatively stable benzylic 
carbocation, stabilised by the phenolic ring. This was confirmed by Middel,274 as he 
proved that the higher electron density of methyl resorcinol increased the rate of 
electrophilic attack. This may explain why the aromatic resorcinarenes 13-16 gave a 
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better yield than the pyrogallol[4]arenes 9-12. As the tolyl aldehydes gave better yields 
than the benzaldehyde reactions, it can be assumed that the presence of an aromatic 
substituent may increase their stability, especially if they contain ortho and para 
directing groups, as the electron donation is favoured by the hyper-conjugation from the 
methyl groups on the final canonical, as seen in Figure 47. 
 
Figure 47: Stability of the carbocation due to mesomeric effect 
The o-tolyl derivatives (10 and 14) were obtained in very low yield (< 44%) 
compared to the meta and para derivatives which is mainly due to steric hindrance. The 
bulkiness of the tolyl methyl group close to the methine bridge impedes the cyclisation 
of the oligomer, which leads not only to a lower yield but also to lower ratio of rccc to 
rctt isomer. Interestingly, the presence of the methyl substituent at the meta position 
leads to an increased in yield, this is due to the mesomeric effect, but still leads to the 
rccc isomer, in favour of the rctt isomer. The p-tolyl is also obtained in high yield 
(94%), this can be explained by the favoured stabilisation of the benzylic carbocation as 
well as the reduced steric hindrance. 
2. CRYSTALLOGRAPHY 
Suitable crystals of C-phenyl-pyrogallol[4]arene 9 were obtained by slow 
evaporation from acetonitrile, exhibiting the rccc boat conformation in the monoclinic 
space group C2/m, with a unit cell a = 20.913(3), b = 21.667(3), c = 11.3077(14) Å, β = 
116.490(16)º and V = 4585.9(10) Å3. Due to the long distances between the oxygens, 
4.634 Å and 3.958 Å, the boat conformation does not allow the intramolecular hydrogen 
bonding that is seen in the cone conformation. This change of conformation can also be 
quantitavely assessed as a distortion factor (Df) by the ratio of the minimal aromatic 
distance of the upper rim (4.886 Å) and the maximal separation (10.639 Å), which is 
0.459 in this rccc conformation, as seen in Figure 48. By comparison, it is ca. 1.0 for 
the macrocyle integrated into the hexameric capsule and ca. 0.5 when the macrocycle is 
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reported in the C2v conformation.82, 275  
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Figure 48: Definition of the Distortion factor (Df) 
However, the boat conformation exhibited by C-phenyl-pyrogallol[4]arene 9 does 
not exhibit the C2v symmetry, as the plane going through the pyrogallol ring that is 
involved in the intermolecular bonding, referred to as horizontal, is slightly tilted at -
13.12° angle compared to the plane through the opposite horizontal pyrogallol and the 
four methines of the macrocycles ring as seen in Figure 49. 
 
Figure 49:C-Phenyl-pyrogallol[4]arene 9 side view 
The solvent did not participate in the hydrogen bonding network and therefore 
the four acetonitrile molecules contained in the unit cell have been treated as a diffuse 
contribution to the overall scattering without specific atom positions by the SQUEEZE 
function of PLATON program.276 The rccc isomer enables the formation of a 
º 
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intermolecular hydrogen bonded network within the upper rims with a donor acceptor 
distance ranging from 2.693 Å (O4…O5) to 3.005 Å (O1…O5). 
 
Figure 50:Hydrogen network of the rccc boat C-Phenyl-pyrogallol[4]arenes 9 
Due to the hydrophobic character of the aromatic pendant chains as well as their steric 
hindrance, the packing results in a hollow tubular network. This effect can be visualised 
by introducing planes within the packing system as shown in Figure 51. The plane 
across the axial pyrogallol ring of the macrocycle (in blue) is nearly at a right angle 
(89.91º) to the plane across the horizontal pyrogallol (in red). The inter-planar spacing 
within the tubes is 5.50 Å between the red planes and 4.88 Å between the blue planes. 
 
Figure 51: Plane representation of the packing system for C-Phenyl-pyrogallol[4]arene 9 
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Preliminary single crystal X-ray crystallographic data for m-tolyl-
resorcin[4]arene 15 obtained from slow diffusion of water in DMSO showed the 
pendant chains are also all in the cis position and orientated in order to minimise the 
steric hindrance (Figure 52). Highly polar DMSO molecules are hydrogen bonded to 
each resorcinolic phenol, leaving the shortest distance to another hydroxyl group over 
6.73 Å, so there is no direct intermolecular hydrogen bonding, which is in accordance 
with others findings.277 The hydrogen bond lengths varied from 2.577 Å (O8…O16) to 
2.705 Å (O4…O15), with an average length of 2.663 Å over the eight interactions 
showing that their strengths are similar. The tiltings of the nearly co-planar resorcinol 
are in the same range, i.e. -6.19º and -9.37º compared to the plane constituted of the C-
H groups of the macrocycle (C2-C8-C14-C20), and a distortion factor of 0.49.  
 
 
Figure 52: m-Tolyl-resorcin[4]arene 15 hydrogen bonding interactions with DMSO. 
When DMSO is absent, an interesting packing that involved both hydrogen 
bonding between electronegative atoms occurs, with all the phenolic hydrogens 
involved and a face-to-face Ar-H…π interactions, this behaviour is seen in the solid state 
for p-tolyl-resorcin[4]arene 16. The two nearly coplanar horizontal resorcinols are titled 
by 13.76º and 12.06° in order to maximise the strong intermolecular interactions, this 
results in the approach of the two perpendicular rings and therefore a reduced distortion 
factor of 0.39. 
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Figure 53: Hydrogen bonding network for p-tolyl-resorcin[4]arenes 16 in the solid state 
There are eight independent hydrogen bonds holding the network together, 
involving all the hydroxyls from the resorcinarenes. Distances between the acceptor and 
the donor atoms range between 2.752 Å and 2.782 Å, (O1…O3 = 2.770 Å; O2…O8 = 
2.763 Å; O4…O6 = 2.782 Å; O5…O7 = 2.752 Å). When a centroid is generated in the 
centre of the resorcinolic aromatic ring, it is possible to define the Ar-H…π distances 
(orange dotted line in Figure 53) which range between 3.299 and 3.179 Å, these 
relatively strong interactions due to the inductive effect of the hydroxyl groups on the 
benzene ring.278  
A similar network was reported for the ‘boat’ conformation of C-methyl-
resorcin[4]arene, used as a T-shaped building block when co-crystallised with pyridine. 
The heterocycle can break up the intramolecular hydrogen bonds that usually keep the 
molecule in the cone conformation.279 As seen for the phenyl analogue 9, the packing 
results in a tubular network, as represented in Figure 54, the presence of the Ar-H…π 
interaction, results in a tighter network noticeable by the shortening of the inter-planar 
spacing 5.50 Å and 4.88, to 2.65 Å and 4.64 Å, respectively. 
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Figure 54: Plane representation of the packing system of p-tolyl-resorcin[4]arene 16 ( hydrogens 
have been omitted for clarity) 
As the hydrogen bonding network elongates in the a axis of the unit cell, the 
packing shows hydrophilic-hydrophobic layers with voids able to accommodate atoms 
with 1.2 Å radius in between the aromatic rings, shown in blue in Figure 55. By 
calculating the solvent accessible surface, the volume of the voids is 621.48 Å3 
occupying ca 19% of the unit cell volume which can explain the low density of 0.86 
g.cm-3 of the crystals. Unfortunately, this void is smaller than what is required for 
hydrogen storage that should be around 2.96 Å3 to accommodate H2.280 Nevertheless, 
further studies are required to investigate the structural recognition and reorganisation 
towards such a guest with expanded voids via the coordination of the hydroxyl group to 
various metals, leading to a new type of metal-organic framework. 
 
Figure 55: Voids within the packing system of p-tolyl-resorcin[4]arene 16 
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When the extra hydroxyl is present as in the case of pyrogallol, the Ar-H…π 
interaction is replaced by a supplementary hydrogen bonding, the resulting packing 
system is altered and is similar to its phenyl homologue. This behaviour is seen for m-
tolyl-pyrogallol[4]arene 11, in the boat conformation with a distortion factor of 0.46, 
crystallised from methanol water (Figure 56). Preliminary single crystal X-ray 
crystallography data showed five intermolecular hydrogen bonds with acceptor to donor 
distances ranging from 2.829 Å (O6…O11) to 2.986 Å (O1…O10). The water 
participates to the formation of the network via one hydrogen bond with a length of 
2.697 Å (O12…O13) which contributes to the displacement of the upper rim by 1.81 Å 
compared to the one below. The strongest interaction exists between the water 
molecules giving it a character nearly covalent with a short length of (O13…O13 = 
2.326 Å) compared to the other intermolecular hydrogen. 
 
Figure 56: Packing of the m-tolyl-pyrogallol[4]arenes 11 (hydrogens have been omitted for clarity) 
Similar behaviour is seen for p-tolyl-pyrogallol[4]arene 12, in the rccc boat 
conformation with a distortion factor of 0.49. As seen in Figure 57, seven hydroxyls 
groups are involved in hydrogen bonds, with donor acceptor bond lengths varying from 
2.739 Å (O1…O9) to 2.903 Å (O2…O10), whereas the hydroxyl from the pyrogallol ring 
containing O4, O5 and O6 is not involved in any hydrogen bonding, as the bond lengths 
with other donors exceed 3.2 Å. The solvent molecules were highly disordered and 
therefore the SQUEEZE program, which is designed for small moiety structures 
containing disordered solvent and water, was used.276 The space filled with the 
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electron density was modelled as water (O13) which lies in between O2 and O11 
(O2…O13 = 2.872 Å and O11…O13 = 2.807 Å) and contributes to the highest tilting of 
the bonded pyrogallol by 15.58º. 
 
 
Figure 57: Packing of the p-tolyl-pyrogallol[4]arenes 12  
Surprisingly, some single crystals of p-tolyl-resorcin[4]arene 17 obtained by 
slow evaporation from acetonitrile, show the rctt conformation in the solid state. The 
rctt was considered to be a fractional amount of the isomeric mixture that was able to be 
crystallised, as the NMR of the product confirmed the rccc as the main isomer in 
solution. However, it was possible to distinguish between the two crystal habits, needle 
and plate, which has been previously reported as isomers rccc and rctt respectively.281 
As expected the difference in conformation had a noticeable effect on the crystal 
packing and the hydrogen network. The chair conformation cannot lead to 
intramolecular bonding and therefore, only intermolecular bonding is possible. The 
hydrogen bonding network is mainly formed by the resorcinol perpendicular to the 
phenyl groups (O1…O4 = 2.763 Å). Three remaining phenols are bound to the 
disordered acetonitrile molecules via the nitrogen (O1…N2 = 2.792 Å; O2…N1 =2.862 
Å; O3…N3 = 2.916 Å) which impede the formation of the aromatic hydrogen bonding. 
One acetonitrile lies in between two tolyl groups and contributes to the expansion of the 
packing in the a axis of the unit cell. 
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Figure 58: Hydrogen bonding network of the rctt p-tolyl-resorcin[4]arenes 17 
 
D. HETEROCYCLIC 
By combining both macrocyclic and heterocyclic chemistry, it would be possible 
to create a new type of inclusion complex. Due to the rapidity of the method a wide 
range of aldehydes could be investigated as potential starting material for these 
synthesis. Although some hetero-calixarenes have been reported previously, replacing 
the resorcinolic entities by various heterocycles such as benzofuran, 
benzothiophene,299and pyridine,20, 79 so far only one heterocycle was attached onto the 
pendant chains of the calixarene macrocycle. The next compounds were investigated as 
a proof of principle and have opened up interesting types of compounds with many 
inclusion and self-assembly properties but it was not pursued any further as it was not 
the main focus of this project. 
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1. THIOPHENE 
Inspired by the synthesis of the 2-thiophenyl-resorcin[4]arene that has been 
previously investigated for its ionophore ability towards chromates,282 a novel 
macrocycle was synthesised by reacting 3-thienylaldehyde with pyrogallol under 
microwave irradiation to give C-thiophen-3-yl-pyrogallol[4]arene 18. The reaction led 
to a good yield due to the mesomeric effect into the heterocyclic ring. The presence of 
the thiophene group seems to favour the rctt conformation. Crystals formed by slow 
evaporation of deuterated DMSO exhibit the rctt chair conformation. Unfortunately, 
due to the highly disordered solvent molecules the refinement of the structure was 
limited, and crystallisation from other polar solvents was not successful. However, 
preliminary X-ray data indicates that each phenolic hydroxyl is hydrogen bonded to the 
oxygen of a DMSO molecule, with bond lengths varying from 2.66 Å to 2.85 Å, 
resulting in the bridging of the macrocycles. 
 
Figure 59: Thiophene footed pyrogallol[4]arene 18 solvated with DMSO 
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2. PYRIDINIUM CHLORIDE 
Pyridinium is an interesting building block in supramolecular chemistry, it was 
previously reported that pyridine can bind to the upper rim of the calixarene to form an 
extended cavity,66 and therefore it could be considered that the pyridine footed 
calixarene could form a tubular network and may be useful for ion transport. The only 
pyridinium footed resorcinarene was reported by Pirondini et al. where isonicotinic acyl 
chloride was conjugated to the hydroxyl cavitands and their coordination with various 
metal using the chloride salt were studied.160 The behaviour of their pyridinium 
derivatives with various metals such as palladium and platinum were investigated with 
longer chain hydroxyl cavitands (dodecol) were formed from the alkene derivatives.160 
Using the previously described methodology, the syntheses of pyridinium footed 
calixarenes were attempted leading to the supposed formation of six compounds 19-24, 
by reaction of pyrogallol and resorcinol with 2-, 3- and 4- pyridinecarboxaldehyde. The 
presence of the pyridine required an excess of hydrochloric acid in order to form the 
pyridinium salt. The crystallisation of the calixarenes were not successful, as they 
resulted in glassy compounds; and to date, no crystal data was obtained. The 
preliminary 1H NMR spectra indicate the presence of the potential macrocycles, that 
was further confirmed by MALDI-TOF analysis, however, pure products were not 
isolated. The coordination of a zinc salt was attempted unsuccessfully, as well with 
other salt of platinum, palladium, nickel and silver. Further work will be pursued 
beyond this project to optimise the synthesis and the properties of those novel 
macrocycles as well as their self-assembly in the solid state. 
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CHAPTER III: POLAR FOOTED CALIXARENES 
Using the method optimised for alkyl footed calixarenes, several polar footed 
pyrogallol[4]arenes and resorcin[4]arene were synthesised, via their corresponding 
aldehydes, masked aldehydes or acetals. The synthesis and full characterisation of 
molecular building blocks that demonstrate potential to self-assemble into nanometre 
scale scaffolds as well as covalently anchor immunogenic peptides were investigated. 
This study therefore focuses on targeting pyrogallol[4]arenes and resorcin[4]arenes  
with pendant chains showing accessible terminal groups, including primary alcohols, 
amines and carboxylic acids. Those macrocycles should provide viable starting 
materials for the addition of biologically relevant functionalities. The self-assembly of 
these molecular building blocks into supramolecular nanometre scale scaffolds was 
investigated in solid-state using X-ray crystallography and electron microscopy. 
 
A. HYDROXY-FOOTED CALIXARENES 
The first synthesis of hydroxyl-footed resorcin[4]arene was reported by Cram in 
1989,21 and was adapted later as a precursor in the synthesis of hydroxyl-footed 
extended cavitands as hosts, using dihydropyran and dihydrofuran as masked 
aldehydes.125 Their abilities to bind to neutral guests, to form self-included capsules 
with metals (lanthanide) and cations (ammonium and phosphonium) have been widely 
investigated.283-285 The latest research around these entities demonstrates their potential 
as new building blocks when transformed to water soluble phosphate footed cavitands. 
The addition of a single hydroxyalkyl pendant chain to the lower rim of 
resorcin[4]arene was achieved by mono-epoxidation of an alkene.158 These new 
materials have found applications in modified stationary phases via of the attachment of 
the pendant chains to polymer supports, like cross linked polystyrene.163 
Extended cavitands such as dendronized derivatives have been obtained via 
repeated reactions with acetonide protected bis(hydroxymethyl)propanoic acid 
anhydride.286 These materials have been shown to demonstrate some interesting host-
guest chemistry with applications in drug delivery, whereby the control of the guest 
properties is ensured by the cavity and the dendronized exterior give control of its 
physical properties.287  
The alcohol functionalised resorcinarene derivatives are not restricted to their 
cavitands; by considering the macrocycle as a ligand Atwood et al. have been able to 
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exploit their ability to form capsules via the coordination of twenty-four copper (II) ions 
to six C-3-hydroxypropyl-pyrogallol[4]arenes. This assembly is isostructural to its 
hydrogen bonded hexameric capsule analogue with an internal volume of 1200 Å3. It is 
proposed that the hydrogen bonded capsule is pre-formed prior to the insertion of the 
metal.79, 100 
In the study towards the development of polar soluble nanocapsules, as potential 
guest transport systems, C-3-hydroxypropyl-pyrogallol[4]arene 25 was synthesised 
using the microwave-assisted method previously described, by reacting equimolar 
quantities of pyrogallol and 2,3-dihydrofuran in acidic ethanol (25%) at 100 ºC for 10 
minutes in a 33% yield (Scheme 10). To see the effect of an additional carbon in the 
pendant chain, C-4-hydroxybutyl-pyrogallol[4]arene 26, was synthesised using dihydro-
2H-pyran in a 32% yield.251 By utilising this new technology, the reaction times have 
been dramatically reduced from one week to a matter of minutes; although with 
marginally lower yields than the synthesis reported.125 The work-up procedure is also 
reduced to a single filtration after trituration with water. 
 
Scheme 10: Synthesis of C-4-hydroxybutyl-pyrogallol[4]arene 26 
1. C-3-HYDROXYPROPYL-PYROGALLOL[4]ARENE 
Suitable crystals for single crystal X-ray crystallography were obtained directly 
from the reaction vessel upon cooling (Figure 60). The excess hydrochloric acid and 
ethanol present in the reaction media play an integral role in the hydrogen bonding 
network. The hydrogen bonding interaction between the chloride and a single phenolic 
hydrogen at the upper rim (H10…Cl- = 2.342 Å and O10…Cl- =3.072 Å) indicates that 
the chloride is in the anion form, as suggested by the computational gas phase 
studies.278 Similar behaviour was seen when an ammonium cation was encapsulated 
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within two resorcinarene macrocycles, whereby the counteranion coordinates to the 
resorcinolic alcohol.288-289  
The presence of the anion that lies in between the pendant chains, may also have 
a role in the hydrogen bonding of the chains as they are directed towards the inside of 
the cavity although O15 and O16 are close enough (2.841  Å) to form a hydrogen bond 
in the solid state.  
 
Figure 60: C-3-hydroxypropyl-pyrogallol[4]arene 25 ethanol hydrochloride obtained from the 
reaction vessel 
The solid state structure of C-3-hydroxypropyl-pyrogallol[4]arene 25 
crystallised from HCl and ethanol shows that the chloride anion is enveloped between 
three of the pendant propanol chains, at the annulus of the macrocycle. As shown in 
Figure 61, the fourth propanol chain is oriented almost perpendicularly with respect to 
the other three (73º) and can be seen to hydrogen bond to a single ethanol molecule 
(O14…O17 = 2.783 Å) and to an equivalent propanol chain on an adjacent macrocycle 
(green) (O14…O14 = 2.994 Å). The hydrogen bonding network is further extended via 
the interplay between this pendant propanol chain and phenolic group of a third 
macrocycle (O12…O14 = 2.681 Å). The third macrocycle (red) is orientated in the same 
direction as the first macrocycle (blue); however, the central axis are offset by 80º with 
respect to one another, as shown in Figure 61. These two macrocycles are further 
tethered via a hydrogen bonding interaction between the two phenolic upper rims 
(O2…O6 = 2.927 Å).  
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The two upper rims of these macrocycles are bridged by a transverse macrocycle 
(green) where there is a offset head-to-head hydrogen bonding network between the 
phenolic groups, as illustrated in Figure 61 (O2…O8 = 2.672 Å, O3…O9 = 2.899 Å, 
O8…O7 = 2.847 Å, O4…O11 = 2.813 Å, O7…O7 = 2.850 Å). 
 
Figure 61: Interplay of the propanol chains containing O14 of C-3-hydroxypropyl-
pyrogallol[4]arenes 25 (hydrogens have been omitted for clarity) 
This extended hydrogen bonding network results in macrocycles packing into a pseudo 
hexagonal motifs along the c axis, represented by dotted lines in Figure 62. 
 
Figure 62: Pseudo hexagonal packing along the c axis of C-3-hydroxypropyl-pyrogallol[4]arenes 
25 (hydrogens have been omitted for clarity) 
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The macrocyclic cavity can be seen to accept a single ethanol guest molecule 
(Figure 63a), that is anchored into place via two hydrogen bonding interactions, 
between the methylene hydrogens of the guest with the electron rich faces of the 
aromatic pyrogallol host (centroid C3 C4 C5 C6 C7 C25…H41A = 2.998 Å and centroid 
C15 C16 C17 C18 C19 C27…H41B = 2.698 Å). 
The ethanol guest is entrapped by an offset head-to-tail open capsule, formed 
between the upper phenolic groups of one calixarene and the three pendant chains of a 
second pyrogallol[4]arene, which envelop the chloride as mentioned previously 
(O8…O16 = 2.892 Å) (Figure 63b). This results in the hydroxyl group of the ethanol 
guest forming an hydrogen bond bridge between two of the three propanol chains that 
make up the open capsule (O18 … O13 = 2.438 Å, O18…O16(A) = 2.584 Å). This 
second interaction of the second chain explains the disorder over two positions 
experienced by O16. 
 
Figure 63: Entrapment of ethanol by C-3-hydroxypropyl-pyrogallol[4]arenes 25 (a) within the 
cavity and (b) wih the neighboring pendant chains (hydrogens and pendant chains have been 
omitted for clarity) 
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When the same C-3-hydroxypropyl-pyrogallol[4]arene 25 is crystallised from 
wet ethanol, a four component capsule can be seen to form and then trap two ethanol 
guest molecules within a cavity of ca 110 Å3.290 As shown in Figure 64, the capsule is 
comprised of the head-to-head arrangement of two macrocycles, seamed together via 
four phenolic hydrogen bonds (O2…O7 = 2.849 Å, O8…O3 = 2.800 Å). The two 
macrocycles are displaced by 4.1 Å with respect to the two C4 axis of the two 
pyrogallol[4]arenes. This offset dimeric capsule is closed by two sets of two propanol 
chains from two independent calixarenes via eight hydrogen bonds with the upper rims 
(O1…O14 = 2.743 Å, O6…O14 = 2.726 Å, O4…O15 = 2.741 Å, O9…O15 = 2.854 Å).  
 
Figure 64: Hydrogen bonding network forming the dimeric capsule comprised of two C-3-
hydroxypropyl-pyrogallol[4]arenes 25 (hydrogen, upper rimss and pendant chains have been 
omitteded for clarity) 
As shown in Figure 65, two ethanol guest molecules occupy 87% of the 
available volume of the cavity. This extremely strong packing is due to the presence of 
two hydrogen bonds between the guest molecules and the hydrogen bonded seamed 
capsule (O5…O17 = 2.729 Å and O14…O17 = 2.853 Å). In addition, the ethanol guests 
can be seen to hydrogen bond via its two methylene protons to the electron rich faces of 
the aromatic pyrogallol host (H41A…centroid: C3 C4 C5 C6 C7 C25 = 2.454 Å and 
H41B…centroid: C15 C16 C17 C18 C19 C27 = 2.457 Å) as in the previously described 
structure containing HCl. Furthermore, there is a hydrogen bond formed between the 
hydroxyl group of the ethanol and the electron rich pyrogallol (H17O…centroid: C1 C21 
C22 C23 C24 C28 = 2.481 Å). This causes the ethanol guest to be drawn deeper into the 
cavity resulting in reduced hydrogen bonds distances between the guest and the host. 
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Figure 65: Entrapment of ethanol within the capsule comprised of two C-3-hydroxypropyl-
pyrogallol[4]arenes 25 ( (hydrogens, upper rims and pendant chains have been omitted for 
clarity) 
Adjacent macrocycles are seen to pack transversally to one another into a head-
to-tail sheet network. They are held in place by hydrogen bonds involving the phenolic 
hydroxyls groups of one macrocycle with the alcohol chains of the next macrocycle 
(O4…O15 = 2.741 Å, O6…O14 = 2.727 Å, O10…O13 = 2.830 Å, O12…O16 = 3.141 Å) 
as shown Figure 66. 
 
Figure 66: Head-to-tail arrangement of C-3-hydroxypropyl-pyrogallol[4]arenes 25(hydrogens 
have been omitted for clarity) 
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The ethanol and water molecules occupy the voids in the crystal lattice in 
between the upper rim cavity (endo) and the pendant chains respectively, but do not 
interfere with the hydrogen bonding network, so forming hydrophilic and hydrophobic 
bilayers. A single water molecule resides at the annulus of the macrocycles between the 
hydrophobic pendant chains. Unlike the chloride of the previous structure there is an 
absence of hydrogen bonding between the water and the pyrogallol[4]arene, with 
acceptor donor distances of 3.111 Å and 3.243 Å. The water is likely to repel the 
hydrophobic pendant chains. As the chains are unable to adopt the same structural motif 
as the chloride structure above, it can therefore be concluded that the disturbance of the 
assembly in presence of ethanol and HCl is mainly attributed to the inclusion of the 
chloride anion. 
When wet acetone replaces wet ethanol as the crystallisation solvent for C-3-
hydroxypropyl-pyrogallol[4]arene, the capsule is transformed into a rod-like structure; 
consisting of a head-to-tail arrangement. The rod-like structure contains cavities that can 
be seen to encapsulate one acetone molecule per calixarene; between the upper rim and 
the pendant propanol chains of the next calixarene. As shown in Figure 67, the acetone 
molecule also sits within the cavity of the upper rim with two of its methyl protons 
orientating towards the electron rich faces of the aromatic pyrogallol host 
(H42B…centroid C3 C4 C5 C6 C7 C25 = 2.696 Å and H42C…centroid C15 C16 C17 
C18 C19 C27 = 2.663 Å). The guest molecule is anchored into place via a hydrogen 
bond between one of the pendant chains of the macrocycles to the carbonyl of the 
acetone (O14…O18 = 2.799 Å).  
The pendant chain, diagonally opposite to the one attached to the guest, can be 
seen to form a hydrogen bond to the upper rim of the pyrogallol[4]arene that holds the 
guest (O11…O18 = 2.740 Å). This intermolecular hydrogen bond fastens the two 
macrocycles into a head-to-tail orientation, leading to the rod-like structure along the a 
axis. The tubular cavity, drawn using geometrical position is represented in blue in 
Figure 68. 
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Figure 67: Entrapment of the acetone molecule within two C-3-hydroxypropyl-pyrogallol[4]arenes 
25 (hydrogens and pendant chains have been omitted for clarity) 
 
 
Figure 68: Tubular network formed by C-3-hydroxypropyl-pyrogallol[4]arenes 25 view along the c 
axis, (hydrogens have been omitted for clarity) 
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The adjacent macrocycle is also attributed to the interconnection of a parallel rod 
in the same direction, by the intercalation of the propanol chain nearly perpendicular to 
the chain containing O13; thereby integrating a discrete hydrogen bonding chain, that 
links to the acetone (O5…O13 = 2.640 Å, O13…O14 = 2.684 Å). This macrocycle 
contributes the elongation of the network along the b axis via a hydrogen bond between 
two adjacent phenolic groups (O6...O12 = 2.693 Å) as illustrated in Figure 69. 
The alternating pattern of the tubes along the c axis is created by the four 
hydrogen bonds involving the phenolic head-to-head connections (O2…O3 = 2.702 Å 
and O8…O9 = 2.844 Å). These interactions are strengthened by the pendant propanol 
chain of the adjacent macrocycle hydrogen bonding with the upper rim of the calixarene 
below (O10…O15 = 2.684 Å).  
 
Figure 69: Egg-box-like structure on the c axis of C-3-hydroxypropyl-pyrogallol[4]arenes 25 
(hydrogens and pendant chains have been omitted for clarity) 
The macrocycle is highly hydrated, with seven hydrogen bonds involving water 
molecules such as H2O17. Due to low crystal diffraction, the hydrogens were not 
located and the following interactions are based on the oxygen-oxygen distances and 
their interactions with the macrocyclic protons. The hydrogen bonding network created 
via O17, links the upper rim of three macrocycles together (O17…O1 = 2.872 Å, 
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O17…O4 = 2.723 Å and O17…O5 = 2.812 Å). The water molecule O19 also plays a role 
in the interconnection of those two macrocycles, by bridging the same propanol chain to 
another pendant chain (O15…O19 = 2.736 Å, O19…O16 = 2.734 Å). Although the water 
molecules are an intricate part of the hydrogen bonding network, they appear to be lying 
in channels between the tubes, as represented in Figure 70. 
 
Figure 70: Water channels in the crystal packing of C-3-hydroxypropyl-pyrogallol[4]arene 25 
(hydrogens have been omitted for clarity)  
 
2. C-4-HYDROXYBUTYL-PYROGALLOL[4]ARENE 
In accordance with the results obtained for the 3-hydroxypropyl analogues, 
single crystal X-ray analysis of C-4-hydroxybutyl-pyrogallol[4]arene 26, which was 
crystallised by slow evaporation of acetone, also led to the formation of a tubular 
structure. Each acetone molecule sits in the cavity created by the pyrogallolarene cup 
and the pendants chains of the following molecule to forms a “solvent channel”; 
however, the acetone is not coordinated to any pendant chains as seen previously. 
Interestingly, its orientation within the cavity of each macrocycles varies, with an 
overall rotation of 90°. The crystal packing, maintained by forty hydrogen bonds, shows 
six molecules i.e. three calixarenes and three acetone molecules, in the asymmetric 
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unit, which fill the unit cell in the P space group. Of the twelve hydrogen binding sites 
available on the upper rim of the pyrogallol[4]arene, four hydrogen donors are involved 
in intramolecular bonding, with average lengths between the oxygens of 2.692 Å, 
holding the cup into the cone conformation. 
 
Figure 71: Hydrogen network forming the tubes made of C-4-hydroxybutyl-pyrogallol[4]arenes 26 
(hydrogens have been omitted for clarity) 
As seen in Figure 71, the pendant chains of one pyrogallol[4]arene are anchored 
to the upper rim of the following macrocycle, via three to four hydrogen bonds ( 
Table 8). This head-to-tail arrangement is maintained by three of the strongest 
intermolecular interactions of the whole packing, i.e. -123.5, -124.5 and -130.0 kJ.mol-
1
.
291-292
 
Atom
1 
Atom
2 
Length 
(Å) 
Atom
1 
Atom
2 
Length 
(Å) 
Atom
1 
Atom
2 
Length 
(Å) 
O13 O20 2.622 O30 O37 2.641 O47 O3 2.623 
O14 O23 2.623 O31 O40 2.607 O48 O6 2.617 
O15 O26 2.579 O33 O46 2.609 O49 O9 2.582 
O16 O29 2.615    O50 O12 2.566 
 
Table 8: Lengths of the hydrogen bonds interactions between the pendant chains and the upper rim 
 
The inversion of the neighbouring tubes is generated through the upper rim interactions 
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leading to head-to-head disposition into an egg-box-like pattern on each side of each 
cup maintained by a network of fourteen hydrogen bonds (Figure 72,  
Table 9). 
 
Figure 72: C-4-hydroxybutyl-pyrogallol[4]arenes’ upper rims hydrogen bonding (a) leading to the 
egg-box-like pattern (b) (each colour represent a different macrocycle in the asymmetric unit, 
hydrogens and pendant chains have been omitted for clarity) 
 
Atom 
1 
Atom 
2 
Length 
(Å) 
Atom 
1 
Atom 
2 
Length 
(Å) 
Atom 
1 
Atom 
2 
Length 
(Å) 
O1 O2 2.841 O8 O24 2.804 O19 O35 2.775 
O4 O39 2.708 O10 O45 2.833 O21 O22 3.138 
O5 O38 2.858 O11 O44 2.861 O28 O27 2.992 
O7 O25 2.757 O18 O36 2.786 O41 O42 2.754 
 
Table 9: Upper rim hydrogen bonds lengths 
  103 
 
 
Due to the absence of water molecules that were present in previous structures, 
the hydrogen bond network of C-4-hydroxybutyl-pyrogallol[4]arene 26 is strengthened 
by the pendant chains, resulting in a tail-to-tail arrangement in both direction of the 
tubes. As represented in Figure 73, these interactions occur along the (1, 1, -1) Miller 
plane (O14…O49 = 2.761 Å, O47…O50 = 2.957 Å, O30…O16 = 2.732 Å, O31…O32 = 
2.726 Å), as well as one of its perpendicular Miller planes (10, 9, -9) (O49…O33 = 
2.692 Å, O47…O31 = 2.782 Å, O15…O16 = 2.807 Å). 
 
 
Figure 73: Pendant chains interactions of C-4-hydroxybutyl-pyrogallol[4]arenes 26 on (a) (1, 1, -
1) and(b) (10, 9, -9) Miller planes, (hydrogens have been omitted for clarity) 
 
When a mixture of acetone and acetonitrile (1:1) is used as crystallisation 
solvent, a single macrocycle, two acetonitrile and one acetone molecules are completing 
the asymmetric unit with P21/m symmetry. The tubular crystal pattern created by using 
acetone alone as the solvent system is altered, whereby the capsule formed by the 
pendant chain and upper rim accommodates the acetonitrile as a guest. As seen 
previously, the butanol chain coordinates to the upper rim via hydrogen bonding 
interactions (O2…O9 = 3.187 Å, O4…O8 = 3.036 Å, O5…O8 = 2.836 Å) forming a rod-
like structure along the a axis (Figure 74). However, the network is distorted by the 
presence of the acetonitrile and the cavity becomes permeable to guest molecules. As 
the pendant chains are coordinated to the central pyrogallol instead of the external one, 
it leads to a slight shift and tilted rods, with a displacement of 14.441 Å with respect to 
the two C4 axis of the pyrogallol[4]arenes. The butanol chains also contributes to the 
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interconnection of the tubes by bridging the upper rims along the c axis via two 
hydrogen bonds (O7…O8 = 2.952 Å and O6…O8 = 2.738 Å).  
 
Figure 74: Packing of the titled rod formed of C-4-hydroxybutyl-pyrogallol[4]arenes along the a 
axis  
 
The macrocycle is translated onto the b axis of the cell via a two fold screw axis, 
leading to the formation of the alternating egg-box-like pattern that enables the channel 
to change the directions of the rods (Figure 75). As a result, the upper rim of the 
translated macrocycles is anchored via two hydrogen bonds (O2…O3 = 2.777 Å). This 
interaction is reinforced by the pendant chains that are also connected (O8…O9 = 2.773 
Å). Compared to the previous structures involving acetone, the guest molecule is not 
anchored onto the upper rim cavity. Although acetonitrile resides in between the 
pendant chains there is no hydrogen bonding involved (N3…O9 = 4.348 Å), therefore 
the involvement of the solvent is likely to be steric. 
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Figure 75: Elongation of the network created by of C-4-hydroxybutyl-pyrogallol[4]arenes 26 along 
the b axis (hydrogens have been omitted for clarity) 
 
The study of the behaviour of C-4-hydroxybutyl-pyrogallol[4]arene 26 in the 
solid state when crystallised from wet acetonitrile was attempted in order to obtain the 
hexamer aggregate as previously reported.81 The asymmetric unit in the P2na1 space 
group consists of one macrocycle, one acetonitrile that resides in between the lipophilic 
part of the pendant chains and two water molecules. Although crystallised from wet 
acetonitrile, no specific hydrogen bonding was present to form a rod-like structure, a 
dimeric capsule or the hexamer. The cone conformation is still maintained by the 
intramolecular binding (Figure 76); however, the structure exhibits a very unusual 
packing system. This effect is attributed to the two highly disordered water molecules 
that compete in the self-assembly and therefore disable the ability of a head-to-head or 
head-to-tail arrangement previously observed.  
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Figure 76: Upper rim interactions of C-4-hydroxybutyl-pyrogallol[4]arenes 26 (hydrogens and 
pendant chains have been omitted for clarity) 
One pyrogallol[4]arene is translated via a two fold screw axis, this symmetry 
generated macrocycle is linked to the first one via a hydrogen bond between two 
phenolic hydroxyls (O1…O8 = 2.749 Å). The interconnection of these two macrocycles 
is reinforced by the presence of a third one, that is hydrogen bonded to the upper rim of 
the translated calixarene (O3…O7 = 2.7834 Å). This third macrocycle also interacts with 
the initial calixarene, via a discrete chain of hydrogen bond interactions involving a 
water molecule (O4…O18 = 2.707 Å and O18…O1 = 2.636 Å), as seen in Figure 76. 
One of the pendant butanol chains resides in the centre of the hydrophilic part of 
the upper rim cavity. Although the alcohol group of this chain is pointing towards one 
pyrogallol face, it is not maintained by hydrogen bonding (O13…O2= 3.497 Å). 
Nevertheless, it is linked to the acetonitrile molecule that resides in between the 
lipophilic part of the four pendant chains via a hydrogen bonded bridge involving water 
(O13…O19 = 2.496 Å, O19…N = 2.950 Å). The pendant chains also contributes to the 
organisation of upper rim and complete the hydrogen bonding network of this crystal 
lattice (Figure 77). Three interactions exist between the upper rim and the pendant 
chains (O2…O15 = 2.743 Å, O5…O14 = 2.737 Å, O9…O14 = 2.787 Å) and one between 
two pendant chains themselves (O14…O16 = 2.831 Å). 
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Figure 77: Involvement of the pendant chains in the packing of C-4-hydroxybutyl-
pyrogallol[4]arenes 26 ( hydrogens and pendant chains have been omitted for clarity) 
As observed with the 3-hydroxypropyl analogues, the solvent system has an important 
role in the solid state, often directing the self-assembly process. The nanometre scale 
rods that adapt or respond to a guest (such as acetonitrile) could potentially find 
applications as a transport channel. The difference of the cavity volume in the presence 
of different guests was assessed using the computer program MCavity,290 it shows that 
when only acetone is present its volume is around 92 Å3, compared to the 128 Å3 when 
acetonitrile is present. These cavities are smaller compared to the hexamer cavities of 
1300 Å3, but comparable to the 143 Å3 cavity when forming a head-to-head dimer.74, 293  
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3. PYROGALLOL[4]ARENE METAL COMPLEX 
If the pyrogallol[4]arenes aggregate on the nano-meter scale, it would favour 
their engulfment by the dendritic cells via endocytosis. Their self-assembly can be 
achieved through crystallisation from ethyl acetate, acetonitrile or chloroform. 
Unfortunately, the solubility of those macrocycles highly relies on the pendant chains 
functionality, which can be an issue when multi-functionalities will be present. To 
overcome this potential issue, the self-assembly involving chelation to metal complexes 
was considered, as they have shown excellent stability.100 The crystallisations of C-3-
hydroxypropyl-pyrogallol[4]arene with various metals, copper, gadolinium, gallium as 
their nitrate salts, were investigated. Unfortunately, to date, none of them resulted in 
crystalline materials suitable for X-ray crystallography. Attention has been turned to the 
zinc metal, as it was shown to have the ability to change the conformation of the 
macrocycle by coordinating to metal.  
The first hydroxycalixarene that was coordinated to zinc, used the 
aminomethylated resorcin[4]arene and zinc chloride. The zinc was not directly attached 
to the calixarene but was intercalated in the packing, creating an cationic ligand as host 
for an ionic self-assembling system.294 In 2000, zinc(II) ions were used to form loops 
with resorcinarene cavitands.295 Subsequently, this work led onto different metals such 
as cadmium, copper as well as zinc that have shown potential to strongly bind to 
fullerenes C60.296 The first pyrogallol[4]arene capsule coordinated by eight zinc centres 
was reported in 2007. These entities were proved to be stable in both solid and liquid 
state entrapping one pyridine in their cavities, it was then shown that this coordination 
also enables the rccc conformation to be maintained.103, 105, 297 
In the search for a metal organic framework, zinc pyridinium nitrate 27 
(Zn(NO3)2Py3) was prepared by mixing zinc nitrate hexahydrate with pyridine resulting 
in white crystals that were then mixed in excess with C-3-hydroxypropyl-
pyrogallol[4]arene 25 in a 1:1 mixture of acetonitrile:methanol. Upon evaporation, 
suitable crystals for single crystal X-ray crystallography were formed, exhibiting a very 
large unit cell (V= 14032.3 Å3) in the P21/c space group. After data collection and 
structure solution, despite the resolution being very low, the preliminary single crystal 
refinement data showed two pyrogallol[4]arenes, in their anionic forms, self-assembled 
with eight zinc centres to form a dimeric capsule. The volume inside the dimer cavity is 
127.6 Å3, as calculated  using the MCavity program.290 Each phenolic oxygen 
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chelates to at least one Zn2+ cation, with the central phenolate anion chelating to two 
metal centres, with distances ranging from 2.011 Å (Zn8…O8) to 2.109 Å (Zn1…O26). 
As seen in Figure 78a, this arrangement leads to two pyrogallol[4]arenes being offset 
from one another by 45.25º about the C4v axis. As shown in Figure 78b, the pyridine 
remains coordinated to each zinc, with distances ranging from 1.982 Å (Zn6…N5) to 
2.075  Å (Zn2…N1), forming what was referred as a Pelton wheel by others.297 If the 
coordinative bond was replaced by hydrogen bonding the distances range between the 
two closest phenolic oxygens would be from 2.886 Å to 2.966 Å. 
 
Figure 78: C-3-hydroxypropyl-pyrogallol[4]arene bis(pyridyl) zinc (II) dimer 28 view along (a) the 
side and(b) from the top( hydrogens have been omitted for clarity) 
 
The phenolates lose their hydrogen bonding potential when coordinated to the 
zinc, whereas the pendant chains retain their functionality. This enable the extension of 
the network between capsules (O14…O29 = 2.691 Å, O15…O32 = 2.753 Å, O13…O29 = 
2.775 Å), as shown in Figure 79. 
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Figure 79: Hydrogen bonding interactions of the pendant chains 
The stability of this new capsule in various solvents remains to be confirmed, 
but potentially, the further functionalisation of the lower rim could be achieved on the 
zinc complex. This would prove to be a useful scaffold that offers selective reversible 
protection of the upper rim. 
 
4. SELF-ASSEMBLY ON THE NANOSCALE 
In order to investigate the self-assembly of C-4-hydroxybutyl-pyrogallol[4]arene 
26 into larger aggregates, on the nanoscale, a study was performed using the electron 
microscopy technique (TEM). When similar studies were performed, it was observed 
that the size and shape of the aggregates can differ depending on the solution 
concentration and the evaporation time.84 The TEM image (Figure 80a) of C-4-
hydroxybutyl-pyrogallol[4]arene 26 evaporated from an acetone and water solution 
(1:1, 1 mM) revealed the formation of a tubular aggregates, with width ranging from 18 
to 25 nm. As seen in the solid state, several rods can interact with one another, which 
led to the assumption that the aggregate are the results of the assembly of eighteen to 
twenty-five rods in a circular manner.  
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The formation of spherical aggregates that have been reported previously was 
also attempted.85 C-4-Hydroxybutyl-pyrogallol[4]arene 26 was found to be insoluble in 
ethyl acetate, as used in the previous studies, and this issue was overcome by using an 
acetone and ethyl acetate mixture (1:1, 1 mM). The TEM image obtained (Figure 80b) 
showed some interesting features, in a form of dumbbell-like aggregates, with a 
diameter of 40 nm in the spherical end part and a diameter of 15 nm in the rod-like 
linker. It can be assumed that the rod is formed by the entrapment of the acetone, whilst 
the ends of the dumbbell correspond to the aggregation of hexameric capsule. As 
previous studies on the alkyl footed pyrogallol[4]arene revealed that the addition of 
water or acetone does not interfere with the spherical aggregation, and using 
observations from the solid state studies, it can be concluded that the dumbbell-like 
aggregates are mainly caused by the polar pendant chains. 
 
 
Figure 80:TEM images of C-3-hydroxypropyl-pyrogallol[4]arene aggregates from a wet acetone 
(a) and an acetone/ethyl acetate(b) solutions and their graphic representations 
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B.  AMINO-FOOTED CALIXARENES 
The amino group is an essential function when considering the attachment of 
amino acids, and it was therefore essential to use amino footed calixarenes as a starting 
derivative towards a peptide scaffold for immunotherapeutic vectors. The 
functionalisation of the pendant chains with an amino group was investigated via 
several synthetic routes. In the literature, such a compound was only reported once via 
the benzylated C-4-hydroxybutyl-resorcin[4]arene in a six step synthesis.161 Such an 
approach was considered; however, during an investigation into the selectivity of the 
protection step, an alternative method became apparent. Instead, access to the amino 
functionality was attempted via the Gabriel synthesis transforming the bromine 
derivative obtained from the hydroxyl to an amine by reaction with potassium 
phthalimide (Scheme 11). Unfortunately, only the calixarene was recovered, it can be 
thought that the phthalimide also reacted on the unprotected phenol leading to the 
formation of a mixture that was not resolved. 
 
Scheme 11: Gabriel synthesis 
The introduction of the amine functionality via the N-Boc-3,4-dihydro-2H-
pyridine instead of the 2H-dihydropyran was considered; however the presence of the 
Boc protecting group under acidic conditions, results in the liberation of CO2 which was 
not compatible with the sealed tube microwave technique (Scheme 12). The reaction 
also resulted in non-cyclised oligomers when attempted under conventional heating 
methods. 
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Scheme 12: Attempted synthesis of Boc protected aminopropyl-pyrogallol[4]arene 
A commercially available, aminobutyraldehyde diethyl acetal was considered as 
a starting material for the synthesis of the calixarene. The aminobutyraldehyde offered 
several advantages as it is already in its protected acetal form which is thought to be an 
essential intermediate in the cyclocondensation process. Due to its similarities with 
GABA (γ-aminobutyric acid), a chief inhibitory neurotransmitter, it can be assumed that 
one of the metabolites of the macrocycles could be assimilated to GABA and therefore 
may have limited toxicity. 
In view of a further selective protection of the phenolic macrocycles, the 
protection of the amino group was considered, with the Fmoc protecting group due to its 
stability in strong acidic conditions, compared with the other well-known Boc 
protecting group. The protected amine was synthesised 33 (44 %) and condensed with 
pyrogallol. The only product 34 obtained (13%) showed some unexpected features. 
Although reactants were used in equimolar amounts, the tetramer was not obtained. 
Instead a product formed of a single pyrogallol ring and two five membered nitrogen 
containing rings, was obtained as a single enantiomer (Scheme 13). 
 
Scheme 13: Synthesis of bis((9H-fluoren-9-yl)methyl)2,2'-(4,5,6-trihydroxy-1,3-
phenylene)dipyrrolidine-1-carboxylate 34 
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It can be assumed that the presence of a longer chain, i.e. made of more than six 
carbons, is necessary between the Fmoc group and the methine bridge. Therefore, a 
linker is required to not only favour the formation of the tetramer in a cone 
conformation but also provide more freedom and less steric hindrance to elongate the 
pendant chains with other entities.  
Suitable crystals for X-ray analysis of bis((9H-fluoren-9-yl)methyl)2,2'-(4,5,6-
trihydroxy-1,3-phenylene)dipyrrolidine-1-carboxylate 34 were isolated from the 
reaction mixture (Figure 81). The two Fmoc groups are nearly parallel to each other 
(angle ca 5º). The packing is formed via two interaction types, the first being the 
hydrogen bonding between the phenolic group in the ortho position of the pyrogallol 
and the carbonyl group from the Fmoc. With strong interactions, indicated by relatively 
short distances between hydrogen donors and acceptors it enables the translation of the 
molecule along the a axis (O1…O6 = 2.739 Å and O3…O5 = 2.726 Å). 
 
Figure 81: Hydrogen bonding between two bis((9H-fluoren-9-yl)methyl)2,2'-(4,5,6-trihydroxy-1,3-
phenylene)dipyrrolidine-1-carboxylates 34 (hydrogens have been omitted for clarity) 
The second interaction involves a tilted edge-to-face Ar-H…π bonding between 
one hydrogen of the Fmoc and the face of the pyrogallol with a 75º angle (centroid 1: 
C1 C2 C3 C4 C5 C6…H41 = 3.187 Å, centroid 2: C45 C46 C47 C48 C49 C50…H85 = 
3.152 Å,). The combination of those interactions involving the two chiral molecules that 
form the asymmetric unit results in the formation of an helical type packing (Figure 82). 
  115 
 
Figure 82: Helicated packing of bis((9H-fluoren-9-yl)methyl)2,2'-(4,5,6-trihydroxy-1,3-
phenylene)dipyrrolidine-1-carboxylates 34 
The unprotected aminobutyraldehyde diethyl acetal was therefore reacted with 
resorcinol and pyrogallol. In order to maintain the acetal functionality, a microwave and 
grinding methods using pTSA as a catalyst were considered but were shown to be 
unsuccessful for the formation of aminoalkyl-pyrogallol[4]arene. It can be assumed that 
under those reaction conditions, a cyclised compound is formed in similar fashion to the 
solid phase synthesis of piperazine using the aminobutyraldehyde acetal and catalytic of 
pTSA in DCM.298 
Using the method described previously, equimolar quantities of 
aminobutyraldehyde diethyl acetal and the appropriate phenol were reacted in a mixture 
of hydrochloric acid and dioxane (25%) at 100 ºC for 10 minutes under microwave 
irradiation. Two new water soluble macrocycles, C-3-aminopropyl-pyrogallol[4]arene 
35 and C-3-aminopropyl-resorcin[4]arene 36 were synthesised as their hydochloride 
salts in a single step, with reasonably low yield, 10% and 26% respectively. Although in 
the protected acetal form, the presence of a strong acid can catalyse the reaction of the 
aldehyde and the amine functionality, therefore forming an imine, which explains the 
reduced yields. Ammonium cations have been widely investigated as guests with alkyl-
footed pyrogallol[4]arenes and resorcin[4]arenes. In solution, they can act as guest in 
the hexameric capsule. The pyrogallol[4]arene is selective over neutral amine, such as 
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trihexylamine, compared to resorcin[4]arene that encapsulate both amines and 
ammounium cations.90 It has been proved that the ratio of ammonium is highly 
important in its encapsulation within the hexameric capsule and its presence does not 
impede the self-assembly.94, 299 In the encapsulation study of tetraethylammonium 
cation by alkyl footed resorcin[4]arene derivatives it was found that the counterion does 
not play any role in the process; however, its nature may change the inclusion of the 
water molcule in the capsule.86 In the solid state, tetraalkylammonium cations can only 
be encapsulated by both resorcin[4]arene and pyrogallol[4]arenes in dimeric capsules, 
as revealed by several crystal structures.289, 300-301 Solid state analysis for both C-3-
aminopropyl-pyrogallol[4]arene 35 and C-3-aminopropyl-resorcin[4]arene 36 
compounds showed the significance of the counter anion. The chloride anion, from the 
hydrochloric acid, plays an essential role in the self-assembly as it is involved in the 
hydrogen bonding network on both the upper and lower rim.  
1. C-3-AMINOPROPYL- PYROGALLOL[4]ARENE HYDROCHLORIDE 35 
Suitable crystals for X-ray analysis of C-3-aminopropyl-pyrogallol[4]arene 35 
were obtained by slow evaporation of a methanolic solution. The cone conformation is 
maintained via four intramolecular hydrogen bonds between eight phenolic hydroxyls 
(O4…O3 = 3.018 Å, O6…O7 = 2.708 Å, O9…O10 = 2.987 Å and O1…O12 = 2.715 Å). 
The ammonium pendant chains can be compared to the trialkylammonium cations that 
have been considered as guests in a dimeric complex of C-methyl-
pyrogallol[4]arenes.302 However due to steric hindrance the usual self-assembly created 
by the direct interactions of two upper rim cannot be achieved by C-3-aminopropyl-
pyrogallol[4]arene 35. Instead, the upper rim of the macrocycle coordinates via 
hydrogen bonds to the solvent (O2…O14 = 2.946 Å, O3…O14 = 2.919 Å, O8…O15 = 
2.602 Å, O7…O16 = 2.595 Å), as well as the chloride anion (O1…Cl2 = 2.860 Å, 
O5…Cl4 = 2.855 Å). The short distances between one phenolic hydrogen and the 
chloride (O11…Cl5 = 2.445 Å, H11O…Cl5 = 1.632Å) give the strong bond a covalent 
character. These distances are much shorter than the ones previously reported (3.057-
3.072Å).302 The chloride anion also acts as a linker between the methanol and the upper 
rim forming a bridge (Cl4…O15 = 3.066 Å, Cl2…O16 = 3.446 Å). Two of the remaining 
phenolic hydroxyls hydrogen bond directly to the adjacent macrocycle (O4…O11 = 
2.806 Å, O10…O5 = 2.754 Å) leading to a head-to-head assembly along the a axis 
(Figure 83). 
  117 
 
Figure 83: Hydrogen bonding of the upper rim and chloride interaction with the pendant chains of 
C-3-aminopropyl-pyrogallol[4]arenes 35.HCl, (hydrogens have been omitted for clarity) 
As seen in Figure 83, the ionic interactions that exist between the ammonium 
group and the chlorides have moderate hydrogen bonding properties. Each cation 
interacts with at least one halide anion (N1…Cl3 = 2.940 Å, N2…Cl1= 3.100 Å, N2…Cl5 
= 3.024 Å N3…Cl4=3.027 Å, N3…Cl5= 3.024 Å and N4… Cl2= 3.026 Å). Surprisingly, 
although two chlorides reside in between the pendant chains, there is only one 
interaction with the ammonium (N3…Cl3= 3.306 Å) as the other distances exceed the 
sum of their van der Waals radii (rCl+rN = 3.31Å < N1…Cl1=3.486 Å, N4…Cl1= 3.478 
Å, N2…Cl3=4.158 Å). Two of the methanol molecules that surround the pendant chains 
constitute a bridge with a chloride anion (O21…Cl3 = 3.104 Å, O21…N4 = 2.831 Å, O18 
…Cl1 = 3.046 Å, O18 …N2 = 2.718 Å). Two distorted methanol are trapped inside the 
space created by the four pendant chains but do not coordinate with any of them. 
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Figure 84: Hydrogen bonding generating the dimeric complex formed from C-3-aminopropyl-
pyrogallol[4]arenes 35, HCl and methanol,( hydrogens and pendant chains have been omitted for 
clarity) 
The combined effect of these ionic interactions and the hydrogen bonded one 
involving the chloride and the solvent, with both the pendant chains and the upper rim, 
leads to the formation of an offset bridged dimer involving a tridendate chloride anion 
(N4…Cl2…O1 = 108.05º, N4…Cl2…O21 = 54.53º, O21…Cl2…O1 = 149.61º) Figure 
84.303 
As shown in Figure 85, the offset head-to-head dimeric semi-closed capsule 
with a calculated internal volume of ca 240 Å3 is locked by the hydrogen bonding 
between the upper rim and the guest molecules, as well as the pendant chains of 
adjacent capsules (O6…N3 = 2.789 Å and O12…N1 = 2.868 Å). This results in another 
tricoordinate chloride center (N3…Cl4…O5 = 118.65º, N3…Cl4…O15 = 114.87º, 
O5…Cl4…O15 = 107.34º). 
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Figure 85: Connection of the dimeric complex formed from C-3-aminopropyl-pyrogallol[4]arenes 
35, HCl and methanol,( hydrogens and pendant chains have been omitted for clarity) 
 
2. C-3-AMINOPROPYL-RESORCIN[4]ARENE HYDROCHLORIDE 36 
Two suitable crystals for single crystal X-ray analysis of C-3-aminopropyl-
resorcin[4]arene 36 hydrochloride were obtained by slow evaporation of a methanolic 
solution. The two sets of data showed P crystal symmetry. However, they show 
different isolated polymorphs. It appears that the second structure could be less stable 
than the first one due to rapid solvent loss resulting in a high disorder of the macrocycle 
core.  
In the first structure, the asymmetric unit consists of one methanol molecule, five 
chloride anions and one C-3-aminopropyl-resorcin[4]arene 36 in a flatened cone 
conformation (Df = 0.65). In line with other ammonium complexes previously 
described,289 this conformation is ensured by two intramolecular hydrogen bonds 
(O1…O8 = 2.845 Å and O4…O5 = 2.864 Å) out of the four possible combinations 
(O2…O3 = 3.261 Å and O6…O7 = 3.190 Å). The resorcinol rings are therefore slighly 
tilted towards those intramolecular interactions creating a distortion in the macrocyclic 
core, which does not adopt the perfect C4v symetry anymore, where the average 
intramolecular hydrogen bonds length is 2.787 Å. The thirty-two interactions necessary 
to form the packing rely on the presence of the chloride anion. The only two direct 
hydrogen bonds involve the methanol molecule (N2…O9 = 2.833 Å and N3…O9 = 2.775 
Å), that bridges two pendant chains of the same macrocycle together (Figure 86). 
  120 
 
Figure 86: Direct hydrogen bonding with the asymmetric unit of C-3-aminopropyl-
resorcin[4]arene 36, HCl and methanol, (hydrogens have been omitted for clarity) 
Like its pyrogallol[4]arene analogue, two C-C-3-aminopropyl-resorcin[4]arenes 36 
form an offset dimer (Figure 87) that originates from three available hydrogens on the 
ammonium cation of one pendant chain (N4…Cl4 = 3.081Å, N4…Cl5 = 3.209Å, 
N4…Cl3 = 3.116Å) combined with the tricoordinate chloride counteranion (Cl4). These 
interactions also take part in the extension of the system in a perpendicular direction of 
the dimer. As the macrocycle is inverted, a link is formed between the upper rim and the 
pendant chains. The absence of four hydroxyl groups on the upper rim that are seen in 
its pyrogallol analogue has an effect on the self-assembly. As the head-to-head 
arrangement of the upper rims of the resorcinarene with the adjacent macrocycle along 
the b axis is achieved via a chloride bridge, whereby the anion coordinates to the upper 
rim of two adjacent macrocycle via hydrogen bonding network (O3…Cl4 = 3.075 Å, 
Cl4…O8 = 3.071 Å, O4…Cl5 = 2.977 Å, Cl5…O7 = 2.997 Å). Those dimeric capsules 
resemble the inclusion of a large ammonium cation with methyl-resorcin[4]arene with 
similar bond lengths (O…Cl- = 2.91 to 3.11 Å), which is contributed to steric 
hindrance.289, 300 
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Figure 87: Offset dimeric complex of C-3-aminopropyl-resorcin[4]arenes 36, HCl and methanol, 
(a) along the b axis and (b) along the a axis,(hydrogens and pendant chains have been omitted for 
clarity) 
As seen in Figure 88, the dimer is locked by the incorporation of pendant chains 
from adjacent capsules within the same plane. This bridging also occurs with the nearly 
parallel resorcinol with one of the ammonium chains from C-3-aminopropyl-
resorcin[4]arene 36  (O2…Cl2 = 2.983 Å, Cl2…N1 = 3.107Å). 
 
Figure 88: Interactions of other pendant chains with the dimeric complex formed by C-3-
aminopropyl-resorcin[4]arenes 36, HCl and methanol, (hydrogens and pendant chains omitted 
for clarity) 
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The pendant chains of the two macrocycles translated in the b axis are connected 
via a bridging methanol molecule that is linked to a chloride anion (O9…Cl3 = 3.157 Å). 
In turn, this then interacts with two ammonium ions from the pendant chains of an 
adjacent resorcin[4]arene (Cl3…N1= 3.213 Å, Cl3…N4= 3.116 Å), as seen in Figure 89. 
 
Figure 89: Interconnection of the pendant chains of C-3-aminopropyl-resorcin[4]arenes 36 
(hydrogens omitted for clarity) 
The chloride that resides at the annulus of the lower rim of the macrocycle, 
within the pendant chain, is locked into position via an interaction with one of the 
pendant chains that ensure the tail-to-tail arrangement (Cl1…N1 = 3.066 Å). One highly 
coordinated choride is responsible for the agglomeration of all the pendant chains 
together and thereby maintains the framework (Cl3…N1 = 3.213 Å, Cl3…N2 = 3.279 Å, 
Cl3…N3 = 3.273 Å, Cl3…N4 = 3.116 Å, Cl3…H9O = 2.437 Å). 
In the second structure, despite involving the same macrocycle and the same 
solvent system, the packing differs. Two C-3-aminopropyl-resorcin[4]arenes, eight 
chloride anions and disordered solvent molecules (predicted to be two water molecules 
using the SQUEEZE program) consitute the asymetric unit.276 
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The macrocycles are in a boat-like conformation (Df= 0.53 and 0.54) due to the 
presence of only one intramolecular H-bond between the phenolic hydrogen (O1…O8 = 
2.826 Å). This conformation results in a set of two nearly coplanar resorcinol (133.84º 
and 138.63º) and two nearly parallel resorcinol units (11.67º and 10.13º).  
The ammonium terminus of one of the pendant chain resides at equidistance of 
the two, almost parallel, resorcinols (O2…N8 = 2.970 Å, N8…O5 = 2.897 Å, O10…N4 = 
2.955 Å, N4…O13 = 2.9910 Å). The ammonium cation is also stabilised by its 
electrostatic interaction with the highly electronegative π electron cloud of the coplanar 
resorcinol ring that it is sitting on (N4…centroid: C49 C50 C51 C52 C53 C66 = 3.191 Å 
and N8…centroid: C9 C10 11 C12 C13 C26 = 3.143 Å).  These distances are shorter 
than the one reported for the inclusion acetylcholine trimethylammonium moiety in C-
ethyl-resorcin[4]arene, where the shortest distance is 3.31 Å.304 As shown in Figure 90, 
these interactions led to the formation of a herringbone-like stacking of the 
macrocycles. 
 
Figure 90: Herringbone-like stacking of C-3-aminopropyl-pyrogallol[4]arenes 35 (hydrogen have 
been omitted for clarity) 
 The presence of the guest and its attraction towards the ring create an electron 
pulling effect on the macrocycle. This results in a distortion of its core, as seen in the 
following diagram based on the x-ray results, Figure 91. The aromatic core is distorted 
in the herringbone polymorph, loosing the symmetry within the macrocyclic backbone 
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(light blue) compared to the highly symmetrical C4v cone conformation (dark blue) and 
the previously observed C2h boat conformation (red). 
 
Figure 91: Representation of the distortion of the macrocyclic core compared to the cone and boat 
conformations. 
There is no direct hydrogen bonding between the upper rims; however, they are 
linked together via water molecule bridges (O13…O17 = 2.870 Å, O12…O17= 2.337 Å). 
Each ammonium cation is coordinated to a chloride anion, this can lead to the 
interconnection of the pendant chains of two macrocycles (Cl2…N3 = 3.195 Å, 
Cl2…N2= 3.163 Å, Cl2…N1 = 3.144 Å and Cl5…N5 = 3.101 Å, Cl5…N7 = 3.176 Å). 
The chloride anion that coordinates with the upper rim of the macrocycles and the 
ammonium cation enables the formation of the network (Cl1…N1 3.156 Å, Cl1…O10 = 
3.003 Å, Cl4…N2= 3.268 Å, Cl4…O11 = 3.083 Å, Cl6…N6 = 3.225 Å, Cl6…O3 = 3.036 
Å and Cl8…N3 = 3.145 Å, Cl8…O9 = 3.001 Å). Compared to the previous structure, due 
to the presence of the ammonium chains within the cavity, the chloride anion cannot 
participate to the formation of the dimeric capsule but allows the formation of head-to-
tail arrangement (Figure 92). 
It can be assumed that the upper rim interactions are maintained via the solvent 
molecules, as they are not hydrogen bonded to the pendant chains. The solvent 
accessible volume is 124.44 Å3 representing 2.5% of the unit cell. Considering the 
molecular volume of methanol to be 34.5 Å3, three molecules of methanol will 
potentially occupy these voids, situated on top of the resorcinol opposite to the π-
bonded ammonium. 
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Figure 92: Chloride involvement in the packing of C-3-aminopropyl-pyrogallol[4]arenes 35 
(hydrogens and pendant chains omitted for clarity) 
The study of the behaviour of polar pyrogallol[4]arenes and resorcin[4]arenes in 
the solid state showed some interesting features, with an array of three dimensional 
frameworks. The effect of changing the crystallisation solvent is considerable and 
should not be dismissed in the study of the self-assembly towards the nano-vectors. 
Further studies should be included in both solid and liquid state. In addition the stability 
of the hydrogen bonded capsule should be investigated in presence of biological 
component such as protein and antibodies, as well as physiological serum. The use of 
metal coordination should also be investigated in more detail. 
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CHAPTER IV: TOWARDS BIOLOGICALLY ACTIVE 
CALIXARENES 
Functionalities such as amines and carboxylic acids are widely used in covalent 
bio-conjugation and are essential in the investigation towards biologically active 
calixarenes. As described in the introduction chapter, most of the research done 
previously by others on these types of molecules was pursued on alkylated calixarenes, 
which cannot be readily functionalised with peptides. It was therefore necessary to 
introduce a functional group that would be easily transformed. It was thought that the 
precursors presented in the previous chapter could be easily conjugated to other 
biologically relevant functionalities such as amino acids, peptides, and further down the 
line, proteins and DNA. To achieve the full functionalisation several synthetic routes 
were attempted. Firstly, the transformation of the hydroxyl group was considered by 
esterification but required the selective protection of the upper rim. Secondly, the 
transformation of the starting calixarene was attempted showing good potential, a more 
reliable method using a combination of polymer bound reagent and microwave 
irradiation was developed towards attaching peptides. This enabled the preliminary 
attachment of one amino acid, a small peptide, and an elongated polyethylene chain. 
Unfortunately, this part of the project has proved to be more challenging than expected 
mainly due to purification difficulties. Although purification methods using C-18 
reverse phase chromatography were developed on the HPLC, the fraction collection did 
not always lead to pure samples in sufficient quantities for full characterisation and 
further work.  
 
A. SELECTIVE PROTECTION 
Most functionalisations of the pendant chains presented in the literature are 
achieved on cavitands, whereby the phenolic alcohols are protected and not accessible 
for hydrogen bonding. Although their conversion back to the unprotected calixarenes 
may be possible using selective reactants such as boron tribromide, it has not been 
reported as these materials are mainly used for their exceptional encapsulation 
properties.  
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To achieve the further functionalisation of the hydroxyl footed 
pyrogallol[4]arene macrocycles, it was thought that a selective protection of the 
hydroxyl groups, either phenolic or or the primary alcohol was required. The acidity of 
the phenolic group (pKa 5.1 for pyrogallol) is much higher than the primary alcohol 
group (pKa ca 15) and therefore is more accessible to electrophilic substitution, 
resulting in selective reactions at the upper rim. These properties can be exploited using 
the experimental conditions in order to favour the chemoselectivity.305-306 Complete 
esterification of all phenolic groups of alkyl footed resorcin[4]arenes and 
pyrogallol[4]arenes with 2-bromo-isobutyryl bromide, using pyridine was achieved in 
the research to make novel star shaped initiators for controlled radical polymerisation of 
styrene.267 Several protecting groups were considered and led to various levels of  
substitutions, summarised in Table 10. 
 Method Subst. 
Acetylation 37 Acetyl chloride, pyridine 
Pyridine, acetic anhydride 
mixture 
Pivalation 38 Pivaloyl chloride, potassium hydroxide or 
diisopropyldiethylamine or triethylamine 
mixture 
Tosylation 39 Tosyl chloride, triethylamine unresolvable 
Boc protection 40 Boc anhydride, DMAP 16/12 
Benzylation 41 Benzyl bromide, sodium iodide, potassium 
carbonate 
mixture 
Methylation 42 Methyl iodide, potassium carbonate 12/12 
Table 10: Attempted protections of hydroxyalkyl-pyrogallol[4]arene (subst. represent the 
substitution level of the hydroxyls (12 being the upper rim, 16 being the upper rim and the 
pendant chains) 
Previous derivatisations of the alkyl footed pyrogallolarenes’ upper rims by complete 
tosylation and partial mesylation were reported.307 Similar behaviours were expected 
during the protection of its alcohol derivative, C-4-hydroxybutyl-pyrogallol[4]arene 26. 
When attempted, only the 4-methylbenzenesulfonic acid was recovered so another 
method was therefore considered within this project. 
The reaction of the phenolic alcohol with acyl chloride, via the use of pivalate as 
a protecting agent is widely used.158, 169 Unfortunately, when attempted selective 
protection was not achieved either by the reaction of acyl chloride nor pivaloyl 
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chloride, using conventional heating methods or under microwave irradiation. The 
microwave irradiation enables the protection step to be reduced from four days to ten 
minutes using acetic anhydride in pyridine with an alkyl footed pyrogallol[4]arene.57, 307 
This protection led to an unresolvable mixture when used with its hydroxyl analogue.  
For the synthesis of bergenin derivatives, a class of trihydroxybenzoic acid glycosides, 
the selective protection of the phenolic groups was achieved by benzylation using 
potassium carbonate as a base and benzyl bromide in a mixture of acetone and DMF.308 
Similar conditions were used for the benzylation of C-4-hydroxybutyl-
pyrogallol[4]arene 26, but the product was seen to decompose into a black tar. It was 
supposed that substitution of the upper rim would be partial, i.e. only eight out of the 
twelve phenols would be substituted due to the steric hindrance of the benzyl bromide. 
By reducing the steric hindrance, using methyl iodide, the selective protection of the 
upper rim was achieved in a 40 % yield.  
 
Scheme 14: Synthesis of C-4-hydroxybutyl-dodecamethylpyrogallol[4]arene 42 
It is reported that the base is most likely to deprotonate one set of four of the 
eight available phenols in resorcin[4]arene, which are more acidic than the second set, 
due to the formation of the hydrogen bonds.125 The pendant alcohol chains could 
potentially react with the excess bridging reagent, which diminishes the yield of 
cavitands. This effect could also account for the low yield obtained in the methylation. 
Suitable crystals for X-ray analysis of C-4-hydroxybutyl-
dodecamethoxypyrogallol[4]arene 42 were obtained by slow evaporation of an 
acetonitrile solution. Due to the partial loss of its hydrogen bonding potential, the cone 
conformation is transformed to a boat, with a distortion factor of Df = 0.40. The 
resulting structure showed an altered behaviour in the crystalline phase that can 
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only be held by the interplay of the pendant chains (O13…O14 = 2.497 Å, O16…O16 = 
2.626 Å , O16…O13 = 2.642 Å and O14…O15 = 2.646 Å). 
 
Figure 93: Asymetric unit of C-4-hydroxybutyl-dodecamethoxypyrogallol[4]arene 42 
The reaction of 1,2,3-trimethoxybenzene and 1,3-dimethoxybenzene with 
equimolar amounts of valeraldehyde was also attempted, using hydrochloric acid as a 
catalyst. However, it did not lead to any reaction, showing the necessity of the electron 
donation of the hydroxyl group to the aromatic ring to ensure the electrophilic 
substitution. The tris-Boc-protected pyrogallol was therefore considered as a potential 
starting material instead of pyrogallol. But the strong acidic condition resulted in the 
liberation of gas that was caused by its deprotection. The cyclisation may occur in the 
presence of another catalyst such as p-TSA or BF3.OEt3, or the use of another acidic 
resistant protecting group. Nevertheless, their presence may impede the formation of the 
cone conformer. 
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B. FUNCTIONALISATION OF THE PENDANT CHAINS 
1. PYROGALLOL[4]ARENE PRECURSORS 
a) Halogenated hydroxycalix[4]arene 
Halogenated hydroxycalixarenes can be obtained by simple condensation of 
halogenated aldehydes with either resorcinol or pyrogallol.21, 147 However, when the 
synthesis of analogues with shorter chain lengths, i.e.  methyl or ethyl were attempted, 
an insoluble polymer that could not be resolved was produced. This behaviour has only 
been reported previously when reacting the phthalimide derivatives.148 It was thought 
that the nature of the acetal, as a dioxolane that is highly reactive was the main factor; 
however, when repeated with a diethyl acetal similar results were observed.  
 
Scheme 15: Attempted synthesis of bromomethylpyrogallol[4]arene 
The formation of the polymer was therefore attributed to the presence of the 
bromine as well as the chain length. Under acidic conditions, the substitution may occur 
at both ortho and para positions of the phenolic hydroxyl, therefore forming a bakelite-
like structure or the oligomer. A similar phenomenon was observed when another 
chloro substituted aldehyde was used, inferring that the presence of a strong 
electronegative atom such as chlorine or bromine adjacent to the acetal may impede the 
stabilisation of the intermediate carbocation. Another method was therefore considered 
to access the brominated compound, utilising hydroxyl footed pyrogallol[4]arenes as a 
starting material. The brominated pendant chains could be further transformed to other 
functionalities, including amines and thiols.152 The bromination of the calixarenes’ 
pendant chains has been reported by using triphenylphosphine and tetrabromomethane 
on the C-4-hydroxybutyl-methoxy-resorcin[4]arene.151 Inspired by Stoll, who 
functionalised the upper rim of the cavitands,139 phosphorous tribromide was chosen as 
the brominating agent and resulted in the C-4-bromobutanyl-pyrogallol[4]arene 43 
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being obtained in a 65% yield. This synthetic route has an advantage over the previous 
protocols, as it does not require any prior protection of the upper rim. This selectivity 
toward aliphatic alcohols is achieved by the nature of the substitution, indeed the 
bromination occurs via an SN2 mechanism that cannot be achieved on aromatic phenols. 
 
Scheme 16: Synthesis of C-bromobutanyl-pyrogallol[4]arene 43 
b) Carboxylic acid footed calixarene 
Octamethyl ether tetracarboxylic acid resorcin[4]arenes were obtained by from a 
reaction of 2,4-dimethoxycinnamate with BF3.OEt2 as a Lewis acid catalyst, followed 
by a hydrolysis step.50 These only examples of ester footed resorcinarenes were then 
transformed to the corresponding acids and to a chiral “bridged basket” by linking the 
pendant chains together by reaction of acyl chloride and dialcohols.179  However, the 
synthesis of these types of macrocycles can lead to a mixture of isomers involving 
several isomers and therefore an alternative method was applied.  
 
 
Scheme 17: Synthesis of resorcin[4]arenes octamethyl ether tetraester 
It has been shown that in presence of a base, even a weak one, the esterification 
reaction is favoured at the phenolic alcohol; however, in presence of acetylating 
catalysts such as pyridine and DMAP the chemoselectivity can be lost.305 The 
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elongation of the pendant chains with a carboxylic acid end was therefore attempted by 
reacting C-3-hydroxypropyl-pyrogallol[4]arene 25 and C-3-aminopropyl-
pyrogallol[4]arene 35 with acetic, glutaric and succinic anhydrides. 
 
Scheme 18: Reaction of C-3-hydroxypropyl-pyrogallol[4]arene with anhydrides 
It was found that all selectivity was also lost, even in the absence of the base. 
The mass spectra analysis showed a polymer-like distribution of the peaks with mass 
difference in between peaks of 101. It can therefore be assumed that acetylation also 
occurs at two phenolic alcohols, possibly resulting in a cyclised diester at the upper rim. 
In contrast, an esterification using an acidic catalyst such as pTSA or sulphuric acid, 
should have favoured the reaction of the primary alcohols, but the product was seen to 
decompose when heated. However, when the aminopropylresorcina[4]arene was reacted 
with succinic anhydride, it appears that the reaction is favoured, but the pure product 
was not isolated. 
In order to introduce the carboxylic acid prior to the formation of the macrocycle 
a commercially available acetal was considered. The acid catalysed cyclocondensation 
of ethyl-3,3-diethoxypropionate with pyrogallol was attempted, leading to the formation 
of a non-resolvable mixture. In view of previous results, the small chain length between 
the aldehyde and the ester group may interfere in the stabilisation of the intermediate 
carbocation. It can also be assumed that electrophilic addition also occurs at the ester 
bond, forming a polymer. The ester itself may well be competing with the acetal, as it 
can be hydrolysed under acidic conditions, however, this effect may drive the 
equilibrium to the right favouring the macrocycle formation. In order to assess the role 
of the carboxylic acid in the reaction, 4-formylbenzoic acid was reacted with 
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pyrogallol under microwave irradiation, forming predominantly the rctt chair (80%) 
conformation in a 86% yield. This high ratio of rctt may be due to the fact that the 
starting aldehyde is sparingly soluble in the acidic ethanolic solution and may therefore 
displace the reaction towards the formation of the kinetic product. 
 
Scheme 19: Synthesis of 4-benzoic-pyrogallol[4]arene acid 45 
As the method used was tuned for the formation of the rccc for the aliphatic and 
aromatic analogues, it can be assumed that the formation of the rctt isomers is probably 
due the presence of the aromatic carboxylic acid, therefore its presence has an effect in 
the cyclisation process. Suitable crystals for single crystal X-ray analysis were obtained 
from deuterated dimethyl sulfoxide, which is highly disordered within the crystal. 
.  
Figure 94: rctt 4-benzoic-pyrogallol[4]arene acid view from (a) top and (b) side  
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2. ATTACHMENT OF ONE AMINO ACID 
With a wide selection of macrocycles prepared from the variety of commercially 
available acetals, many coupling reactions were attempted to attach a relevant amino 
acid or linker onto the macrocycles’ pendant chains. In order to avoid the selective 
protection of the upper rim and the potential solubility issue, the functionalisation of the 
acetal was envisaged first. A protected amino acid, Fmoc-(tBuO)glutamic acid, was 
coupled to aminobutyraldehyde via a DIC/HOBt coupling in an 84% yield. 
Unfortunately, when reacted with pyrogallol under acidic conditions, the condensation 
did not lead to the tetramer.  
 
Scheme 20: Transformation of the aminobutyraldehyde diethylacetal; a) PS-DCC, PS-DIEA, 
b)Pyrogallol, HC, EtOH, 100 ºC, 10min, µW 
Similar results were obtained when other linkers were used, such as N-protected 
aminocaproic and aminoundecanoic acids. It was therefore decided that the extension of 
the pendant chains should be pursued via attachment to the cyclised macrocycle instead. 
A bifunctional linker such as gluteraldehyde was also considered. However, the absence 
of selectivity during the Schiff base formation, will result in a polymer-like structure 
that may include several calixarenes together and therefore was not pursued further. 
Instead, the coupling reaction between an amine and a carboxylic acid in the presence of 
a non protected phenol was considered as it was reported that it did not interfere.176  
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Several reactions were therefore attempted on aminopropyl macrocycles, using 
various coupling agents combined with different bases, activators and protected amino 
acids to avoid any side reactions. This results are summarised in Table 2. Although 
most reactions succeeded in yielding the calixarene, the purification, in particular the 
removal of the side products, including the urea and base, was challenging. This was 
particularly problematic due to the unpredicted solubility issues of the target 
calixarenes. The hydrophilic nature of the upper rim, also proved to be a problem when 
trying to separate out the pure products by HPLC. 
 
Macrocycle Amino Acid Coupling Agents 
RsC3NH2 Boc-Ala DCC, DMAP 
RsC3NH2 Boc-Ala EDC.HCl, DIEA 
RsC3NH2 Boc-Ala DIC, HOBt 
RsC3NH2 Boc-Ala DIC, DIEA 47 
RsC3NH2 Boc-Ala DIC, DIEA, HOBt 
RsC3NH2 Fmoc-Asp(OtBu) DIC, Pyridine 
RsC3NH2 Boc-Ala DIEA, HOBt, NHS 
RsC3NH2 Boc-Ala DIEA, NHS 
RsC3NH2 Fmoc-Ala PS-DCC, DIEA 48 
PgC3NH2 Ac-cysteine PS-DCC, PS-DIEA 
Table 11: Attempted coupling of aminoacids to the macrocycle 
 
The attachment of butyloxylcarbonyl protected alanine was successful when 
reacted with N,N’-diisopropylcarbodiimide (DIC, 5 eq.), Hünig’s base (DIEA, 4 eq.) 
and aminopropylresorcin[4]arene (RsC3NH2, 1 eq.), with and without 1-
hydroxybenzotriazole. However, the yields were very low (< 5%) and only traces of the 
desired compound could be identified by 1H NMR. Moreover, the removal of both 
N,N’-diisopropylurea and diisopropylethylamine was difficult and sufficient material 
was not recovered for full analysis via reversed phase HPLC. Nevertheless the MALDI 
analysis, which has sensitivity up to the ng/mL, showed that one fraction contained the 
tri-Boc-ala-aminopropylresorcin[4]arene. 
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In order to avoid the presence of the side product, generated by the coupling 
agent, i.e. N,N’-diisopropylurea (DICU) or N,N’-dicyclohexylylurea (DCU), polymer 
bound reagents were considered. This method has been shown to be highly useful when 
working on small scales as they can be removed by simple filtration.309 In addition, this 
valuable technique can also be combined with microwave irradiation. The tetra-
substituted Fmoc protected alanine aminopropylresorcin[4]arenes were obtained by 
combining PS-DCC and microwave irradiation at 100 °C for five minutes, with and 
without HOBt. Although the yields obtained were low (< 1%), comparable to the liquid 
phase reaction, the absence of HOBt led to a higher ratio of the fully substituted 
compound according to the mass spectrometry analysis. In order to check the effect of 
the base, the attachment of protected aspartic acid to aminopropylpyrogallol[4]arene 
was attempted using only resin bound reagents PS-DCC and PS-DIEA, coupled with 
microwave irradiation at 100 ºC for 20 minutes. According to the mass spectra analysis, 
the reaction contained a mixture of unreacted starting material and mono-functionalised 
calixarene, but was not isolated for further analysis. 
3. ATTACHMENT OF STEALTH MOLECULES 
The attachment of a long pegylated chain would extend the size of the particle as 
well as improve the solubility in water. The attachment of a pegylated chain was 
attempted using DIC coupling in solution, although the 1H NMR data indicates the 
presence of the calixarenes, the purification was challenging due to solubility issues. 
This was overcome by the use of a polymer bound coupling agent which faciliated the 
purification process. Therefore the attachment of a succinyl functionalised PEG chain 
has been successfully achieved, as indicated by 1H NMR.  
 
Figure 95: Pegylated macrocycle 
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4. ATTACHMENT OF PEPTIDES 
The mutation of p53, which is the most common abnormality found in 50% of human 
cancers, is expressed in twelve out of eighteen primary uveal melanomas.310 This key 
human antigen is essential in the pathway involving the control of apoptosis and cell 
cycle arrest. Due to its over expression in many cancers, it is a target of choice for 
immunotherapy. Therefore, peptides derived from the oncogenic protein p53 were 
chosen as model antigens and were synthesised using the microwave-assisted SPPS 
method. 
Peptide synthesis first appeared in 1882, and this well-known process was 
revolutionised in 1959 by Bruce R. Merrifield when he introduced the concept of an 
insoluble support.311 Today, solid phase peptide synthesis (SPPS), employing a variety 
of functionalised resins derived from Merrifield’s resin, is the most widely used 
method. Used in combination with microwave irradiation, it leads to a more efficient 
and rapid synthesis of pure peptide.312  
 
Figure 96: SPPS synthesis 
The synthesis is based on protection, deprotection and coupling methods, all on 
a solid polymeric support, combined with microwave irradiation. Wang resin, a 
modified Merrifield resin, is the most commonly used resin due to its mild cleavage 
requirements. As represented in Figure 96, the peptides are synthesised on the 
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Wang resin preloaded with a Fmoc protected amino acid on the C-terminus (Figure 
96a). The amino acid is then deprotected with piperazine and coupled with the 
carboxylic acid of the following amino acid in the sequence, using O-benzotriazole-
N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU), DIEA / NMP as a 
coupling reagent (Figure 96b). When the sequence is completed, the resin is cleaved 
with an appropriate acidic mix (e.g. TFA) and the peptide precipitated in diethyl ether 
(Figure 96c).  
The attachment of the cleaved peptide to the calixarene was considered using 
solution phase chemistry, but this method was limited to peptides sequences with no 
functional side chains, as their protection groups are designed for removal in the 
cleavage step. Asp-Ala-Ala-Ala (6eq.) was reacted with aminopropylresorcin[4]arene (1 
eq. ) in the presence of PS-DCC without any base 50, which resulted in no substitution 
as indicated by the MALDI analysis. The attachment using the unbound Ala-Ala-Ala-
p53(108-122) unprotected peptide 51 (MW= 1873.01g.mol-1, 2 eq.) to C-3-
aminopropyl-pyrogallol[4]arene 35 (1 eq.) using polymer bound reagent PS-DCC (8.eq) 
and PS-DIEA (6 eq.) was subsenquently attempted. The resulting solid that was 
obtained was used for MS analysis. It revealed the presence of a mixture containing the 
free peptide m/z = 1874.01 [M]+ and 1897.91 [M + Na]+ . Another peak at m/z = 
2603.31 corresponds to the mass of a single peptide chain and one calixarene. However, 
this would lead to a m/z ratio of 2637.01, the difference of mass could potentially 
correspond to the loss of two hydroxyls groups, indicating that the peptide was attached 
at three sites on the macrocycle. The spectra also revealed a m/z = 3428.68 
corresponding to the mass of two pyrogallol[4]arene covalently bound to one single 
peptide. Although this method proved that the peptide could be covalently attached, it is 
not selective enough and does not enable the controlled growth onto all pendant chains. 
Therefore, another approach was considered, whereby the peptides grafted onto the 
Wang resin was synthesised until completion and then attached to the macrocycle.  
As an alternative, the calixarene linkage was therefore attempted on the resin 
bound protected peptide. In order to couple the functional feet of the calixarenes onto 
the peptide linked to the resin, it was necessary to introduce a carboxylic function or 
introduce a linker such as succinic or glutaric anhydride onto the resin.  
In an attempt to optimise the conjugation method, small peptides containing 
three alanines were first considered. The tri-alanine epitope is a sequence available 
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for trypsin-like cleavage site; associated with the proteosome and therefore could 
constitute an excellent linker between the calixarene and the peptide of interest.245 In 
order to induce more flexibility between the resin bound peptide and the calixarene 
pendant chain, dodecanedioic acid was used as a lipophilic spacer. Unfortunately, when 
the spacer bound resin was reacted with either aminopropyl pyrogallol[4]arene or the 
aminopropyl resorcin[4]arene, the functionalisation was not complete as indicated by 
MALDI mass spectrometry. The NMR results also showed trace of both peptide and 
undecanedioic acid, indicating that the didodecanedioic acid tends to react with the 
peptide preferentially, resulting in a peptidic dimer. 
The direct coupling of the carboxylic footed pyrogallol[4]arene was also 
attempted using similar methods, although it was thought to be restrained by its chair 
conformation. All syntheses led to a complex mixture with similar mass to the expected 
compounds however, this could not be resolved. Generally it corresponded to both di- 
and tri- substituted calixarenes and none of the fully substituted compound was 
obtained. This was thought to be induced by the flexibility and therefore the 
accessibility of the peptides residue towards the pendant chains. As seen in the previous 
chapter, the solvent and the nature of the pendant chain play an essential role on self-
assembly in the solid state, it can be assumed that this effect is also present in solution 
and may impede the funtionalisation reaction.  
 
 
Scheme 21: p53(108) sequence Gly-Phe-Arg-Leu-Gly-Phe-Leu-His-Ser-Gly-Thr-Ala-Lys-Ser-Val-
Ala 
 
The immunogenic peptides, p53(108) was synthesised using the SPPS method 
and was then modified using glutaric anhydride in order to attach the 
aminopropylpyrogallol[4]arene. Only one compound was isolated, with 74 % purity as 
evaluated by HPLC. According to the MALDI analysis, only the non-conjugated 
modified peptide was recovered 52. Similar results were obtained when a longer 
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sequence was used. Ala-Ala-Ala-p53(108)-Ala 51 was also synthesised using the SPPS 
method, according to the MALDI spectrum, the sequence was successfully synthesised 
(m/z = 1861.97, [M]+ and 1882.95, [M+K]+ ) and small part of the peptide was still 
Fmoc protected (m/z = 2083.03, [M+Fmoc]+), showing the importance of the 
deprotection step within the synthesis. Piperazine deprotection should be performed 
prior to the cleavage step as its use in solution phase can also be challenging. These 
results also indicated that the coupling is independent of the amino acid and could be 
caused by the coupling agent. 
Although HBTU seems to be the coupling agent of choice for amino acids to 
form peptides, DIC appears to be more efficient when coupling to other amines.313 The 
solid supported carbodiimide was also expected to be a efficient reagent. Unfortunately, 
the polymer bound coupling was not efficient when applied to the peptide bound resin, 
due to accessibility of the reagent within the pores of the polymer.  
Inspired by Merrifield’s work and the peptide synthesis just realised, a novel 
solid supported method involving pyrogallol[4]arene macrocycle was considered. This 
method could offer the accessibility to a simplified method that could give a way to a 
wide range of compounds in the high throughput range thereby leading to a synthetic 
automated process. This tool would be highly desirable for the biological screening 
assay, by mean of grafting the peptide directly onto macrocycles, leading to potential 
peptides library.  
 
C. SOLID SUPPORTED SYNTHESIS 
When the Wang resin was used as a solid support in the peptide synthesis, the 
structure of the linker, hydroxymethylphenol (HMP), was attractive. Its similarity to the 
C-hydroxybutyl-resorcin[4]arene and C-hydroxybutyl pyrogallol[4]arene, due the 
presence of both phenolic and alkyl alcohol functional groups, led to the consideration 
that the calixarenes could be covalently bound to the resin (Figure 97). The work on 
selective protection showed that the benzyl chloride of the Merrifield resin could 
selectively react with phenolic hydroxyl on the upper rim of the calixarene. This method 
could potentially overcome the problem encountered during the attachment of long 
peptide onto the pendant chains of the calixarenes.  
The concept of functionalising polymeric resins with calixarene derivatives 
has been considered by others for various different purposes. The ability of the 
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phenolates to substitute chlorine, has also been considered as a potential pathway for the 
attachment of this class of macrocycles onto commercially available resins.314-315 These 
useful new materials have been investigated for the extraction of metals,164, 316-317 
especially in two-phase extraction systems.318 Calixarenes have been previously 
transformed by attaching polymerisable groups to give access to a novel high 
performances polymeric materials for photolitography.319 Macrocycle based polymers 
were obtained by condensation of calix[4]resorcinarene with formaldehyde, to asses 
their ion-exchange capacities.265 A polymeric matrix immobilised resorcin[4]arene was 
used to immobilised palladium in order to catalyse hydrogenation.320 More recently, 
calixarenes have been attached to TentaGel resin and tested in solid-phase synthesis by 
condensation of thymine unit onto the upper rim.321 The emergence of solid phase 
organic chemistry (SPOC), due to its ease of purification was therefore an attractive 
concept.  
 
 
Figure 97: Similarities of HMP linker and C-4-hydroxybutyl-pyrogallol[4]arene 
The degree of incorporation of any linker to a polymeric support correlates not 
only with the substitution but also with its swelling capability.322 It has been shown that 
more than 99 % of the reactive sites on a resin are in the microporous interior of the 
bead. These become accessible during the swelling process and the pore sizes are large 
enough to accommodate the 10 Å diameter calixarene. 
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1. ATTACHMENT ONTO THE RESIN 
The linkage of phenols on Merrifield resin has been widely studied, involving a 
different bases. Benzyloxybenzylamine (BOBA) is linked to Merrifield resin by 
reacting sodium hydroxide in dimethylsulfoxide for twenty hours.323 Phenolate can be 
obtained by heating a slurry of sodium hydride in tetrahydrofuran to reflux for over 
sixteen hours.314 Sodium hydride is a strong base that has been previously used to attach 
alkyl alcohol to polystyrene resins.324 As the use of sodium hydride may impede the 
selectivity when other alcohols are present it should be avoided when selectivity is 
sought.325 In order to obtain a selective functionalisation, several bases were considered, 
it was thought that a weaker base would be more selective and therefore sodium 
hydroxide and sodium hydride were avoided. In addition, some pyrogallol[4]arenes 
were seen to decompose under strong basic conditions. Several phenols were attached to 
a Merrifield resin by reacting phenols with sodium methoxide in dimethylacetamide for 
sixteen hours.326 Although proving that the phenols reacted faster than the 
hydroxybenzyl alcohol, it could not be used with the calixarenes due to solubility issue 
but could be reevaluated with other solvent systems, or a step-wise addition approach. 
Caesium carbonate can be used with N-methylpyrrolidone at 150 °C in a microwave 
reactor for five minutes, to prepare Wang resin, giving better results than the traditional 
use of potassium carbonate and potassium iodide.327 Potassium carbonate was 
considered in order to deprotonate the phenolic hydroxyls of the calixarenes. Although 
the substitution occurred, the method offers some disadvantages. The drawbacks of the 
method were the solubility of the base as well as the presence of three different phases. 
A phase transfer catalyst, tert-butyl ammonium chloride, was added to overcome the 
solubility problem but only resulted in partial attachment. In order to minimise the 
number of phases, weaker liquid bases including diisopropylethylamine, triethylamine 
and pyridine were also tried. Diisopropylethylamine is the only base that is able to 
deprotonate the phenols, without forming a quaternised amine with the chlorine which 
may sterically hinder the substitution. According to the IR analysis, the use of pyridine 
resulted in the maximum substitution.  The results of this study are summarised in Table 
12. The functionalisation of the polymer has yet to be optimised, nevertheless it enabled 
the project to carry on to the proof-of concept of pyrogallol[4]arene substituted resin. 
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Base considered Outcome 
Sodium methoxide Solubility issue 
Potassium carbonate  
Caesium carbonate  
Limited substitution due to a three phase 
reaction 
Diisopropylamine/NMP No substitution  
Tritehylamine Weak substitution 
Pyridine dried on potassium hydroxide Partial substitution 54 
Table 12: Bases considered for the attachment to the resin 
 
Infrared is a useful tool to assess functional changes, especially when groups 
have characteristic bands such as carbonyl are used. Since the emergence of the resin in 
organic synthesis, several infrared techniques have been optimised to obtain the 
maximum information with the minimum amount of sample, moving away from the 
traditional use of potassium bromide discs preparation of the sample. Diffuse 
reflectance FTIR (DRIFT) enables the reduction of the amount of sample required and 
single bead analysis is now possible.328 When all available methods, such as single 
bead, beam condenser Macro-ATR, Macro-Raman and KBr methods were compared, it 
was found that they all give similar results.329 With the Wang resin, several 
characteristic peaks are observable with all methods except Raman, a sharp band at 
3573 cm-1 and a broad band at 3449 cm-1 attributed to the free and intra-resin hydrogen 
bonded hydroxyl groups, and a strong CH2-OH bending vibration at 1232 cm-1. 
The analysis of the functionalisation was performed using a Perkin -Elmer AT-
FTIR. By comparing the unsubstituted Merrifield resin, the C-3-hydroxypropyl-
pyrogallol[4]arene and the substituted resin, comparable changes are observable. 
Different sample preparations were attempted either using the beads directly, the ground 
beads, potassium bromide disks with varying concentration of the sample and a pressed 
disk of the resin. However, the best spectrum was obtained when using the beads 
directly. Although the spectral baselines were distorted, it was still possible to observe 
the main changes that account for successful substitutions. 
As shown in Figure 98, the disappearance of the C-Cl band at 1262-1266 cm-1 
present in the unsubstituted Merrifield resin is observed when the substitution occurred. 
The three main bands for the pyrogallol[4]arene substituted resin are visible at 
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3181, 1692 and 1303 cm-1, indicating the presence of hydrogen bonded hydroxyls 
considered as phenols. The appearance of the characteristic bands of the 
pyrogallol[4]arene confirm its presence, as it was shown previously when other 
calixarenes were used.314 
  
Figure 98: Comparison between the PS-Cl and PS-PgC3OH 
The quantification of the substitution was determined by Volhard’s method 
(Scheme 22). The chloride ion concentration was obtained by titration of the unreacted 
silver ions, from a standard silver nitrate solution, with a potassium thiocyanate 
solution, using ferric ammonium sulphate in an acidic solution as a coloured indicator. 
Generally, a known amount of resin is reacted with a base such as methylmorpholine to 
displace the chloride. Pyridine was used for the substitution, as it can be directly 
assessed by titration of the reaction washes. As previously reported, this method may 
show some inconsistency and therefore should be used in combination with other 
analytical methods.330  
 
Scheme 22: Volhard's titration 
400900140019002400290034003900
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SEM also gives an important insight into the nature of the polystyrene beads, 
their size and consistency. The size of the commercial polystyrene beads was found to 
be not homogenous within the sample, varying from 50 - 100 µm, as seen in Figure 99. 
 
Figure 99: SEM image of the pyrogallol[4]arene resin beads 
Although it is not quantitative, SEM can also be used as an elemental analysis 
useful tool to compare the functionalised resin with the starting material. In order to see 
a significant difference, elements with high Kα values, such as sulphur, were introduced 
to the resin bound macrocycle. In order to check the functionalisation occurs at either 
the phenolic or the aliphatic alcohols, the resin was reacted with methanesulfonyl 
chloride. The resulting resin was washed and analysed by SEM-EDX.  
      
Figure 100: SEM-EDX of the PS-Cl and PS-PgC3OSO2CH3 
As seen in Figure 100, although chlorine still appears on the beads surface, 
showing the attachment was not complete, sulphur is also present on the surface of the 
beads confirming the presence of the macrocycles. 
  
146 
The presence of the pyrogallol[4]arene on the polystyrene resin was also 
assessed by ATR-IR. The hydroxyl stretch of the phenols (3362 cm-1) is still present 
proving that the hydroxyl groups are on the surface on the beads as shown in Figure 
101. 
 
Figure 101: IR PS-Cl and PS-PgC3OSO2CH3, red boxes highlight the comparable regions of the 
spectra to Figure 97 
2. CLEAVAGE OF THE MACROCYCLE 
Once the attachment of the macrocycles onto the resin was efficiently assessed, 
the retrieval of the product and subsequently its cleavage was developed. In the search 
for the solid-supported synthesis of steroids it has been shown that stannic chloride 
(SnCl4) is effective for the cleavage of phenolic compound from Merrifield resin.325-326 
Wang resin is one of the solid supports of choice for solid-phase peptide synthesis due 
to its ease of removal by treatment with acid such as trifluoroacetic acid can also act as 
a deprotecting agent. It was therefore considered first due to its lower toxicity and 
higher ease of use. For pyrogallol[4]arene functionalised resin, the cleavage was 
thought to occur at a different point than the Wang resin. As the phenolic alcohols are 
directly attached to the methylene group of the Merrifield resin, it decreases the 
mesomeric effect within the aromatic ring. The TFA-cleaved product has been seen to 
form a derivative, in the ortho position of the phenol;326 however, due to the calixarene 
structure, this position is not available for the rearrangement and therefore was avoided. 
 
400900140019002400290034003900
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Figure 102: TFA cleavage site on Wang resin and pyrogallol[4]arene resin 
When PS-PgC3OH was treated with a TFA solution (95 %) for two hours at 
room temperature, the resulting product, after evaporation and trituration in water, was 
isolated as the pure C-3-hydroxypropyl-pyrogallol[4]arene as analysed by NMR. In 
order to identify the nature of the remaining alcohol, near-IR was attempted, although 
the main differences were observable in the visible IR shifts.  
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Figure 103: IR spectra of unsubstituted resin (PS-Cl), the free C-3-hydroxypropyl-
pyrogallol[4]arene (PgC3OH) and the substituted resin before cleavage (PS-PgC3OH) and after 
(PS-X) 
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When comparing the IR spectra, in Figure 103, it is noticeable that the 
calixarene functionalised resin has the same spectrum as the free macrocycle. The 
comparison of the Merrifield resin and the cleaved resin also proved that the cleavage 
occurred. 
3. FUNCTIONALISATION OF THE PYROGALLOL[4]ARENE RESIN 
In the search for pegylated Merrifield resin and its attachment to cyclodextrin 
(CD), it has been shown that there are advantages to use a mono-functional linker 1,6-
hexamethylene diisocyanate (HMDI), that can be reacted stepwise onto the alcohol 
chain of the PEG and the alcohol of the CD. This functional change is visible in IR by 
the introduction of a carbonyl.331 This method was employed to confirm that the 
remaining hydroxyl chains of the pyrogallol[4]arene were available to react and was 
confirmed by IR. However, one drawback is that the carbamate linker may be cleaved 
by the TFA mix and consequently it could not be used for further functionalisation.332  
Esterification has been achieved using ten equivalents of acid pre-treated with 
DIC (5 eq.) in DMF for five minutes, followed by the addition to a mixture of the resin 
with DMAP as a catalyst. The use of the microwave irradiation not only increased the 
yield but also reduced the amount of acid required to achieve the maximum substitution 
in a minimum time (7 minutes, 100 W). Interestingly it has been shown that the use of a 
closed vessel can lead to a rearrangement of the DIC urea, leading to lower yield. HOBt 
(5eq.) has been shown to increase the esterification yield when used in combination 
with DCC (5eq.) and DMAP (1 eq.).333-334 The efficacy of this reported method was 
assessed by introducing the sulphur N-acetylcysteine via a DIC coupling. The IR results 
in Figure 104 showed the presence of the pyrogallol[4]arene on the resin, but the low 
content of carbonyl peak indicate the low substitution.  
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Figure 104: IR spectra of unsubstituted resin (PS-Cl) and the substituted resin before cleavage 
(PS-PgC3OCys(Ac))  
The SEM-EDX results showed the presence of the sulphur on the surface of the beads, 
implying a successful functionalisation (Figure 105). 
 
 
Figure 105: SEM EDX Spectra of (a)PS-Cl 200-400( b) PS-PgC3OCys(Ac) 
The analysis of the substitution was also assessed by UV, by determining the 
Fmoc-chromophore liberated in the supernatant following the cleavage with piperazine. 
As the Fmoc concentration is directly correlated to the substitution level, it can be 
compared to commercially available substituted resins that are used for peptide 
synthesis. In view of the further functionalisation of the resin with amino acids and 
peptides, it would also be a useful tool for monitoring the reaction. 
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The functionalisation of the pyrogallol[4]arene resin was then extended to a 
small peptide. Tri-alanine peptide was grafted to the pyrogallol[4]arene resin via a DIC 
coupling. The MALDI analysis of both starting pyrogallol[4]arene and the peptido-
pyrogallol[4]arene revealed that three tri-alanine peptidic chains were successfully 
attached onto the calixarene. These results demonstrate the feasibility of this novel 
synthetic process but still require further investigation to confirm the attachment onto 
the pendant chains. 
Further analyses, such as TGA, are required to assess the substitution as well as 
the efficiency of the methods. The good swelling properties of the resin result in the 
formation of a gel that can be analysed by NMR either directly324 or by an insert.335 
Although working on a solid phase, it has been shown that 13C NMR can be used to 
analyse Merrifield resin using a conventional spectrometer, by enhancing the signal to 
noise ratio and decreasing the resolution.268, 336 As 13C NMR has also been proved 
efficient on a pegylated resins,57, 334 this analytic method should be optimised in future 
work. In addition, this type of solid supported work could be extended to chlorotrityl 
resin, as it is known to react readily with phenols,337 and can be readily cleaved with 
TFA. Silyl chloride linkers have been proved to attach effectively primary and 
secondary alcohols as well as phenols to Merrifield resin.338 Improvement of the 
cleavage step could be achieved by microwave irradiation; the use of a cleavage mix of 
1:1 TFA/DCM, for three hours can results in low yield,339 but this can be improved by 
microwave heating for thirty minutes at 500 W at 75 °C.340 Recently, a method using 
microwave irradiation reported the efficient cleavage of peptide by reacting a mixture of 
TFA/TIS/H2O (95 : 2.5 : 2.5) at room temperature for 15 minutes followed by a fifteen 
minutes  irradiation (30 W) at 50 °C.341 Other cleavage mix involving 
trifluoromethanesulfonic acid (TfOH) and trimethylsilyl triflate (TMSOTf) could also 
be attempted as they appear to be more effective with than TFA at cleaving 
hydroxybenzamide.323 Hydrochloric acid could also be used but can sometimes lead to 
unexpected residues.327 
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CHAPTER V: CALIXARENES DERIVATIVES IN 
BIOLOGICAL SYSTEM 
As mentioned previously, the pyrogallol[4]arene derivatives have been less 
extensively studied than their calix[4]arene analogues. Because the macrocycle will be 
considered for immunisation in the future, it is therefore necessary to investigate their 
toxicity before using them as immunotherapeutic vectors. Potentially the macrocycles 
that have been functionalised with peptides will be employed but as a starting point, 
pyrogallol[4]arenes alone were investigated for toxicity and inertness in vitro. This 
work involves heamolytic properties on red blood cells and their effect on dendritic 
cells. The latter was assessed by studying the effect of varying concentration of the lead 
macrocycle on the viability and proliferation of the cells. Preliminary studies, including 
haemolytic properties and cytotoxicity studies did not show any toxicity at the workable 
concentrations. 
 
A. INTRODUCTION 
 Phenol derived calix[4]arenes (Figure 106a) have received most attention for 
their interactions with various biological systems and Coleman has performed 
pioneering work in assessing their cytotoxity, by showing their lack of haemolytic 
properties unlike many other polyphenols.19, 342 The low toxicity of calixarenes 
combined with their complexing ability provide promising use as vectors in 
pharmacology.343-344 They can therefore stabilise medicines, prolong their effects of and 
decrease their side effects creating a new convenient medicinal form. Sulfonation of 
these compounds gives access to para-sulfonato-calix[n]arenes (Figure 106b), that have 
been widely studied, mainly by Coleman and co-workers, who presented a review of 
their biochemistry and biodistribution.345-346 Combined with drugs, their biological 
activities are quite widespread as they have been shown to have anti-viral, anti-bacterial 
and antithrombotic activities as well as the ability to inhibit enzymes such as L-lysyl 
oxidase, which is up-regulated in tumours to increase metastasis.347 Phosphonated 
calixarene derivatives (Figure 106c) also show good promise as anticancer agents. Their 
efficacy and non-toxicity have been confirmed by using high doses from 10 to 40 mg of 
calix[4]arene per take of pharmaceutical salt.348 
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Figure 106: (a) General formulae of the amphiphilic calixarenes, Alk=CH3(CH2)n with n= 4,6,8,10 
and R= H, PO(OEt)2or PO(OH)21, (b) para-sulfonato-calix[n]arene and (c) patented 
phosphonated calix[n]arene  
Tert-butyl-calix[4]arene covalently bound to an antifungal drug, amphotericin 
(Figure 107a) was shown to have an antifungal activity that is ten times less toxic than 
the unbound drug.349  
 
Figure 107: (a) Amphotericin B-calix[4]arene conjugate, R=H or t-Bu349, (b) Guanidinium 
calixarene derivative R =hexyl, propyl, methyl350 
Water soluble guanidinium calixarene derivatives (Figure 107b) have been made 
by reacting the amine derivative with N,N’-di(tert-butoxycarbonyl)thiourea in the 
presence of mercury (II) chloride. Their ability to bind to plasmid DNA in the 
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millimolar concentration range without any toxicity can be exploited in the 
condensation of DNA to perform cell transfection.350 The toxicity of those derivatives 
was assessed by using a MTT assay, a cell proliferation and viability assay based on the 
reduction of a yellow tetrazole (MTT, 3-(4,5-dimethylthiazol-2-yl)-diphenyl tetrazolium 
bromide) within living cell mitochondria; no toxicity was found up to 25 µM.351 They 
showed promise as an antibacterial agent in several studies.352-354 Similar derivatives 
have shown comparable broad spectrum and lower cytotoxicity compared to 
commercially available agents, leading to the conclusion that they have a place as an 
adjuvant for antimicrobial chemotherapy or disinfection.355 
Ureidocalix[8]arenes were shown to modulate C6 glioma cell proliferation and 
were proposed as an anticancer agent (Figure 108a).356 In order to rule out their 
apoptotic effect, flow cytometry analysis after staining by propidium iodide and the 
MTT cell proliferation assay were performed. Pegylated calix[n]arenes, Figure 108b, 
not only enhance the innate defence mechanism in murine macrophages by mediation of 
an L-arginine dependent mechanism of activation but are also effective in MHC class II. 
It has also been assessed that the optimal chain length for high antimicrobial activities is 
PEG-6.357 
 
Figure 108: (a) Ureidocalix[8]arene, R=GlcNAc, butyl, H 356; (b) Pegylated calix[n]arene, 357 R2 = 
C4H8 or C8H17, R3= H or (CH2CH2O)n=6 to 12  
N-Acetyl-D-glucosamine substituted calix[4]arenes (Figure 109a) were used as a 
stimulator of NK-cell mediated antitumour immune response, showing better response 
than N-acetyl-D-glucosamine substituted dendrimers that are conventionally used.358 
Glycomimetic antigens, based on carbohydrated calix[4]arene attached to antigenic 
peptides, were evaluated as part of an anticancer vaccine (Figure 109b). After 
immunisation, an increase in efficacy was found for the one conjugated to calix[4]arene 
compared to the monovalent antigen.359 
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Figure 109: Glycosylated calix[4]arene: (a) N-Acetyl-D-glucosamine substituted (b) carbohydrated 
calix[4]arene attached to antigenic peptides 
Cyclohexapeptidomimetic calix[4]arene derivatives were first reported for their 
antiangiogenic and antitumour properties,360 and then patented as growth factor binding 
compounds.361 Other antimicrobial peptide mimetics based on calixarenes have the 
potential to treat diseases, neutralise endotoxins, inhibit endothelial cell proliferation 
and act as angiogenic factors (Figure 110a).362-363 Their ability to inhibit the binding of 
vascular endothelial growth factor to its receptor was proved both in vitro and in vivo in 
a nude mouse xenograft model.364 Towards the development of calix[4]arene-based 
radiotherapeutic agents, Grote Gansey et al. studied the conjugation to biomolecules 
such as human or mouse serum albumin (HSA/MSA) and an antibody directed against a 
pregnancy hormone was chosen as a model tumour specific antibody mAb-506A. Their 
functionality remained inherent when up to six equivalents of calixarenes were attached 
and did not lead to any immunogenic response (Figure 110b).365  
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Figure 110: Peptidic calix[4]arene 
Nucleotide-calix[4]arene conjugates have shown excellent water solubility and 
preliminary studies assessed their ability to inhibit DNA replication in vitro (Figure 
111).366 
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Figure 111: Nucleotide calix[4]arene conjugate366 
Amino-functionalised calix[4]arene pentamers, represented in Figure 112, also 
exhibit DNA binding with reduced toxicity, emphasizing their potential as a gene 
transfection agent.367 
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Figure 112: Calix[4]arene pentamer367 
Most reported biological studies related to calixarenes macrocycles concentrated 
on the tert-butylphenol derivatives, and studies including their hydroxyl derivatives, i.e. 
resorcin[4]arene and pyrogallol[4]arene, have received less attention.252 Resorcinol, the 
resorcinarene precursor, when incorporated into some drugs, is thought to have 
particular structural characteristics that contributes to the increased potency and activity 
of medicine.368 One of the simplest and most commonly used classes of resorcinol 
derivatives are the resorcinolic lipids, identified from numerous plants, fungi and 
bacteria and thought to play a defensive role as antimicrobial and antifungal agents.369-
370
 Their antiseptic properties are associated with their low surface tension which 
enables the compounds to penetrate membranes, and their chemical reactivity is 
associated with the two hydroxyl groups.371 The antiseptic properties of hexyl-
resorcinol are exploited in several commercially available treatments such as sprays and 
gargles, e.g. Beecham’s throat plus and Strepsils Extra Lozenges. Substituted resorcinol 
derivatives can also exhibit depigmental action and have proved to be effective in the 
inhibition of tyrosinase, an enzyme known to catalyse the production of melanine.372 
 
Figure 113: Resorcinol and hexyl-resorcinol 
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These antiseptic properties seem to be retained in the tetrameric form, as 
fluorinated substituted resorcin[4]arene have been purposely used to coat medical 
devices such as stents.373  Prolyl bearing lipophilic resorcin[4]arenes (Figure 114), that 
self-assemble into solid-lipid nanoparticles, can be modified on the surface to maximize 
the interaction with specific antibodies for drug targeting.374  
 
Figure 114: Prolyl bearing lipophilic resorcin[4]arene 
The ability of calixarene derivatives, in particular alkyl and aryl resorcinarene 
derivatives, for use as excipients for active substances, was evaluated in 2006 by 
Wolf.375 The protein localised into the eukaryotic cell nuclei, histone, can bind to 
resorcinarenes via hydrogen bonding and cluster effects.376-379 
 
Figure 115: Histone binding resorcinarene cluster38 
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Glycosylated dendrimers, based on resorcinarene, have also been applied to 
biological systems.380-381 When the phenoxy groups are replaced by saccharides, the 
lipophilic chains take over the self-assembly in the transformation of nanoparticles into 
an “artificial virus”.382  Their potential as vectors was assessed in hepatic cells (Figure 
116).383 Glycosylated resorcinarenes bound to DNA form virus-like particles, with 
decreased toxicity, capable of receptor-mediated hepatocyte targeting.384 An artificial 
bi-stable resorcinarene host guest system was engineered to mimic a biological protein-
DNA interaction which was controlled and switched by UV light.385 
 
 
Figure 116: Glycosylated lipophilic resorcin[4]arene382 
Studies exposed the ability of calixarenes to interact with the immune system 
with only little toxicity, showing good promise in terms of the pyrogallol[4]arenes 
derivatives. As pyrogallol is a biologically active compound and is used in biology to 
assess peroxidase activity, it could be expected to show little to no toxicity.386 However, 
pyrogallol can be seen to have an inhibiting effect in vitro on the growth of 
juxtaglomerular cells.387 It can also induce hepatocytoxicity in both mice and humans 
resulting in liver damage, as indicated by the levels of hepatic injury markers such as 
serum transaminase and bilirubin.388 
Although the mechanism of pyrogallol is considered different to catechol and 
phenol interactions in the formation of reactive oxygen species (ROS) which can be 
responsible for DNA damage,389 the pyrogallol[4]arenes reduce the oxidation properties 
by locking the benzene positions four and six due to the methine bridge.  
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In 1995, hundreds of calixarene derivatives were patented as part of a pharmaceutical 
preparation with antibacterial, antifungal, anticancer and anti-HIV activity. 
Interestingly, the p-fluorotolyl-propanoate-pyrogallol[4]arene potassium salt (Figure 
117a) showed a low EC50 on the micromolar range.390 
In order to assess the effect of the extra hydroxyls on the phenolic rings, the 
amino footed pyrogallol[4]arene (PgC3NH2, Figure 117b), known to be water soluble in 
its hydrochloric salt form, was considered. As this macrocycle will be the base to any 
peptidic derivatives in this study, it was essential to assess its effect on its own before 
seing its combined effect. 
 
Figure 117: (a) Antimicrobial macrocycle and (b) C-3-aminopropyl-pyrogallol[4]arene 35 
As the pyrogallol[4]arene will be considered as a vector for peptide delivery, it 
was essential to see its effect first when put in contact with blood, then its effect on 
dendritic cells that would be the cells targeted for immunisation. In general, the 
concentration of the tested calixarene was calculated depending on the amount of 
peptide used. In a typical immunisation experiment, 100 µg of peptides MHC class I, 
consisting of ten amino acids with an average weight of 1000 g.mol-1, was used per 
injection per take. This is equivalent to 10 µmol per take as the ratio of calixarene to 
peptide is one to four, making the maximum dose of calixarene per take 2.5 µmol. 
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B. PYROGALLOL[4]ARENE IN VITRO 
1. HAEMOLYTIC PROPERTIES  
The haemolytic properties of the C-3-aminopropyl-pyrogallol[4]arene 35 were 
assessed in order to evaluate its effect on blood, using a similar method to the one 
reported by Coleman.391 The test consisted of monitoring the lysis of the red blood cells 
when treated with increasing concentrations of calixarenes. For this quantitative 
colourimetric determination of the haemoglobin release, Drabkin’s reagent was used, as 
it oxidises the iron from the heme, which can then coordinate to cyanide forming 
cyanmethemoglobin which has an absorbtion band at 540 nm by UV-vis. This 
comparative test was performed on washed erythrocytes extracted from freshly drawn 
human blood anti-coagulated using EDTA, to reduce the effect of other cells present in 
blood such as leukocytes and thrombocytes.  
The total haemolysis was obtained when the red blood cells were subjected to 
hypotonic stress by incubating them in water. The percentage of haemolysis is the ratio 
of the absorbance of sample with the calixarenes, corrected with the negative control 
and absorbance positive control, as shown in Equation 1. 
Equation 1:% Haemolysis 
100%
540540
540540 ×
−
−
=
PBSofAwaterwithsampleofA
PBSofAcalixarenewithsampleofA
Haemolysis
nmnm
nmnm
 
The first experiment was performed using the extract of sample directly. As the 
red haemoglobin absorbs at 450 nm, it can have an impact on the readings at 540 nm. 
Therefore, the samples should also be centrifuged before being added to the Drabkin’s 
reagent, in order to minimise any false positive results.  
The C-3-aminopropyl-pyrogallol[4]arene 35 was only sparingly soluble in PBS, 
therefore to increase solubilisation DMSO was added and maintained at less than 10% 
DMSO. This was thought to affect the cells as DMSO was previously seen to induce 
haemolysis. 392-394 However it did not have an effect over an incubation time of 30 
minutes. As seen in Figure 118, the haemolysis increased considerably with increasing 
concentration of pyrogallol[4]arene. There is no significant haemolytic effect below 
1 mM with the maximum value of 42% at 10 mM and the 50% haemolysis is 
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extrapolated to 11 mM. Those haemolytic percentage values are much higher than the 
ones obtained for the para-sulfonato calix[n]arenes where the maximum response of 
30% was obtained for a concentration of 200 mM.391  
 
Figure 118: Haemolysis percentage relative to the overall concentration of of C-3-aminopropyl-
pyrogallol[4]arene 35 after an incubation of 30 minutes, the data are represented by the mean 
value (n=2) ± SD, all p values <0.01 relative to untreated cells. 
Those preliminary results allowed for the optimisation of the methods, 
nevertheless the experiment should be repeated with three different donors in a wider 
concentration range in order to obtain the HC50. In addition, the compound could be 
dissolved in another solvent that does not induce haemolysis. The results were therefore 
encouraging to continue using the macrocycle with cells such as dendritic cells. 
2. CYTOTOXICITY ON DENDRITIC CELLS 
a) Generation of Dendritic Cells 
Dendritic cells were generated from bone marrow of HLA-DR4 
immunologically naive mice, using a well-established technique, adapted from Inaba et 
al.395 Briefly, bone marrow was flushed from mice hind limbs, extracted and washed 
several times and then cultured with a specific growth factor (GM-CSF), and a synthetic 
analogues of ds-RNA (Poly-IC). The cells were washed on day two and four, to remove 
any non-adherent cells. A week after the collection of the cells, the cells were harvested 
and used for further test. Although this method is effective, it uses 24 well-plates, 
which can restrict the growth and the washing step that can be problematic. It has 
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been shown that the growth of a pure population of dendritic cells is affected by a lower 
plating density, a prolonged culture period and a reduction of the GM-CSF dose.396 
Therefore, an alternative method of culturing dendritic cells in Petri dishes was 
attempted (method B). 397 The cultures were further split into two, to compare the 
maturation induced by LPS on dendritic cells. 
Based on cell count on harvest day, this new method (B) showed similar results 
with respect to the production of immature dendritic cells and improved results in the 
production of mature dendritic cells. However, the cell count is not sufficient to 
estimate the purity of the population as it can include other cells such as granulocytes, 
but can be assessed by their surface marker expression using flow cytometry analysis. 
In order to phenotype the dendritic cells and recognise myeloid dendritic cells, the 
positive expression of both MHC class II and CD11c were checked. CD86 is a surface 
marker that is at high levels in PBMC and DC and at low levels in resting B cells and T 
lymphocytes. Its levels increase as it is a marker of preliminary maturation that has been 
induced using LPS. The results of the flow cytometry analysis are presented below in 
Figure 119. 
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Figure 119: Effect of the BMDC generation method on the cell surface markers expression, Method 
A adapted from Inaba et al.395, Method B adapted from Lutz et al.396 
As seen in Figure 119, within the four subtypes, 50% (at most 61%) of the 
population is MHC II and CD11c positive. These values indicate that when using both 
techniques, the population contains other non dendritic cells. This issue could be 
overcome using cell enrichment tools such as CD11c magnetic beads.398 In terms of 
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maturation, CD86 was used to asses the degree of maturity and by its expression it 
appears that both methods led to similar results. CD86 is a surface marker that is at high 
levels in PBMCs and DCs and at low levels in resting B cells and T lymphocytes. More 
recently another surface marker CD83 appeared to be more specific to DCs.399 In 
addition, the use of double staining with a multi-colour flow cytometer would allow 
assessment of the exact population that is expressing both CD86, MHC II and CD11c, 
showing the integrity of the dendritic cells. These tests should also be performed in 
combination with one another, after incubation with the calixarene to see if they can 
induce the maturation and the expression of MHC I. This indicates that both techniques 
are valuable and can be considered for further experimentations that consist of assessing 
the viability of the cells when in contact with a pyrogallol[4]arene solution.  
b) Viability depending on the ATP levels 
The toxicity and inertness of C-3-aminopropyl-pyrogallol[4]arene 35 and C-3-
aminopropyl-resorcin[4]arene 36  were also assessed in vitro on dendritic cells that were 
cultured using the method previously described. A cell viability bioluminescent test has 
been performed using the ViaLight® HS Kit measuring the adenosine triphosphate 
(ATP) levels. As ATP is a crucial co-enzyme that contributes to the transport of energy 
within a living cell, any form of cell injury results in rapid decrease in cytoplasmic ATP 
levels. This assay is based on the reaction of an enzyme, Luciferase, which is oxidised 
in presence of ATP, that catalyses the emission of light. This assay has been proved 
efficient in cell viability assessement.400-401 
Equation 2: From ATP to light 
LIGHTCOPPAMPinOxyluciferOLuciferinATP i
Mg
Luciferase ++++ →++
+ 22 2
  
After a twenty-four hours incubation period with different concentrations of 
calixarene derivatives, diluted in the culture medium, a nucleotide releasing agent was 
added to each well and left to react for ten minutes. The ATP monitoring reagent was 
then added and the light was measured using a luminometer. The luminescence was 
then compared to the untreated cells that were considered as a 100 % release of ATP.  
As shown in Figure 120, the ATP release is relatively stable from nano-molar to 
micro-molar concentrations, with similar values to the non-treated (control) cells. 
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Generally, the resorcinol and pyrogallol derivatives follow the same trend. However, 
this changes at a concentration of 0.5 mM, with a rise in luminescence observed for the 
pyrogallol[4]arene derivative, which may be caused by the conjugated character of the 
macrocycles. 
 
Figure 120: Percentage of cytoplasmic ATP release relative to the untreated cells depending on the 
concentration of C-3-aminopropyl-pyrogallol[4]arene 35 and C-3-aminopropyl-resorcin[4]arene 
36 (in mol/L), mean values (n=2) ±SD, p values are relative to the untreated cells 
The ToxiLight® Bioassay, a non-destructive bioluminescent cytotoxicity assay, 
was used to indirectly quantify the release of adenylate kinase (AK) from damaged 
cells.402 This assay follows the same principle as the one previously described, as it 
involves the reaction of adenosine diphosphate (ADP) with AK that is released by 
damaged cells, followed by the reaction with Luciferase that enables measurement of 
the ATP. 
Equation 3: Role of AK 
AMPATPMgADPADPMg KinaseAdenylate + →+ ++ 22
 
 
The quantification of the light was performed relative to the untreated cells, 
depending on the calixarene concentration in the culture media. This assay only requires 
the use of the cell culture supernatant and therefore it can be performed at different 
time-points. In this case twenty-four hours and a week later, it was performed on the 
same cells that were washed with calixarene containing media. The results show some 
unexpected features, such as those seen in Figure 121, indicating reduced cell damage 
with increasing concentrations and time for both the pyrogallolarene and 
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resorcinarene. This suggests that they could be non-toxic at workable concentrations. 
This effect is likely to be caused by the high concentration of calixarene or the cell 
culture media. If it were to damage the cells, they would likely be washed away, 
resulting in a decrease of ATP within the media.  
 
Figure 121: Percentage of ATP release relative to the untreated cells depending on the 
concentration of C-3-aminopropyl-pyrogallol[4]arene 35 and C-3-aminopropyl-resorcin[4]arene 
36 after 24hours and a week (in mol/L), mean values (n=2) ±SD. 
The effect of the calixarenes on the dendritic cell growth can also be observed 
by optical microscopy, as illustrated in Figure 122. At a 1 mM concentration of 
PgC3NH2, the cells appeared totally lysed and only fragments remained. At 0.1 mM, 
cells are still present but their morphology indicates that they have been subjected to a 
stress that impedes their proliferation. At a concentration below 10 µM, the C-3-
aminopropyl-pyrogallol[4]arene 35 is seen to have no effect on the dendritic cells as 
their morphology is very similar to the untreated cells (ctrl) suggesting that they are still 
viable. 
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Figure 122: Photomicrographs (x10) of dendritic cells cultured with different concentration of C-3-
aminopropyl-pyrogallol[4]arene (PgC3NH2) (M) incubated for 24 hours. 
c) Proliferation assay using propidium iodide 
Propidium iodide (PI) is a fluorescent agent that can intercalate with the DNA of 
cells with permeable membranes, damaged or dead cells and does not react with living 
healthy cells. Combined with the Elispot technology, it can be used to estimate the cell 
viability. Fixed numbers of dendritic cells were cultured with various concentrations of 
C-3-aminopropyl-pyrogallol[4]arene 35 for 1 hour and 24 hours, before the percentage 
of PI positive cells compared to the total cell count was assessed. In view of the results, 
PI was incorporated in all cells, even in the absence of pyrogallol[4]arene. The ability of 
the dendritic cells to engulf external antigens, induces a certain permeability to the cells 
which may explain the incorporation of PI. Nevertheless, the PI assay can be used to 
assess the proliferation rather than toxicity or cell damage.  
As seen in Figure 123, the results obtained after one hour appears to be less 
reproducible, which may be induced by the external stress caused to the cells. However, 
the results appear more reproducible after an incubation of 24 hours; it seems that the 
calixarene has no significant effect compared to the untreated cells below 0.5 mM.  
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Figure 123:Percentage of PI positive cells depending on the concentration of calixarene in mol/L 
after 1 hour and 24 hour, represent by the mean (n=2) ±SD, p<0.05. 
These method developments have been performed for all viability assays, with 
preliminary data indicating that the calix[4]arene macrocycles do not cause cell death at 
workable concentrations below 0.5 mM. These tests are part of a proof of concept but 
cannot be conclusive; they need to be repeated in order to obtain full statistical analysis. 
It is essential to perform several tests to assess the toxicity of any new compounds, 
including viability, proliferation, functionality and integrity of the cells. Solutions of 
calixarenes, containing no cells should also be used in the assays in order to avoid any 
false positives.  
Future work should include extensive studies on the ability of the calixarenes, 
both as a precursor and as part of the vaccine formulation, to induce the maturation of 
the dendritic cells in addition to their cytoxicity studies. The attachment of biologically 
active material could be applied to bigger entities such as proteins and DNA, which 
would increase the potential as a drug delivery scaffold. Although preliminary studies 
have been performed for these types of molecules they need to be extended before 
proving to be safe for use as a vector in the vaccine form. They have to be safe, 
traceable and soluble offering definitive advantages over the other available systems 
that have already been approved by the FDA and MHRA.  
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CHAPTER VI: CONCLUSION AND FUTURE WORK  
The formulation of the peptide nano-scaffold vaccine could potentially contain 
multifunctional capsules that have the capacity to use both the class I and the class II 
pathways, as well as carry traceable markers such as fluorescein. This will enable the 
production of both an adaptive and innate immune response, therefore preventing 
tumour recurrence. Although the major objective of the project: to engineer a novel 
pyrogallol[4]arene based vector towards the delivery of immunogenic peptides to 
dendritic cells was not wholly achieved, the investigation into potential nano-scaffolds 
for these peptides has been examined with some success.  
As mentioned in the introduction of Chapter V; tert-butyl phenol based 
calixarene have previously shown promise in several biological applications. Until this 
study resorcin[4]arene and pyrogallol[4]arene calixarene analogues have not been 
explored. It can be expected that the peptide containing nano-scaffolds have similar 
toxicity to their polar precursors. However, those studies remain to be completed, and 
will be required for each potential vector, prior to any in vivo studies. The preliminary 
cytotoxicity studies indicate that both the potential precursors of the vectors, i.e. C-3-
aminopropyl-pyrogallol[4]arene 35 and C-3-aminopropyl-resorcin[4]arene 36 have 
minimal toxicity on both red blood cells and dendritic cells. Although it appears that the 
viability of the cells is conserved, it is necessary to investigate the effect that larger 
aggregates may have. In view of many studies involving nanometre scale materials, it is 
understood that the nano-size may have a beneficial effect on dendritic cells and further 
studies should be performed investigating their effect on the cell maturation. The 
potential metabolites that would be generated by the scaffolds could be investigated by 
using artificial proteosomes or an animal study.  
The major challenge of the project was to selectively biofunctionalise the 
pendant chains of the macrocycles. Although selective protections were investigated it 
did not lead to the target materials in sufficient quantities to fully characterise them and 
test their bioavailabilities. By having access to a plethora of commercially available 
acetals and aldehydes, the biofunctionalisation was attempted prior to the 
cyclocondensation of the macrocycles. This synthetic pathway proved to be somewhat 
more complicated than expected. The complex nature of the cyclisation process that is 
multifactorial, requires the optimisation of several conditions to achieve the desired 
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macrocycles in the desired cone conformation. Firstly, the starting material, i.e. the 
aldehyde, was required to have for the functional groups at least three carbons away 
from the carbonyl group in order to increase the cyclisation process. If the aldehyde is 
aromatic, it requires the presence of substituent that would favour the stabilisation of a 
carbocation. The choice of solvent is also fundamental in order to achieve the formation 
of thermodynamic compounds. 
Utilising new greener techniques for preparation of pyrogallol[4]arenes, that 
employ microwave radiation has led to an improved efficiency by reducing 
considerably the reaction time. It is now possible to gain a rapid access to a library of 
materials and optimise the reactions condition towards the targeted compounds. The 
microwave synthesis allowed the production of a library of aliphatic and aromatic 
compounds, and also demonstrated the possibility to extend this to heterocyclic 
aldehydes. The only restriction to a wide range of novel macrocycles, is the availability 
of the starting aldehydes, that could be investigated further. The synthesis of 
commercially unavailable lead aldehydes will therefore be the subject of further studies. 
The study into the self-assembly of the nanoscale capsules from these 
functionalised macrocycles requires further exploration in order to understand the effect 
of the subsistent on the self-assembly process. The interaction of the macrocycles can be 
seen on the nanoscale and it would be interesting to see how the presence of the peptide 
could interfere or favour the self-assembly process. Peptides are known to self-assemble 
due to the availability of a high number of hydrogen donors and acceptors, which 
contributed to protein folding. Since the capsule sizes are on the nanoscale this will 
have an impact on their interaction with the dendritic cells. It would be interesting to see 
that effect and compare the immune response. 
In terms of the optimisation of the microwave method, still more can be 
achieved whereby the method to synthesise the aromatic macrocycles could be further 
refined to obtain a total control over the various stereoisomers. The crystal data indicate 
that the rccc form can be isolated from the reaction mixture, but unfortunately, it is not 
homogenous. In view of these findings, it can be concluded that the control of the 
stereoisomer production is multifactorial and therefore its total control can be 
challenging. The choice of the reaction conditions is very important; however, the 
electronic properties of the starting material have an effect as well as its steric 
  
170 
hindrance. As the synthesis of non-functionalised macrocycle was not the main focus it 
was not investigated deeper but will be the study of future work. 
The self-assembly of the macrocycle, is highly influenced by the solvent as 
shown in chapter III. This effect can be exploited and tuned towards further 
applications, but may also lead to complications. If the macrocycles were to be found to 
change their potential to self-assemble into a capsule, it may be necessary to lock them 
into place using other methods e.g. coordination with a metal such as copper or 
gadolinium. This may also be achieved by covalently binding the upper rims together 
using alkyl dihalides. 
The solubility of the biofunctionalised macrocycles may also be problematic, as 
experienced during this project it can be challenging to selectively functionalise the 
pendant chain in order to obtain a fully functionalised macrocycle. Even if the 
functionalisation occurs, it can be difficult to isolate. It appears that the solubility 
character of the macrocycles is highly influenced by the pendant chains and therefore 
the non-bound amino acid and peptides. In addition, the macrocycles have the ability to 
entrap starting materials such as peptides within its pendant chain. In order to 
overcomes some of these problems, the addition of PEG to the macrocycles will need 
further investigation and optimisation.  
Solid phase functionalisation of the macrocycles could potentially overcome the 
solubility issues incurred previously. However, due to time constraints, only the 
feasibility studies have been achieved at this stage and it remains to be proved that only 
the phenolic groups of the calixarene are bound to the solid support. This could 
potentially be addressed by using Fmoc-protected amino acid grafted onto the starting 
aldehyde. In addition, this would enable the detection of the degree of functionalisation 
by UV titration of the deprotected Fmoc. The peptide can then be synthesised onto the 
resin and fluorophores can also be included.  
The inclusion of a fluorophore on the pendant chain terminus would be a very 
useful tool for the investigation of the calixarene in vitro, whereby, the engulfment of 
the macrocycles by the dendritic cells could be followed by the use of fluorescence 
microscopy. If a cleavage site was to be included and the fluorescent peptide was not 
completely cleaved, it would be possible to follow the presentation of the peptides onto 
the cells surface. By attaching other fluorophores onto the macrocycle core, it could be 
possible to follow this process within the cell. By understanding this uptake 
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mechanism, it could possible to target the DCs that would trigger this cascade of events 
leading to the presentation of the peptide to other macrophages.  
If the nanovectors were to be realised and fully characterised, several studies 
into assessing the potential future use of the calixarenes for immunotherapeutic 
purposes should be considered, using the well-established protocol to assess peptide 
immunogenicity. First, it would be necessary to compare both in-house synthesised and 
commercially bought p53 peptides. Then the effect of the vectors should be assessed by 
comparing the immunological response of the peptide alone and the peptide-calixarene 
complex. Finally the effect of the calixarenes should be compared to the traditional 
adjuvant IFA in order to potentially remove it. 
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CHAPTER VII: EXPERIMENTAL 
A. GENERAL INFORMATION 
All chemicals were used as received by the suppliers (SigmaAldrich, Acros, 
AlfaAesar) unless stated otherwise. All other solvents were used as supplied 
(Laboratory, Analytical or HPLC grade), without prior purification.  Microwave 
experiments were performed on CEM Discover®-SP microwave (CEMCorporation, 
UK), dynamic with temperature or pressure control, 30 second pre-stirring, power max 
function (simultaneous air cooling). Peptides syntheses were carried out on CEM 
Discover®-SPS Microwave peptide synthesiser (CEMCorporation, UK).  
Thin layer chromatographies were performed on glass plates coated with silica 
and C60 silica. Flash chromatography was performed using BIOTAGE SPX2.0 
(Biotage, UK). High performance liquid chromatography were performed on a HPLC 
Agilent 1100 series (Agilent, UK) using a Hypersil Gold C18 column (ThermoFisher, 
UK), 250 mm, 5 µm particle size using HPLC grades solvents (ThermoFisher, UK). 
Nuclear magnetic resonance (NMR) spectra were recorded on a JEOL ECX 400, 
(JEOL, USA) spectrometer internally referenced to TMS in the deuterated solvent 
stated; 1H (400 MHz) and 13C proton decoupled 100 MHz. All chemical shifts (δ) are 
quoted in ppm and coupling constants (J) in Hz. Residual signals from the solvents were 
used as an internal reference.  
Mass spectra were obtained upon an APCI Platform spectrometer, Shimadzu 
Axima CFR+3 (Shimadzu, Japan) and Bruker Ultraflex3 (Bruker Corporation, 
Germany) MALDI-TOF mass spectrometer using a raster mode and a 1000 averages, 
using CHCA as a matrix with only molecular ions and major peaks reported.  
Single crystal analyses were performed at on the Oxford Diffraction Xcalibur, 
Sapphire3, the EPSRC X-ray crystallography service at the University of Southampton 
and Daresbury synchrotron laboratory. The structure was solved and refined using the 
programs SHELXS-97403 and SHELXL-97404 respectively. The program X-Seed405 was 
used as an interface to the SHELX programs and POVRAY406 to prepare the figures. 
Infrared spectra were recorded on a Perkin-Elmer Spectrum 100 Fourier 
transform spectrophotometer with a diamond attenuated total reflectance (ATR) 
sampling accessory (PerkinElmer, UK).  
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UV-vis spectrometry was achieved on a JASCO V530 (Jasco, USA) TEM 
images were generated on a JEOL JEM-2010, accelerating voltage 200 keV, tungsten 
filament, electron beam current 10 µA; using a Gatan SC1000 ORIUS CCD camera. 
SEM were performed on JEOL JSM-A840A scanning electron microscope (SEM), (Jeol 
Ltd, UK). 
 
B. CHAPTER II 
1) C-Alkyl-pyrogallol[4]arene and C-alkyl-resorcin[4]arene 
1-8 
 
The aldehyde of choice (R = (CH2)CH(CH3)2, (CH2)2CH3, (CH2)3CH3, 
(CH2)4CH3, 1 eq., 4 mmol) was added to a solution of pyrogallol (R’= OH) or resorcinol 
(R’= H) (1 eq. 4 mmol) in ethanol (2 mL) and concentrated HCl (37%, 500 µL) 
contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the mixture was 
heated (100 ºC) by microwaves (100 W, PowerMax) for 10 min. Upon cooling to room 
temperature, the rccc product crystallised from solution, whereupon it was collected by 
vacuum filtration as the pure product, yields are summarised in the following table. 1H 
NMR, 13C NMR and MS for all of the isolated products are consistents with the 
literature values from synthesised using conventional heating methods.82-83 
 
 R R' %Y m/z 
[M+Na]+ 
 R R' %Y m/z 
[M+Na]+ 
1 OH (CH2)CH(CH3)2 85 799 5 H (CH2)CH(CH3)2 90 735 
2 OH (CH2)2CH3 61 743 6 H (CH2)2CH3 96 679 
3 OH (CH2)3CH3 62 799 7 H (CH2)3CH3 67 735 
4 OH (CH2)4CH3 68 855 8 H (CH2)4CH3 84 791 
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2) C-Butyl-pyrogallol[4]arene 3 
HO
OH
OH
+
OH
H+
MW
HO
OH
OH
4
3
 
Valeraldehyde (1 eq., 4 mmol, 425 µL) was added to a solution of pyrogallol (1 
eq. 4 mmol, 0.504 g) in an appropriate solvent (1.5 mL) and concentrated HCl (37%, 
500 µL) contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the 
mixture was heated (Figure 42), by microwaves (100 W, PowerMax) for a given time 
(Figure 40) after which the mixture was added directly into cold water (5 mL), collected 
by vacuum filtration and washed with water (2 mL x 3) and used crude for NMR 
analysis. 
C-butyl-pyrogallol[4]arene (rccc): 1H NMR (400 MHz, d6-DMSO) δ = 8.60 (br. s, 12H, 
OH), 6.88 (s, 4 H, ArH), 4.15 (t, 3J = 7.9 Hz, 4H, C1H), 2.15 (q, 3J = 7.9 Hz, 8 H, C2H2), 
1.16 (quin, 3J = 7.9 Hz, 8 H, C3H2), 1.33 (m, 8 H, C4H2), 0.85 (t, 2J  = 7.3 Hz, 12 H, 
C5H3) ppm. 13C NMR (101 MHz , d6-DMSO) δ = 139.5, 132.8, 124.5, 113.5, 33.7, 32.6, 
30.2, 22.1, 14.2 ppm. MALDI-TOF m/z for C44H56O12 calcd. 776.38, found 799.07 
[M+Na]+. 
 
Time 
(min) T( °C) Solvent 
Yield 
(%) 
rccc 
a
 
(%) 
 Time 
(min) T( °C) Solvent 
Yield 
(%) 
rccc 
a
 
(%) 
1 Oligomer b  40 Oligomer b 
2 57 77  60 Oligomer b 
3 65 79  80 77 85 
4 60 80  120 Decompose b 
5 73 83  
5 
140 
EtOH 
Decompose b 
6 76 86  MeOH 56 66 
7 79 86  nPrOH 40 88 
8 66 83  nBuOH 76 96 
9 72 86  EtOAc 25 96 
10 
100 EtOH 
70 86  
5 100 
H2O 56 4 
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Suitable crystals were obtained by slow evaporation of deuterated DMSO, 
crystal data for C-butyl-pyrogallol[4]arene 3 DMSO clathrate: C55H89O17.50S5.50, M = 
1206.59 g mol-1, triclinic, space group P (No. 2), a = 12.7282(3) Å, b = 13.3196(2) Å, 
c = 19.2932(3) Å, α = 104.3940(10)°, β = 97.5090(10)°, γ = 99.0330(10)°, V = 
3079.26(10) Å3, T = 120(2) K, Z = 2, Dc = 1.301 g cm-3, µ = 0.272 mm-1, F000 = 1294, 
crystal size = 0.19 × 0.17 × 0.08 mm3, R1 = 0.0780, wR2 = 0.1859, GooF = 1.015 
Crystallographic data in have been deposited with the Cambridge Crystallographic Data 
Centre as supplementary publication no CCD 755190 
 
3) C-Phenyl-pyrogallol[4]arene 9 
 
 Benzaldehyde (1 eq., 4 mmol, 405 µL) was added to a solution of pyrogallol (1 
eq. 4 mmol, 0.504 g) in ethanol (1.5 mL) and concentrated HCl (37%, 500 µL) 
contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the mixture was 
heated (100 ºC) by microwaves (100 W, PowerMax) for 10 min. Upon cooling to room 
temperature, the rccc product crystallised from solution, whereupon it was collected by 
vacuum filtration and washed with water (2 mL x 3) to obtain red solid (0.565 g, 6.69 x 
10-4 mol, 66 %).  
1H NMR (400 MHz, d6-DMSO) δ = 8.51 (s, 12H, OH), 6.92 (t, 2J=7.3Hz, 8H, C10H), 
6.83 (t, 2J=7.3Hz, 4H, ArC11H), 6.60 (d, 2J=7.3Hz, 8H, C9H), 5.99 (s, 4H, ArC1H), 5.66 
(s, 4H, C7H) ppm. 13C NMR (101 MHz, d6-DMSO) δ = 152.5, 145.7, 128.9, 128.6, 
127.1, 126.9, 124.5, 120.6, 102.0 ppm. MALDI-TOF m/z for C52H40O12 calcd. 856.25, 
found 879.25 [M+Na]+ 
Crystal data for C-phenyl-pyrogallol[4]arene 9 rccc: C52H40O12, M = 856.84, 
0.18 × 0.09 × 0.09 mm3, monoclinic, space group C2/m (No. 12), a = 20.913(3), b = 
21.667(3), c = 11.3077(14) Å, β = 116.490(16)°, V = 4585.9(10) Å3, Z = 4, Dc = 
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1.241 g/cm3, F000 = 1792, Xcalibur, Sapphire3, MoKα radiation, λ = 0.71073 Å, T = 
150(2)K, 2θmax = 50.0º, 11089 reflections collected, 4146 unique (Rint = 0.0625). Final 
GooF = 0.977, R1 = 0.0925, wR2 = 0.2211, R indices based on 1959 reflections with I 
>2sigma(I) (refinement on F2), 305 parameters, 0 restraints. Lp and absorption 
corrections applied, µ = 0.088 mm-1. 
4) C-o-Tolyl-pyrogallol[4]arene 10 
 
o-Tolyl-aldehyde (1 eq., 4 mmol, 368 µL) was added to a solution of pyrogallol 
(1 eq. 4 mmol, 0.504 g) in ethanol (1.5 mL) and concentrated HCl (37%, 500 µL) 
contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the mixture was 
heated (100 ºC) by microwaves (100 W, PowerMax) for 10 min. Upon cooling to room 
temperature, a solid precipitated from solution, whereupon it was collected by vacuum 
filtration and washed with water (2 mL x 3) to obtain a brown solid (0.275 g, 3.01 x 10-4 
mol, 41%) of which the rccc isomer is (50%). 
1H NMR (400 MHz, CDCl3) δH = 6.90 (t, 3J = 3.8 Hz, 8H, ArC1H), 6.69 - 6.36 (m, 4H, 
AA’XX’), 6.26-5.99 (m, 4H, AA’XX’), 4.635 (s, 4H, CH), 1.12 (12 H, CH3) ppm. 13C 
NMR (101 MHz, CDCl3) δ = 148.7, 140.6, 139.8, 134.2, 123.5, 123.3, 120.0, 118.6, 
95.6, 59.8, 37.8, 23.6 ppm. MALDI-TOF m/z for C56H48O12 calcd. 912.31, found 935.97 
[M+Na]+. 
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5) C-m-Tolyl-pyrogallol[4]arene 11 
 m-Tolyl-aldehyde (1 eq., 4 mmol, 471 µL) was added to a solution of pyrogallol 
(1 eq. 4 mmol, 0.504 g) in ethanol (1.5 mL) and concentrated HCl (37%, 500 µL) 
contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the mixture was 
heated (100 ºC) by microwaves (100 W, PowerMax) for 10 min. Upon cooling to room 
temperature, the rccc product crystallised from solution, whereupon it was collected by 
vacuum filtration and washed with water (2 mL x 3) to obtain a pink solid (0.857g, 9.69 
x 10-4 mol, 96%). 
1H NMR (400 MHz, CDCl3) δ = 6.16 - 5.96 (m, 4H, C5H), 5.96 - 5.84 (m, 4H, C6H), 
5.81 (br. s., 4H, C4H), 5.77 - 5.48 (m, 4H, C3H), 5.15 (s, 4H, C1H), 4.97 (br. s, 4H, 
C2H), 1.26 (br. s., 12H, CH3) ppm. 13C NMR (101 MHz, CDCl3) δ = 150.9, 143.7, 
138.9, 134.2, 127.9, 124.2, 123.7, 119.3, 100.7, 39.8, 19.7 ppm. MALDI-TOF m/z for 
C56H48O12 calcd. 912.31, found 935.97 [M+Na]+. 
Preliminary crystal data for m-tolyl-pyrogallol[4]arene rccc: C56H48O13, M = 928.94, 
yellow block, triclinic, 0.10 × 0.05 × 0.02 mm3, space group P (No. 2), a = 11.3087(7), 
b = 11.6653(8), c = 19.9865(14) Å, α = 92.610(5), β = 102.904(5), γ = 108.740(6)°, V = 
2414.0(3) Å3, Z = 2, Dc = 1.278 g/cm3, F000 = 976, Xcalibur, Sapphire3, MoKα 
radiation, λ = 0.71073 Å, T = 173(2)K, 2θmax = 58.7º, 19468 reflections collected, 8097 
unique (Rint = 0.3778). Final GooF = 1.281, R1 = 0.1652, wR2 = 0.4065, R indices 
based on 2652 reflections with I >2sigma(I) (refinement on F2), 638 parameters, 0 
restraints. Lp and absorption corrections applied, µ = 0.091 mm-1. 
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6) C-p-Tolyl-pyrogallol[4]arene 12 
 
p-Tolyl-aldehyde (1 eq., 4 mmol, 472 µL) was added to a solution of pyrogallol 
(1 eq. 4 mmol, 0.504 g) in ethanol (1.5 mL) and concentrated HCl (37%, 500 µL) 
contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the mixture was 
heated (100 ºC) by microwaves (100 W, PowerMax) for 10 min. Upon cooling to room 
temperature, the rccc product crystallised from solution, whereupon it was collected by 
vacuum filtration and washed with water (2 mL x 3) to obtain a pink solid, (0.857 g 
9.38 x 10-4 mol, 94%) 
1H NMR (400 MHz, CDCl3) δH =6.95 (d, 2J= 7.8 Hz, AA’XX’, 8 H), 6.82 (d, 2J= 7.8 
Hz, AA’XX’, 8 H), 6.43 (s, 4 H, ArH), 5.32 (s, 4 H, CH), 1.41 (s, 12H, CH3) ppm. 13C 
NMR (101 MHz, d6- CDCl3) δ= 150.8, 140.9, 138.9, 127.0, 125.9, 119.2, 100.5, 39.6, 
19.1 ppm; MALDI-TOF m/z for C56H48O12 calcd. 912.31, found 935.97 [M+Na]+ 
Crystal data for p-tolyl-pyrogallol[4]arene: 2(C56H48O12)O, M = 1841.89, 
colourless block, 0.14 × 0.06 × 0.02 mm3, monoclinic, space group P21/n (No. 14), a = 
11.2436(8), b = 22.0850(15), c = 21.1825(17) Å, β = 92.624(4)°, V = 5254.4(7) Å3, Z = 
2, Dc = 1.164 g/cm3, F000 = 1936, Bruker-Nonius Roper CCD camera on goniostat, 
MoKα radiation, λ = 0.71073 Å, T = 173(2)K, 2θmax = 53.5º, 57148 reflections 
collected, 11152 unique (Rint = 0.1657). Final GooF = 1.004, R1 = 0.1137, wR2 = 
0.2936, R indices based on 4051 reflections with I >2sigma(I) (refinement on F2), 625 
parameters, 0 restraints. Lp and absorption corrections applied, µ = 0.082 mm-1. 
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7) C-Phenyl-resorcin[4]arene 13 
 Benzaldehyde (1 eq., 4 mmol, 405 µL) was added to a solution of resorcinol (1 
eq. 4 mmol, 0.440 g) in ethanol (1.5 mL) and concentrated HCl (37%, 500 µL) 
contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the mixture was 
heated (100 ºC) by microwaves (100 W, PowerMax) for 10 min. Upon cooling to room 
temperature, the rccc product crystallised from solution, whereupon it was collected by 
vacuum filtration and washed with water (2 mL x 3) to obtain a orange solid (0.570 g, 
7.19 x 10-4 mol, 72 %)  
1H NMR (400 MHz, d6-DMSO) δ  = 8.51 (s, 8H, OH), 6.92 (s, 4H, ArC1H), 6.81 (d, 
2J=7.3 Hz, 8H, C10H), 6.71 (d, 2J=7.3 Hz, 8H, C9H), 6.58 (m, 4H, C11H), 6.09 (s, 4H, 
ArC4H), 5.60 (s, 4H, C7H) ppm. 13C NMR (101 MHz, d6-DMSO) δ= 152.5 145.7, 
128.9, 128.6, 127.1, 126.9, 124.5, 120.6, 102.0 ppm. MALDI-TOF m/z for C52H40O8 
calcd. 792.27, found 815.27 [M+Na]+. 
 
8) C-o-Tolyl-resorcin[4]arene 14 
 
 o-Tolyl-aldehyde (1 eq., 4 mmol, 368 µL) was added to a solution of resorcinol 
(1 eq. 4 mmol, 0.440 g) in ethanol (1.5 mL) and concentrated HCl (37%, 500 µL) 
contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the mixture 
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was heated (100 ºC) by microwaves (100 W, PowerMax) for 10 min. Upon cooling to 
room temperature, the product precipitated from solution, whereupon it was collected 
by vacuum filtration and washed with water (2 mL x 3) to obtain a yellow brown solid 
(0.375 g, 4.42 x 10-4 mol, 44%) of which the rccc isomer is (50%) according to the 
NMR. 
1H NMR (400 MHz, d6-DMSO) δ  = 8.53 (s, 4 H, OH), 8.43(s, 4 H, OH), 6.80 (t, 3J = 
7.3 Hz, 4 H, AA’XX’), 6.70 (m, 3J = 7.3 Hz, 8 H, ArCH), 6.49 (s, 4 H, ArCH), 6.30 (d, 
J = 6.2 Hz, 4 H ArCH, AA’XX’), 6.10 (s, 4 H, ArCH), 5.66 (s, 4 H, CH), 1.72 (s, 12 H, 
CH3) ppm. 13C NMR (101 MHz, d6-DMSO) δ = 152.6, 152.4, 144.3, 135.2, 129.2, 
124.4, 124.4, 120.5, 118.9, 18.7 ppm. MALDI-TOF m/z for C56H48O8 calcd. 848.33, 
found 848.33 [M]+. 
 
9) C-m-Tolyl-resorcin[4]arene 15 
HO OH
+
OH
HCl, EtOH
MW, 100 ºC, 5 min
1
7HO OH
2
4
3
4
5
6
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 m-Tolyl-aldehyde (1 eq., 4 mmol, 471 µL) was added to a solution of resorcinol 
(1 eq. 4 mmol, 0.440 g) in ethanol (1.5 mL) and concentrated HCl (37%, 500 µL) 
contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the mixture was 
heated (100 ºC) by microwaves (100 W, PowerMax) for 10 min. Upon cooling to room 
temperature, the rccc product crystallised from solution, whereupon it was collected by 
vacuum filtration and washed with water (2 mL x 3) to obtain a brown solid (0.794 g, 
9.46 x 10-4 mol, 94%). 
1H NMR (400 MHz , CDCl3) δ = 6.11 (t, 3J = 7.4 Hz, 4 H, C5H), 5.98 (d, 3J = 7.3 Hz, 4 
H, C6H), 5.87 (d, 3J  = 7.4 Hz, 4 H, C4H), 5.79 (s, 4 H, C3H), 5.47 (s, 4 H, C7H), 5.39 (s, 
4 H, C1H), 4.91 (s, 4 H, C2H), 1.34 (s, 12 H, CH3) 
13C NMR (101 MHz, d6-DMSO) δ= 144.9, 143.0, 138.5, 137.0, 131.2, 129.6, 125.8, 
126.1, 124.8, 124.7, 39.2, 19.6 ppm; MALDI-TOF m/z for C56H48O8 calcd. 848.33, 
found 848.33 [M]+ 
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Preliminary crystal data for m-tolyl-resorcin[4]arene rccc DMSO solvate: 
C56H48O8.6(C2H6SO), M =, Yellow block, 0.65 × 0.41 × 0.34, triclinic, space group P 
(No. 2), ), a = 13.235(3), b = 13.610(3), c = 22.988(5) Å, α = 89.161(17), β = 
84.311(18), γ = 72.655(18)°, V = 3932.7(14) Å3, Z = 4, Dc = 1.245 g/cm3, F000 = 1568, 
Xcalibur, Sapphire3, MoKα radiation, λ = 0.71073 Å,  T = 173(2)K, 2θmax = 57.2º, 
32596 reflections collected, 17264 unique (Rint = 0.1941). Final GooF = 0.933, R1 = 
0.1699, wR2 = 0.4018, R indices based on 3893 reflections with I >2sigma(I) 
(refinement on F2), 437 parameters, 0 restraints.  Lp and absorption corrections 
applied, µ = 0.288 mm-1 
 
10) C-p-Tolyl-resorcin[4]arene 16/17 
  
 p-Tolyl-aldehyde (1 eq., 4 mmol, 472 µL) was added to a solution of resorcinol 
(1 eq. 4 mmol, 0.440 g) in ethanol (1.5 mL) and concentrated HCl (37%, 500 µL) 
contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the mixture was 
heated (100 ºC) by microwaves (100 W, PowerMax) for 10 min. Upon cooling to room 
temperature, the rccc product crystallised from solution, whereupon it was collected by 
vacuum filtration and washed with water (2 mL x 3) to obtain a red solid (0.738 g, 8.66 
x 10-4 mol, 87%). 
1H NMR (400 MHz, d6-DMSO) δ = 5.98 (d, 3J = 7.8 Hz, 8 H), 5.86 (d, 3J = 7.8 Hz, 8 
H), 5.46 (s, 4 H, C7H), 5.34 (s, 4 H, C1H), 4.96 (s, 4 H, CH), 1.49 (s, 12H, CH3) ppm. 
13C NMR (101 MHz, d6-DMSO) δ= 140.3, 131.9, 129.8, 127.1, 127.0, 126.3, 120.0, 
46.8, 19.1 ppm; MALDI-TOF m/z for C56H48O8 calcd. 848.33, found 848.33 [M]+ 
Crystal data for p-tolyl-resorcin[4]arene rccc: C56H48O8, M = 848.94, yellow 
fragment, 0.08 × 0.04 × 0.02 mm3, triclinic, space group P (No. 2), a = 
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13.3943(10), b = 14.5076(10), c = 17.4518(11) Å, α = 99.329(4), β = 100.179(4), γ = 
90.615(4)°, V = 3291.0(4) Å3, Z = 2, Dc = 0.857 g/cm3, F000 = 896, Bruker-Nonius 
APEX II CCD camera on goniostat, MoKα radiation, λ = 0.71073 Å, T = 120(2)K, 
2θmax = 53.4º, 1597107 reflections collected, 11488 unique (Rint = 0.1148). Final GooF 
= 0.946, R1 = 0.1042, wR2 = 0.2643, R indices based on 4766 reflections with I 
>2sigma(I) (refinement on F2), 589 parameters, 0 restraints. Lp and absorption 
corrections applied, µ = 0.057 mm-1. 
Preliminary crystal data for p-tolyl-resorcin[4]arene acetonitrile rctt: 
C56H48O8.4(CH3CN), M = 1066.94, Yellow block, 0.16 × 0.09 × 0.02 mm3, triclinic, 
space group P (No. 2), a = 11.678(2), b = 11.836(2), c = 11.902(3) Å, α = 
85.132(18), β = 62.42(2), γ = 84.296(17)°, V = 1449.6(5) Å3, Z = 2, Dc = 1.255 g/cm3, 
F000 = 580, Xcalibur, Sapphire3, MoKα radiation, λ = 0.71073 Å, T = 173(2)K, 2θmax = 
58.1º, 13812 reflections collected, 7763 unique (Rint = 0.1408). Final GooF = 0.980, R1 
= 0.1304, wR2 = 0.3258, R indices based on 1530 reflections with I >2sigma(I) 
(refinement on F2), 327 parameters, 0 restraints. Lp and absorption corrections 
applied, µ = 0.077 mm-1. 
 
11) C-Thiophen-3-yl-pyrogallol[4]arene 18 
 
3-Thienylaldehyde (1 eq., 4 mmol, 375 µL) was added to a solution of 
pyrogallol (1 eq. 4 mmol, 0.504 g) in ethanol (1.5 mL) and concentrated HCl (37%, 500 
µL) contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the mixture 
was heated (100 ºC) by microwaves (100 W, PowerMax) for 10 min. Upon cooling to 
room temperature, a solid precipitated from solution, whereupon it was collected by 
vacuum filtration and washed with water (2 mL x 3) to obtain a grey solid (0.230 g, 
2.61 x 10-4 mol, 26%). 
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1H NMR (400 MHz , d6-DMSO) δ = 7.03 (dt, 4J = 1.9, 5 Hz, 4 H, C5H), 6.36 (dd, J = 
0.8, 5.0 Hz, 4 H, C4H ), 6.24 (m, 2 H, ArC1H), 5.95 (br. s, 4 H, C3H), 5.69 (m, 4 H, 
C2H), 5.36 (s, 2 H, ArC1H) ppm 13C NMR (101 MHz , d6-DMSO) δ = 44.02, 120.70, 
120.85, 122.07, 123.93, 128.86, 141.96, 142.33, 145.58 ppm, MALDI-TOF m/z for 
C44H32O12S4 calcd. 880.08, found 903.44 [M+Na]+ Elemental analysis for C44H32O12S4 
calcd: C, 59.99; H, 3.66; found: C, 56.27; H, 2.19. 
Crystal data for C-Thiophen-3-yl-pyrogallol[4]arene: C32H41.50O11.50S7, M = 
834.57, colourless block, 0.05 × 0.07 × 0.13 mm3, triclinic, space group P (No. 2), a = 
12.0585(6), b = 16.0631(8), c = 20.9249(8) Å, α = 99.314(4), β = 103.039(4), γ = 
90.589(4)°, V = 3891.9(3) Å3, Z = 4, Dc = 1.424 g/cm3, F000 = 1750, Xcalibur, 
Sapphire3, MoKα radiation, λ = 0.71073 Å,  T = 173(2)K, 2θmax = 46.5º, 50598 
reflections collected, 11169 unique (Rint = 0.1294). Final GooF = 1.045, R1 = 0.1305, 
wR2 = 0.2686, R indices based on 6675 reflections with I >2sigma(I) (refinement on 
F2), 954 parameters, 0 restraints. Lp and absorption corrections applied, µ = 0.462 mm-
1
. 
 
12) C- Pyridin-2-yl-pyrogallol[4]arene 19 
 2-Pyridinecarboxaldehyde (1 eq., 4 mmol, 381 µL) was added to a solution of 
pyrogallol (1 eq. 4 mmol, 0.504 g) in ethanol (1.5 mL) and concentrated HCl (37%, 500 
µL) contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the mixture 
was heated (100 ºC) by microwaves (100 W, PowerMax) for 5 min. After which, 
concentrated HCl (37%, 500 µL) was added to the mixture and reacted for further 5 
min. Upon cooling to room temperature, the product precipitated from solution, 
whereupon it was collected by vacuum filtration and washed with cold ethanol (2 mL x 
3) to obtain a waxy crude solid (0.40 g). 
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1H NMR (400 MHz, d6-DMSO) δ = 8.88 (br. s., OH), 8.64 (m, 4 H, C6H), 8.34 (m, 4 H, 
C4H), 7.77 (m, 4 H, C5H), 7.33 (m, 4 H, C3H), 6.25 (m, 4 H, C1H), 5.97 (m, 4 H, CH) 
ppm. MALDI-TOF m/z for C48H36N4O12 calcd. 860.23, found 861.02 [M+H]+. 
 
13) C- Pyridin-3-yl-pyrogallol[4]arene 20 
 
3-Pyridinecarboxaldehyde (1 eq., 4 mmol, 376 µL) was added to a solution of 
pyrogallol (1 eq. 4 mmol, 0.504 g) in ethanol (1.5 mL) and concentrated HCl (37%, 500 
µL) contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the mixture 
was heated (100 ºC) by microwaves (100 W, PowerMax) for 5 min. After which, 
concentrated HCl (37%, 500 µL) was added to the mixture and reacted for further 5 
min. Upon cooling to room temperature, the product precipitated from solution, 
whereupon it was collected by vacuum filtration and washed with cold ethanol (2 mL x 
3) to obtain a yellow crude solid (0.996 g). 
1H NMR (400 MHz, d6-DMSO) δ = 8.71 - 8.56 (m, 4 H, C4H), 8.51 - 8.22 (m, 4 H, 
C3H), 8.06 - 7.78 (m, 8 H, C6H+ C5H), 6.22 (m, 4 H, C1H), 5.77 - 5.51 (m, 4 H, C2H) 
ppm. MALDI-TOF m/z for C48H36N4O12 calcd. 860.23, found 861.02 [M+H]+. 
14) C- Pyridin-4-yl-pyrogallol[4]arene 21 
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 4-Pyridinecarboxaldehyde (1 eq., 4 mmol, 378 µL) was added to a solution of 
pyrogallol (1 eq. 4 mmol, 0.504 g) in ethanol (1.5 mL) and concentrated HCl (37%, 500 
µL) contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the mixture 
was heated (100 ºC) by microwaves (100 W, PowerMax) for 5 min. After which, 
concentrated HCl (37%, 500 µL) was added to the mixture and reacted for further 5 
min. Upon cooling to room temperature, the product precipitated from solution, 
whereupon it was collected by vacuum filtration and washed with cold ethanol (2 mL x 
3) to obtain a orange crude solid (0.948 g). 
1H NMR (400 MHz, d6-DMSO) δ = 8.65 (m, 8 H, C3H), 7.47 (m, 8 H, C4H), 6.20 (m, 
4H, C1H), 5.85 (m, 4 H, CH) ppm. MALDI-TOF m/z for C48H36N4O12 calcd. 860.23, 
found 861.02 [M+H]+. 
 
15) C- Pyridin-2-yl-resorcin[4]arene 22 
 2-Pyridinecarboxaldehyde Pyridin-2-yl aldehyde (1 eq., 4 mmol, 381 µL) was 
added to a solution of resorcinol (1 eq. 4 mmol, 0.440 g) in ethanol (1.5 mL) and 
concentrated HCl (37%, 500 µL) contained in a CEM pressure vial (10 mL). After pre-
stirring (30 sec), the mixture was heated (100 ºC) by microwaves (100 W, PowerMax) 
for 5 min. After which, concentrated HCl (37%, 500 µL) was added to the mixture and 
reacted for further 5 min. Upon cooling to room temperature, the product precipitated 
from solution, whereupon it was collected by vacuum filtration and washed with cold 
ethanol (2 mL x 3) to obtain a crude yellow solid (0.652 g). 
1H NMR (400 MHz, d6-DMSO) δ = 8.73 - 8.51 (m, 4 H, C6H), 8.49 - 8.26 (m, 4 H, 
C4H), 7.88 - 7.66 (m, 4 H, C5H), 7.63 - 7.38 (m, 4 H, C2H), 6.67 - 6.37 (m, 4 H, C1H ), 
5.95 - 5.66 (m, 4 H, CH) ppm. MALDI-TOF m/z for C48H36N4O8 calcd. 796.25, found 
797.04 [M+H]+ 
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16) C- Pyridin-3-yl-resorcin[4]arene 23 
 
3-Pyridinecarboxaldehyde (1 eq., 4 mmol, 376 µL) was added to a solution of 
resorcinol (1 eq. 4 mmol, 0.440 g) in ethanol (1.5 mL) and concentrated HCl (37%, 500 
µL) contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the mixture 
was heated (100 ºC) by microwaves (100 W, PowerMax) for 5 min. After which, 
concentrated HCl (37%, 500 µL) was added to the mixture and reacted for further 5 
min. Upon cooling to room temperature, the product precipitated from solution, 
whereupon it was collected by vacuum filtration and washed with cold ethanol (2 mL x 
3) to obtain a crude yellow solid (0.884 g). 
1H NMR (400 MHz, d6-DMSO) δ  = 9.76 (m, OH), 8.66 (m, 4 H, C4H), 8.39 (m, 4 H, 
C3H), 7.81 (m, 4 H C6H), 7.53 (m, 4 H, C5H ), 6.60 - 6.30 (m, 8 H, C1H + C7H), 5.81 - 
5.75 (m, 4 H, CH) ppm. MALDI-TOF m/z for C48H36N4O8 calcd. 796.25, found 797.32 
[M+H]+. 
 
17) C- Pyridin-4-yl-resorcin[4]arene 24 
 
4-Pyridinecarboxaldehyde (1 eq., 4 mmol, 378 µL) was added to a solution of 
resorcinol (1 eq. 4 mmol, 0.504 g) in ethanol (1.5 mL) and concentrated HCl (37%, 500 
µL) contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the 
mixture was heated (100 ºC) by microwaves (100 W, PowerMax) for 5 min. After 
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which, concentrated HCl (37%, 500 µL) was added to the mixture and reacted for 
further 5 min. Upon cooling to room temperature, the product precipitated from 
solution, whereupon it was collected by vacuum filtration and washed with cold ethanol 
(2 mL x 3) obtain a beige crude solid (0.884 g). 
1H NMR (400 MHz, d6-DMSO) δ  = 9.56 (br. s., 8H, OH), 8.72 (m, 8 H, C3H), 7.49 (m, 
8 H, C4H), 6.59 (m, 4 H, C7H), 6.21 - 6.10 (m, 4 H, C1H), 5.56 (m, 4 H, CH) ppm. 
MALDI-TOF m/z for C48H36N4O8 calcd. 796.25, found 797.02 [M+H]+. 
 
C. CHAPTER III 
18) C-3-Hydroxpropyl-pyrogallol[4]arene 25 
HO
OH
OH
+
HCl, EtOH
MW, 100 ºC, 10 min
HO
OH
OH
4
O
OH
25
 
2,3-Dihydro-pyran (1.0 eq., 4 mmol, 302 µL) was added to a solution of 
pyrogallol (1 eq. 4 mmol, 0.504 g) in ethanol (1.5 mL) and concentrated HCl (37%, 500 
µL) contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the mixture 
was heated (100 ºC) by microwaves (100 W, PowerMax) for 10 min. Upon cooling to 
room temperature, the product crystallised from solution, whereupon it was collected by 
vacuum filtration and washed with cold ethanol to obtain a pink crystalline solid 
(0.277g, 0.33 mmol, 33%).  
1H NMR (400 MHz, d6-DMSO) δ  = 6.87 (s, 4H, ArC1H), 4.13 (t, 3J=7.8 Hz, 4H, C7H), 
2.15 (m, 8H, C11H2), 1.44 (m, 8H, C10H2), 1.18 (m, 8H, C9H2) ppm. 13C NMR (101 
MHz, d6-DMSO) δ = 139.5, 132.9, 124.5, 113.5, 61.0, 33.7, 32.6, 29.2 ppm. MALDI-
TOF m/z for C40H48O16 calcd. 784.29, found 807.32 [M+Na]+. IR (ν ATR): 3250, 2926, 
1689, 1609, 1457, 1284, 1197, 1094, 1031, 972, 506 cm-1.  
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Crystal data for C-3-hydroxpropyl-pyrogallol[4]arene ethanol hydrochloride: 
2(C40H48O16) 2(C2H6O) CH4O 2(Cl), M = 1760.61, colourless, block, 0.49 × 0.29 × 0.12 
mm3, monoclinic, space group P21/c (No. 14), a = 10.3676(10), b = 18.003(2), c = 
22.7013(17) Å, β = 91.344(9)°, V = 4236.1(7) Å3, Z = 2, Dc = 1.380 g/cm3, F000 = 1864, 
Xcalibur, Sapphire3, Mo Kα radiation, λ = 0.7107 Å, T = 173(2)K, 2θmax = 57.5º, 
22931 reflections collected, 9719 unique (Rint = 0.0676). Final GooF = 1.093, R1 = 
0.1113, wR2 = 0.3191, R indices based on 4975 reflections with I >2sigma(I) 
(refinement on F2), 579 parameters, 0 restraints. Lp and absorption corrections 
applied, µ = 0.167 mm-1. 
Crystal data for C-3-hydroxpropyl-pyrogallol[4]arene ethanol hydrate: 
(C40H48O16) (C2H6O) H2O, M = 848.87, colourless, block, 0.30 × 0.22 × 0.17 mm3, 
triclinic, space group P (No. 2), a = 12.1034(11), b = 13.3287(8), c = 14.0589(12) Å, α 
= 85.637(6), β = 65.052(9), γ = 79.177(6)°, V = 2019.8(3) Å3, Z = 2, Dc = 1.396 g/cm3, 
F000 = 904, Xcalibur, Sapphire3, Mo Kα radiation, λ = 0.7107 Å, T = 173(2)K, 2θmax = 
57.7º, 19654 reflections collected, 10609 unique (Rint = 0.0603). Final GooF = 0.843, 
R1 = 0.0616, wR2 = 0.1153, R indices based on 3113 reflections with I >2sigma(I) 
(refinement on F2), 567 parameters, 0 restraints. Lp and absorption corrections 
applied, µ = 0.109 mm-1. 
Crystal data for C-3-hydroxpropyl-pyrogallol[4]arene Acetone Water: 
(C40H48O16) 2(C3H6O) H2O, M = 882.86, colourless cubic, 0.15 × 0.13 × 0.06 mm3, 
triclinic, space group P (No. 2), a = 9.0689(5), b = 12.1833(6), c = 20.4988(10) Å, α = 
91.570(4), β = 92.234(4), γ = 101.876(4)°, V = 2213.3(2) Å3, Z = 2, Dc = 1.325 g/cm3, 
F000 = 936, Xcalibur, Sapphire3, MoKα radiation, λ = 0.71073 Å, T = 150(2)K, 2θmax = 
50.0º, 14427 reflections collected, 7751 unique (Rint = 0.0446).  Final GooF = 0.959, R1 
= 0.0727, wR2 = 0.1973, R indices based on 3795 reflections with I >2sigma(I) 
(refinement on F2), 583 parameters, 0 restraints. Lp and absorption corrections 
applied, µ = 0.105 mm-1. 
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19) C-3-Hydroxybutyl-pyrogallol[4]arene 26 
 
3,4-Dihydro-2H-pyran (1.0 eq., 4 mmol, 365 µL) was added to a solution of 
pyrogallol (1 eq. 4 mmol, 0.504 g) in ethanol (1.5 mL) and concentrated HCl (37%, 500 
µL) contained in a CEM pressure vial (10 mL). After pre-stirring (30 sec), the mixture 
was heated (100 ºC) by microwaves (100 W, PowerMax) for 10 min. Upon cooling to 
room temperature, the product crystallised from solution, whereupon it was collected by 
vacuum filtration and washed with cold ethanol to obtain a pink crystalline solid (0.268 
g, 0.32 mmol, 32%). 
1H NMR (400 MHz, d6-DMSO) δ  = 8.64 (s, 8H, OH), 8.08 (s, 4H, OH), 6.89 (s, 4H, 
ArC1H), 4.13 (t, 3J= 7.8 Hz, 4H, C7H), 3.35 (m, 8H, C11H2), 2.14 (m, 8H, C10H2), 1.44 
(m, 8H, C8H2), 1.18 (m, 8H, C9H2) ppm. 13C NMR (101 MHz, d6-DMSO) δ =139.5, 
132.8 124.5, 113.5, 61.0, 33.7, 32.6, 30.7, 24.3 ppm. MALDI-TOF m/z for C44H56O16 
calcd. 840.36, found 840.91 [M ]+. 
Crystal data for C-4-hydroxybutyl-pyrogallol[4]arene 26 acetone clathrate: 
(C44H56O16) (C3H6O), M = 898.97, colourless rod, 0.10 × 0.02 × 0.02 mm3, triclinic, 
space group P (No. 2), a = 18.13(2), b = 18.45(2), c = 23.83(4) Å, α = 108.74(2), β = 
107.06(2), γ = 100.91(2)°, V = 6853(16) Å3, Z = 6, Dc = 1.307 g/cm3, F000 = 2880, 
Bruker SMART APEX2 CCD diffractometer, synchrotron radiation, λ = 0.6939 Å, T = 
120(2)K, 2θmax = 48.8º, 50280 reflections collected, 24034 unique (Rint = 0.0942). Final 
GooF = 1.007, R1 = 0.0865, wR2 = 0.2264, R indices based on 10912 reflections with I 
>2sigma(I) (refinement on F2), 1779 parameters, 9 restraints. Lp and absorption 
corrections applied, µ = 0.099 mm-1. 
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Crystal data for C-4-hydroxybutyl-pyrogallol[4]arene 26 acetonitrile acetone 
solvate: (C44H56O16) 2(CH3CN) (C3H6O), M = 1004.06, colourless block, 0.30 × 0.18 × 
0.1 mm3, monoclinic, space group P21/m (No. 11), a = 9.6489(3), b = 18.2583(9), c = 
14.4414(4) Å, β = 104.706(2)°, V = 2460.83(16) Å3, Z = 2, Dc = 1.355 g/cm3, F000 = 
1070, Bruker-Nonius Roper CCD camera on goniostat, MoK  radiation radiation, λ = 
0.71073 Å, T = 120K, 2θmax = 53.0º, 27400 reflections collected, 5244 unique (Rint = 
0.0764). Final GooF = 1.026, R1 = 0.0864, wR2 = 0.2232, R indices based on 3147 
reflections with I >2sigma(I) (refinement on F2), 364 parameters, 0 restraints.  Lp and 
absorption corrections applied, µ = 0.109 mm-1. 
Crystal data for C-4-hydroxybutyl-pyrogallol[4]arene 26 acetonitrile hydrate: 
2(C44H56O16) 2(CH3CN) H2O, M = 1797.90, colourless block, 0.30 × 0.30 × 0.30 mm3, 
orthorhombic, space group Pna21 (No. 33), a = 18.875(4), b = 15.211(3), c = 14.964(3) 
Å, V = 4296.3(15) Å3, Z = 2, Dc = 1.390 g/cm3, F000 = 1916, Bruker SMART APEX2 
CCD diffractometer, Synchrotron radiation, λ = 0.6939 Å, T = 120(2)K, 2θmax = 53.0º, 
27665 reflections collected, 8675 unique (Rint = 0.0628). Final GooF = 1.051, R1 = 
0.0620, wR2 = 0.1736, R indices based on 8269 reflections with I >2sigma(I) 
(refinement on F2), 625 parameters, 5 restraints.  Lp and absorption corrections 
applied, µ = 0.106 mm-1. 
 
20) Zinc complex: C-3-hydroxypropyl-
pyrogallol[4]arene bis(pyridyl) zinc (II) dimer 28 
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Zinc nitrate hexahydrate (1 eq., 21 mmol, 6.4 g) was dissolved in pyridine dried 
over potassium hydroxide pellets (3.6 eq., 77 mmol, 6 mL), the reaction mixture was 
heated at 60 ºC for 30 min and left to cool at room temperature, upon evaporation 
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the zinc pyridine complex (Zn(NO3)2Py3) 27 crystallised in near quantitative yield. The 
zinc pyridine (4.1 eq., 2.62 mmol, 1.121 g) was added to C-hydroxypropyl-
pyrogallol[4]arene 25 ( 1 eq., 6.41 x 10-4 mol, 0.500 g) in methanol (2 mL). The 
solution was heated until dissolution and was left to evaporate. After a week, crystals 
suitable for X-ray crystallography were obtained.  
Crystal data for squeezed C-3-hydroxypropyl-pyrogallol[4]arene bis(pyridyl) 
zinc (II) dimer: 2(C40H36O16) 9(C5H5N) 8(Zn) C2H4, M = 2773.18, 0.04 × 0.08 × 0.10 
mm
3
, yellow block, monoclinic, space group P21/c (No. 14), a = 17.0144(6), b = 
29.7554(10), c = 31.9759(11) Å, β = 119.910(3)°, V = 14032.3(8) Å3, Z = 4, Dc = 1.313 
g/cm3, F000 = 5676, Xcalibur, Sapphire3, MoKα radiation, λ = 0.71073 Å, T = 173(2)K, 
2θmax = 55.5º, 126244 reflections collected, 30515 unique (Rint = 0.0971). Final GooF = 
1.377, R1 = 0.1277, wR2 = 0.2805, R indices based on 16373 reflections with I 
>2sigma(I) (refinement on F2), 1578 parameters, 4 restraints.  Lp and absorption 
corrections applied, µ = 1.414 mm-1. 
 
21) 2-((1,3-Dioxolan-2-yl)methyl)isoindoline-1,3-dionyl-
pyrogallol[4]arene 30 
 
A mixture of potassium phthalimide (1.5 eq., 14.48 mmol, 2.68g) and 2-(2-
bromoethyl)-1,3-dioxolane (1.0 eq., 9.6 mmol, 1 mL) was stirred in DMF (20 mL) at 
60°C overnight. Water (100 mL) was added and the reaction mixture was extracted with 
chloroform (3x75 mL). The combined organic phases were washed with water (100 
mL), dried over magnesium sulphate and evaporated under vacuum. The resulting 
crystals (1.01 g, 4.3 mmol, 31%) were dried under vacuum.  
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The crude 2-(2-(1,3-dioxolan-2-yl)ethyl)isoindoline-1,3-dione was dissolved in ethanol 
(1 mL) and added to a solution of pyrogallol (1 eq., 4.3 mmol, 0.542g) in ethanol ( 500 
µL) and concentrated HCl (37%, 500 µL). The reaction mixture was stirred at room 
temperature (2 hours) and then heated for 5 days (65 ºC). The product could not be 
identified or isolated.  
 
22) 2-(2-(1,3-Dioxolan-2-yl)ethyl)isoindoline-1,3-dionyl-
pyrogallol[4]arene 32 
 
A mixture of potassium phthalimide (1.2 eq., 12 mmol, 2.23 g) and 3-(3-
bromopropyl)-1,3-dioxolane (1.0 eq., 10 mmol, 1.20 mL) was stirred in DMF (20 mL) 
at 60°C overnight. Water (100 mL) was added and the reaction mixture was extracted 
with chloroform (3 x 75 mL). The combined organic phases were washed with water 
(100 mL), dried over magnesium sulphate and evaporated under vacuum. The resulting 
crystals (2.81 g, 11.3 mmol, 94%) were dried under vacuum and used without further 
purification. 
The crude 2-(2-(1,3-dioxolan-2-yl)ethyl)isoindoline-1,3-dione was dissolved in 
ethanol (1 mL) and added to a solution of pyrogallol (1 eq., 4.3 mmol, 0.542g) in 
ethanol ( 500 µL) and concentrated HCl (37%, 500 µL). The reaction mixture was 
stirred at room temperature (2 hours) and then heated for 5 days (65 ºC). The product 
could not be identified or isolated. 
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23) Bis((9H-fluoren-9-yl)methyl)2,2'-(4,5,6-trihydroxy-
1,3-phenylene)dipyrrolidine-1-carboxylate 34 
 
Under nitrogen, to a solution 9-fluorenylmethyl chloroformate (1.0 eq., 5.78 
mmol, 1.5 g) in THF (25 mL) was added 4-aminobutyraldehyde diethyl acetal (1.0 eq., 
5.78 mmol, 1 mL) and N,N-diisopropylethylamine (1.0 eq., 5.78 mmol, 1 mL). The 
solution was stirred at room temperature for 12 hours, water (150 mL) was then added 
and the mixture was extracted with diethyl ether (3 x 50 mL). The combined organic 
phases were washed with water (100 mL), dried over magnesium sulphate and 
evaporated. The resulting oil was purified by flash chromatography (1 EtOAc/ 1 Hex Rf 
= 0.62) to obtain 0.98g (2.5 mmol, 44 %) of pure (9H-fluoren-9-yl)methyl (4,4-
diethoxybutyl)carbamate. 
1H NMR (400 MHz, d6-DMSO) δ  = 7.88 (d, 3J =7.4 Hz, 2 H), 7.68 (d, 3J =7.4 Hz, 2 H), 
7.42 (t, 3J =7.4 Hz, 2 H), 7.30 (d, 3J =7.4 Hz, 2 H), 4.33 (t, 3J =5.7 Hz, 1 H), 4.28 (d, 3J 
= 7 Hz, 1 H, CHFmoc), 3.59 (m, 8 H, CH2 ), 2.96 (m, 4 H), 1.08 (t, J = 7.0 Hz, 6 H, 
CH3) ppm. 13C NMR (101 MHz, d6-DMSO) δ =156.1, 143.9, 140.7, 127.6, 127.1, 
126.6, 125.1, 101.9, 65.1, 64.5, 46.7, 30.6, 24.7, 15.30 ppm.  
Under nitrogen, to a solution of (9H-fluoren-9-yl)methyl (4,4-
diethoxybutyl)carbamate (1 eq., 2.77 mmol, 1.09 g) in ethanol (5 mL) was added 
dropwise over 30 min a solution of pyrogallol (1 eq., 2.77 mmol, 0.35 g) in a 25% HCl 
ethanolic mixture. The reaction mixture was stirred at room temperature overnight and 
then heated at 40°C for 4 hours. Upon cooling, the resulting precipitate was filtered, 
washed with ice-cold ethanol and crystallised from acetonitrile/water to yield to yellow 
needles (0.25 g, 0.3 mmol, 13 %).  
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Crystal data for bis((9H-fluoren-9-yl)methyl)2,2'-(4,5,6-trihydroxy-1,3-
phenylene)dipyrrolidine-1-carboxylate: C44H40N2O7, M = 708.78, colourless block, 0.56 
× 0.38 × 0.18 mm3, triclinic, space group P21 (No. 4), a = 8.4426(4), b = 17.5344(8), c 
= 12.6136(6) Å, α = 90.00, β = 104.534(3), γ = 90.00°, V = 1807.51(15) Å3, Z = 2, Dc = 
1.302 g/cm3, F000 = 748, Bruker-Nonius Roper CCD camera on goniostat, MoKα 
radiation, λ = 0.71073 Å,  T = 120(2)K, 2θmax = 52.0º, 18915reflections collected, 6940 
unique (Rint = 0.03447). Final GooF = 1.083, R1 = 0.1349, wR2 = 0.3500, R indices 
based on 6330 reflections with I >2sigma(I) (refinement on F2), 482 parameters, 1 
restraints.  Lp and absorption corrections applied, µ = 0.088 mm-1. 
 
24) C-3-Aminopropyl-pyrogallol[4]arene 35 
 
4-Aminobutyraldehyde diethyl acetal (1.0 eq., 4 mmol, 711 µL) was added to a 
solution of pyrogallol (1 eq. 4 mmol, 0.504 g) in dioxane (2.4 mL) contained in a CEM 
pressure vial (10 mL). Concentrated HCl (37%, 0.6 mL) was then added. After pre-
stirring (30 sec), the mixture was heated (100 ºC) by microwaves (100 W, PowerMax) 
for a given time (10 min). Upon cooling to room temperature, the waxy solid formed 
was was collected by vacuum filtration and washed with cold dioxane (2 mL). The 
resulting solid was then heated in methanol (5 mL) for 2 hours, yielding in pink crystals 
that were collected by vacuum filtration (76 mg, 0.1 mmol, 10%). 
1H NMR (400 MHz, d6-DMSO) δ  = 8.62 (s, OH), 8.06 (s, OH), 6.92 (s, 4H, ArC1H), 
4.16 (t, 3J =19.33 Hz, 4H, C7H), 2.82 (t, 3J =17.32 Hz, 8H, C10H2), 2.32 (m, 8H, C8H2), 
1.47 (m, 8H, C9H3) ppm. 13C NMR (101 MHz, d6-DMSO) δ = 139.8, 132.9, 123.9, 
113.6, 33.9, 30.3, 26.0 ppm. MALDI-TOF m/z for C40H52N4O12 calcd: 780.36 found: 
781.11 [M+H]+; 803 [M+Na]+. 
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Crystal data for C-3-aminopropyl-pyrogallol[4]arene 35 hydrochloride salt: 
2(C44H56Cl4N4O12) 2(Cl) 2O, pink block, M = 2244.65m 0.32 × 0.24 × 0.18 mm3, 
triclinic, space group P (No. 2), a = 13.652(3), b = 13.737(3), c = 17.278(4) Å, α = 
90.87(3), β = 109.05(3), γ = 109.85(3)°, V = 2851.8(14) Å3, Z = 1, Dc = 1.3207 g/cm3, 
F000 = 1188, Xcalibur, Atlas, Gemini ultra, Cu Kα radiation, λ = 1.5418 Å,  T = 
173(2)K, 2θmax = 156.9, 17293 reflections collected, 12242 unique (Rint = 0.0240). Final 
GooF = 1.075, R1 = 0.0781, wR2 = 0.2426, R indices based on 7731 reflections with I 
>2sigma(I) (refinement on F2), 713 parameters, 3 restraints. Lp and absorption 
corrections applied, µ = 0.280 mm-1. 
 
25) C-3-Aminopropyl-resorcin[4]arene 36 
 
Under nitrogen, resorcinol (1.0 eq., 25 mmol, 2.75 g) was dissolved in ethanol 
(15 mL) and stirred for 30 min and hydrochloric acid (37%, 3.75 mL) was added. After 
30 min stirring, 4-aminobutyraldehyde diethyl acetal (1.0 eq., 25 mmol, 4.32 mL) was 
added dropwise over one hour. The reaction mixture was stirred at room temperature for 
2 hours, at 45°C for 15 hours and 60°C for 12 hours. The yellow solid formed upon 
cooling was collected by vacuum filtration and recrystallised from methanol (5 mL) to 
yield to a yellow powder (1.16 g, 1.6 mmol, 26 %). 
1H NMR (400 MHz, d6-DMSO) δ  = 6.82 (s, 4H, ArC1H), 6.18 (s, 4H, ArC4H), 4.22 (t, 
3J =7.8 Hz, 4H, C7H), 2.88 (t, 3J =7.8 Hz, 8H, C10H2), 1.93 (q, 3J = 19.08 Hz, 8H, 
C8H2), 1.49 (m, 8H, C9H3) 13C NMR (101 MHz, D2O) δ: 151.9, 125.9, 123.5, 102.9, 
48.9, 39.4, 33.7, 31.1, 25.1 ppm. MALDI-TOF m/z for C40H52N4O8 calcd. 716.86, found 
738.91 [M+Na]+. 
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Crystal data for C-3-aminopropyl-resorcin[4]arene 36 hydrochoride salt: 
(C40H56N4O8) 5(Cl) (CH4O), M = 930.18, colourless plate, 0.18 × 0.15 × 0.03 mm3, 
triclinic, space group P (No. 2), a = 12.4545(2), b = 14.9875(3), c = 16.6760(3) Å, α = 
105.6440(10), β = 99.7590(10), γ = 105.2270(10)°, V = 2793.80(9) Å3, Z = 3, Dc = 
1.106 g/cm3, F000 = 982, Bruker-Nonius APEX II CCD camera on goniostat , MoKα 
radiation, λ = 0.71073 Å,  T = 120(2)K, 2θmax = 55.3º, 55916 reflections collected, 
12668 unique (Rint = 0.0568). Final GooF = 1.052, R1 = 0.0970, wR2 = 0.2508, R 
indices based on 9082 reflections with I >2sigma(I) (refinement on F2), 562 parameters, 
0 restraints. Lp and absorption corrections applied, µ = 0.306 mm-1. 
Crystal data for C-3-aminopropyl-resorcin[4]arene 36 hydrochloride salt: 
C40H56O8.20N4Cl3.70', M = 855.25, colourless fragment, 0.20 × 0.15 × 0.10 mm3, triclinic, 
space group P (No. 2), a = 15.6853(2), b = 18.1004(3), c = 21.7168(4) Å, α = 
65.4010(10), β = 74.2660(10), γ = 65.5410(10)°, V = 5066.45(14) Å3, Z = 4, Dc = 1.121 
g/cm3, F000 = 1810, Bruker-Nonius Roper CCD camera on goniostat, MoKα radiation, λ 
= 0.71073 Å,  T = 120(2)K, 2θmax = 50.0º, 100168 reflections collected, 17814 unique 
(Rint = 0.0891)  Final GooF = 1.046, R1 = 0.0842, wR2 = 0.2083, R indices based on 
12634 reflections with I >2sigma(I) (refinement on F2), 1057 parameters, 0 restraints. 
Lp and absorption corrections applied, µ = 0.264 mm-1. 
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D. CHAPTER IV 
26) C-4-Hydroxybutyl-
dodecacetyloxypyrogallol[4]arene 37 
 
To a solution of C-hydroxybutyl-pyrogallol[4]arene 26 (1 eq., 2.5 x 10-4 mol, 
0.210 g) in THF (1.25 mL) contained in a CEM pressure vial (10 mL), acetic anhydride 
(13.1 eq., 3.2 mmol, 310 µL) and pyridine (3 eq., 7.6 x 10-4 mol, 0.3 mL) was added. 
After pre-stirring (30 sec), the mixture was heated (140 ºC) by microwaves (200 W, 
PowerMax) for 5 min. Upon cooling, a yellow solid precipitated which was collected by 
vacuum filtration and washed with water (2 x 3 mL). The solid was recrystallised from 
ethanol to give a white solid (0.188 g) containing an unresolvable mixture. 
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27) C-4-Hydroxypropyl-dodecapivaloyl-
pyrogallol[4]arene 38 
 
To a stirred solution of C-hydroxypropyl-pyrogallol[4]arene 25 (1 eq., 2.5 
mmol, 2g) in DCM (100 mL), at 0 ºC, was added triethylamine (24 eq., 61.1 mmol, 8.56 
mL) followed by pivaloyl chloride (16 eq., 40.7 mmol, 5 mL) and catalytic amount of 
DMAP (0.2 g). The reaction mixture was warmed up to room temperature and stirred 
for 15 hours. After which it was quenched by the careful addition of a saturated solution 
of ammonium chloride (25 mL) and stirred for 1 hour. The solution was washed with 
water (2 x 100 mL) and brine (100 mL). The organic phase was collected, dried over 
magnesium sulfate and evaporated under vacuum, but was seen to decompose.  
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28) C-4-Hydroxybutyl-tosylpyrogallol[4]arene 39 
 
Under nitrogen, to a solution of C-hydroxybutyl pyrogallol[4]arene (1 eq., 5 
mmol, 4.25g) in acetonitrile (250 mL), was added triethylamine (22 eq., 0.11 mol, 15 
mL) and stirred at 80 ºC for 1 hour. Tosyl chloride (20 eq., 0.1 mol, 19.20 g) in 
acetonitrile (50 mL) was added dropwise over 15 min. The reaction mixture was heated 
to reflux for 6 hours, the product was seen to decompose to a black tar. Upon cooling, 
the solid formed was collected by vacuum filtration was found to be 4-
methylbenzenesulfonic acid. 
 
29) C-4-Hydroxypropyl-dodecaboc-pyrogallol[4]arene 
40 
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To a solution of C-hydroxypropyl-pyrogallol[4]arene 25 (1 eq., 4.3 mmol, 3.4g) 
in THF (50 mL) was added portionwise di-tert-butyl dicarbonate (14 eq., 60.5 mmol, 
13.2g) and a catalytic amount of DMAP (0.2 g). The reaction mixture was stirred at 
room temperature for 18 hours, evaporated under vacuum. The resulting solid was 
dissolved in ethyl acetate (80 mL) and washed with water (2 x 40 mL) and sodium 
hydroxide (2M, 40 mL). The organic phase was dried over magnesium sulfate and 
evaporated under vacuum; to give a white solid that appears to contain a mixture of 
compounds that were not further purified.  
30) C-4-Hydroxybutyl-
dodecabenzyloxypyrogallol[4]arene 41 
 
Under nitrogen, to a solution of C-4-hydroxybutyl-pyrogallol[4]arene 26 (1.0 
eq., 10 mmol, 8.4 g) in DMF (120 mL) potassium hydroxide (20 eq., 0.2 mol, 15.61 g) 
was added and the mixture was stirred at room temperature for 1 hour. In an ice bath, to 
a solution of sodium iodide (13.2 eq., 0.132 mol, 13.2 g) in DMF (25 mL) was added 
dropwise benzyl bromide (13.2 eq., 0.132 mol, 15.66 mL). After complete dissolution, 
the benzyl iodide solution was added dropwise to the pyrogallol[4]arene solution over 1 
hour. The reaction mixture was heated under reflux. The reaction mixture was 
evaporated under vacuum and the product was seen to decompose into a black tar.  
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31) C-4-Hydroxypropyl-
dodecamethoxypyrogallol[4]arene 42 
 
Under nitrogen, a mixture of C-4-hydroxybutyl-pyrogallol[4]arene 26 (1.0 eq., 5 
mmol, 4.2 g) and dried potassium carbonate (2.9 eq., 14.5 mmol, 2g) in acetone (300 
mL) was stirred at room temperature for one hour. Methyl iodide (12.2 eq., 61 mmol, 
3.8 mL) was added dropwise over one hour and the mixture was heated under reflux for 
four days. The reaction mixture was filtered and washed with acetone. The filtrate was 
evaporated and the residue was dissolved in a mixture of dichloromethane and water 
(300 mL). The aqueous phase was acidified with 1N HCl until the pH reached 1. The 
aqueous phase was extracted with DCM (3 x 100 mL) and the combined organic phases 
were washed with water (100 mL) and dried over dry magnesium sulphate, before being 
evaporated to dryness. The resulting solid was recrystallised from acetonitrile to give 
yellow crystals (2.016 g, 2 mmol, 40% yield). 
1H NMR (400 MHz, CDCl3) δ  = 6.40 (s, 4H, ArC1H), 4.46 (t, 3J= 7.8 Hz, 4H, C7H), 
1.81 (m, 8H, C8H), 1.58 (m, 8H, C10H2) 1.41 (m, 8H, C9H2), 0.83 (s, 36H, OCH3) ppm. 
13C NMR (101 MHz, CDCl3) δ =149.5, 145.9, 133.3, 120.1, 62.8, 60.3, 60.1, 36.5, 35.3, 
32.7, 24.4 ppm. MALDI-TOF m/z for C56H80O16 calcd. 1008.54, found 1009.54 [M+H 
]+. 
Crystal data for C-4-hydroxybutyl-dodecamethoxypyrogallol[4]arene: 
C56H80O16, M = 1009.20, colourless slab, 0.32 × 0.22 × 0.11 mm3, monoclinic, space 
group P21/c (No. 14), a = 13.96(6), b = 15.04(4), c = 22.30(10) Å, β = 92.49(16)°, V = 
4678(32) Å3, Z = 4, Dc = 1.433 g/cm3, F000 = 2176, MoKα radiation, λ = 0.71073 Å, T = 
120(2)K, 2θmax = 50.0º, 18445 reflections collected, 7705 unique (Rint = 0.0719). Final 
GooF = 1.042, R1 = 0.1010, wR2 = 0.2820, R indices based on 5430 reflections 
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with I >2sigma(I) (refinement on F2), 677 parameters, 3 restraints. Lp and absorption 
corrections applied, µ = 0.104 mm-1. 
 
32) C-4-Bromobutanyl- pyrogallol[4]arene 43 
 
 
Under nitrogen, C-4-hydroxybutyl-pyrogallol[4]arene 26 (1.0 eq., 5 mmol, 4.2 
g) was dissolved in DCM (30 mL) at cooled down at 0°C. Phosphorous tribromide (1.3 
eq., 6.6 mmol, 6.6 mL) was added dropwise over 10 min and the mixture was stirred 
until it reached room temperature (1.5 hr). The reaction mixture was stirred at 40 ºC 
over 5 hours. The reaction mixture was then evaporated under vacuum and the resulting 
oil was sonicated in water (30 mL) for 15 min, filtered and dried under vacuum to 
obtain a pink solid (3.50 g 3.2 mmol, 65%). 
1H NMR (400 MHz, d6-DMSO) δ  = 8.64 (s, 8H, OH), 8.08 (br. s., OH), 6.88 (s, 4H, 
ArC1H), 4.13 (m, 4H, C7H), 2.16 (m, 8H, C11H2), 1.84 (m, 8H, C10H2), 1.43 (m, 8H, 
C8H2) 1.20 (m, 8H, C9H2) ppm. 13C NMR (101 MHz, d6-DMSO) δ =139.5, 132.8, 
124.6, 113.5, 61.0, 33.7, 32.6, 30.7, 24.3 ppm. HPLC purity >90%. tR=1.409. ESI-MS 
for C44H52Br4O12 calcd. 1092.02, found 1091, 1093, 1095 m/z:  [M+H, Br ratio]+. 
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33) C-3-Succinylaminopropyl-resorcin[4]arene 44 
 
Under nitrogen, C-3-aminopropyl-resorcin[4]arene 36 (1.0 eq., 50 mg, 7 x 10-4 
mol) and succinic anhydride (4 eq., 3 x 10-4 mol, 30 mg,) and DIEA (4 x 10-4 mol, 70 
µL) were dissolved in DMF (2 mL) and stirred at room temperature for 2 hours. The 
solid formed by trituration with methanol (2 mL) was filtered and dried under vacuum 
to give a powder (30 mg) but the pure product was not isolated. 
 1H NMR (400 MHz, CD3OD) δ : 7.39 (s, 4H, ArC1H ), 6.18 (s, 4H, ArC4H), 4.26 (t, 3J 
=8.1 Hz, 4H, C7H), 3.55 (m, 8H, C10H2), 3.25 (t, 3J =7.1 Hz, 8H, C10H2), 3.02 (q, 3J 
=7.1 Hz, 8H, C12H2), 2.91(s, 2H), 2.62 (q, 3J =15.7 Hz, 12H, C13H2), 2.31 (m, 
8H,C9H3), 1.24 (m, 2H) ppm.13C NMR (101 MHz, CD3OD) δ : 175.9, 174.2, 153.1, 
141.6, 125.6, 55.8, 43.7, 40.5, 34.7, 30.6, 29.7, 18.6, 17.1, 13.1 ppm. MALDI-TOF m/z 
for C56H68N4O24 calcd.: 1181.15 , found: 1140 [M+K]+. 
 
34) C-4’carboxyphenyl-pyrogallol[4]arene 45 
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In a CEM pressure vial (10 mL), pyrogallol (1.0 eq., 4 mmol, 0.504 g) and 4-
formylbenzoic acid (1.0 eq., 4 mmol, 711 µL) were dissolved in ethanol (1.5 mL). 
Concentrated HCl (37%, 500 µL) was then added and the mixture was subjected to 
microwave irradiation (100 W, PowerMax) for 10 min at 100 ºC. Upon cooling, a solid 
product formed from solution which was then collected by vacuum filtration and 
washed with water (3 x 2 mL) to obtain a pale pink solid (0.88 g, 0.86 mmol, 86%), the 
NMR indicate the presence rctt (80%) and the rccc (20%). 
rccc: 1H NMR (400 MHz, d6-DMSO) δ = 12.39 - 12.14 (b. s, 1 H, COOH), 7.46 (d, 3J = 
8.1 Hz, 2 H, ArH4), 6.79 (d, 3J = 8.1 Hz, 2 H, ArH3), 5.97 (s, 0.5 H, ArH1), 5.81 (s, 1 H, 
CH), 5.10 (s, 0.5 H, ArH1) ppm.  
rctt: 1H NMR (400 MHz, d6-DMSO) δ = 12.39 - 12.14 (b. s, 4 H, COOH), 7.46 (d, 3J = 
8.4 Hz, 8 H, ArH4), 6.69 (d, 3J = 8.4 Hz, 8 H, ArH3), 5.98 (s, 2 H, ArH1), 5.71 (s, 4 H, 
CH), 5.11 (s, 2 H, ArH1) ppm. 
13C NMR (101 MHz, d6-DMSO) δ = 166.9, 152.7, 142.4, 139.7, 132.2, 128.2, 121.1, 
120.6, 46.0 ppm. MALDI-TOF m/z for C56H40O20 calcd. 1032.21, found 1055.28 
[M+Na]+ 
Crystal data for C-4’carboxyphenyl -pyrogallol[4]arene rctt acid DMSO 
clathrate, C40H20O16S10, M = 1077.16, 0.026 × 0.085 × 0.138 mm3, pink block, triclinic, 
space group P (No. 2), a = 12.0838(13), b = 13.9326(18), c = 15.430(2) Å, α = 
111.106(12), β = 99.481(10), γ = 103.207(10)°, V = 2270.5(5) Å3, Z = 2, Dc = 1.576 
g/cm3, F000 = 1096, MoKα radiation, λ = 0.71073 Å,  T = 173(2)K, 2θmax = 50.0º, 19405 
reflections collected, 7982 unique (Rint = 0.1728). Final GooF = 1.342, R1 = 0.2208, 
wR2 = 0.4296, R indices based on 1816 reflections with I >2sigma(I) (refinement on 
F2), 277 parameters, 0 restraints.  Lp and absorption corrections applied, µ = 0.556 mm-
1
. 
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35) Fmoc glutamic aminopropyl pyrogallol[4]arene 46 
 
In a CEM pressure vial (10 mL)., PS-DCC (1.1 eq., 2.2 x 10-4 mol, 165 mg) PS-
DIEA (1.1 eq., 2.2 x 10-4 mol, 59 mg) and Fmoc-glutamic acid t-butyl ester (1.1 eq., 2.2 
x 10-4 mol, 93 mg) were stirred in DMF (1.5 mL) at room temperature for 30 min. 
Aminobutyraldehyde (1 eq., 2 x 10-4 mol, 36 µL) was added and the mixture was 
subjected to microwave irradiation for 5 min at 100 ºC (100 W). The mixture was 
filtered and washed with DMF (2 x 1 mL) and evaporated. The resulting in a yellow 
wax, which was dissolved in methanol (1.5 mL) with pyrogallol (1.0 eq., 2 mmol, 0.252 
g). Concentrated HCl (37%, 500 µL) was then added and the mixture was subjected to 
microwave irradiation (100 W, PowerMax) for 10 min at 100 ºC. The macrocycle could 
not be isolated. 
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36) C-tert-Butyl (1-(butylamino)-1-oxopropan-2-
yl)carbamate-resorcin[4]arene 47 
 
N-Boc-alanine (5 eq., 1 mmol, 0.19 g,) and C-3-aminopropyl-resorcin[4]arene 
36 (1 eq., 2x10-4mol, 148 mg) were dissolved in DMF (3 mL). DIC (6 eq., 1.2 mmol, 
180 µL) and DIEA (4 eq., 8 x 10-4 mol, 130 µL) were added and the mixture was stirred 
at room temperature for 24 hours. After trituration with methanol, the precipitate was 
collected under vacuum and analysed by NMR to show trace of the expected compound. 
1H NMR (400 MHz, d6-DMSO) δ  = 8.84 (s, 8H) , 7.70 (s, 4H), 7.07 (s, 4H), 6.70 (s, 
4H), 6.09 (s, 4H), 4.16 (t, 3J =8.2 Hz, 4H,), 3.86 (m, 4H), 3.02 (m, 12H), 1.97 (m, 8H), 
1.23 (m, 32H), 1.09 (m, 8H) 13C NMR (CD3)2SO δC (ppm): 172.6, 163.6, 154.3, 151.9, 
123.9, 79.5, 54.6, 49.1, 43.4, 42.5, 41.5, 27.5, 22.3, 21.1, 20.5, 20.1, 18.6, 11.9  
MALDI-TOF m/z for C72H104N8O20 calcd.: 1401.64, found: 1402.78 [M+H]+ 
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37) C-3-(9H-fluoren-9-yl)methyl (1-(butylamino)-1-
oxopropan-2-yl)carbamate-resorcin[4]arene 48  
NH
HO OH
4
NH2
HO OH
4 PS-DCC, DIEA
DMF
+
OH
O
HN
O
O
O
HN
O
O
36 48
 
Method 1: In a CEM pressure vial (10 mL)., Fmoc-alanine (6 eq., 3.5 x 10-4 mol, 
0.109 g) and PS-DCC (4.5 eq., 2.7 x 10-4, 201 mg) and HOBt (6.1 eq., 3.7 x 10-4, 201 
mg) were stirred in DCM/DMF mixture (1:1, 1 mL). C-3-aminopropyl-resorcin[4]arene 
36 (1.0 eq., 6 x 10-5 mol, 42 mg) and of DIEA (1.0 eq., 6 x 10-5, 10 µL) were added with 
DCM/DMF mixture (1:1, 1 mL). the mixture was subjected to microwave irradiation 
(100 W, PowerMax) for 10 min at 100 ºC. After filtration under vacuum, the resin was 
washed with DMF (2 mL). The solution was evaporated to dryness and triturated with 
methanol/diethyl ether (1:1, 2 mL) and used for analysis. MALDI-TOF m/z for 
C112H112N8O20 calcd. 1890.2, found 1911.01 [M+Na]+ 
Method 2: In a CEM pressure vial (10 mL), Fmoc-alanine (6 eq., 3.5 x 10-4 mol, 
0.109 g) and PS-DCC (4.5 eq., 2.7 x 10-4, 201 mg) were stirred in DCM/DMF mixture 
(1:1, 1 mL). C-3-aminopropyl-resorcin[4]arene 36 (1.0 eq., 6 x 10-5 mol, 42 mg) and 
DIEA (1.0 eq., 6 x 10-5, 10 µL) were added with DCM/DMF mixture (1:1, 1 mL). The 
mixture was subjected to microwave irradiation (100 W, PowerMax) for 10 min at 100 
ºC. After filtration under vacuum, the resin was washed with DMF (2 mL). The solution 
was evaporated to dryness and triturated with methanol/diethyl ether (1:1, 2 mL) and 
used for analysis. MALDI-TOF m/z for C112H112N8O20 calcd.: 1890.2, found: 1911.01 
[M+Na]+ 
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38) Pegylated C-3-aminopropylpyrogallol[4]arene 49 
 
In a CEM pressure vial (10 mL)., 2,2-dimethyl-4,21-dioxo-3,8,11,14-tetraoxa-
5,20-diazatricosan-23-oic acid (6 eq., 2.9 x 10-4 mol, 125 mg) and PS-DCC (8.6 eq., 2.4 
x 10-4, 105 mg) were stirred in DCM/DMF mixture (1:1, 1 mL). C-3-aminopropyl-
pyrogallol[4]arene 35 (1.0 eq., 2.8 x 10-5 mol, 22 mg) and PS-DIEA (25 eq., 7 x 10-4, 
200 mg) were added with DCM/DMF (1:1, 1 mL) to the mixture. It was then subjected 
to microwave irradiation (25 W, PowerMax) for 10 min at 75 ºC. After filtration under 
vacuum, the resin was washed with DMF (2 mL). The solution was evaporated to 
dryness and triturated with methanol/diethyl ether (1:1, 2 mL) to obtain 66 mg of the 
crude product that was used for NMR analysis showing trace of the tetra substituted 
compound. 
1H NMR (400 MHz, d6-DMSO) δ = 7.87 (m, 4 H), 6.75 (s, 4 H, ArH), 4.16 (m, 4 H, 
CH), ), 3.56 (s, 8 H), 3.42 (dd, 16 4.2, 32 H), 3.36 (q, J=5.2 Hz, 20 H), 3.05 (q, J=6.40 
Hz, 8 H), 2.94 (q, J=6.40 Hz, 8 H), 2.83 (m, 8 H), 2.38 (d, J=6.87 Hz, 4 H), 2.29 (m, 4 
H), 2.32 (m, 8 H), 1.58 (q, J=6.30 Hz, 16 H, CH2+CH2), 1.36 (s, 36 H, CH3) ppm. 
13C NMR (101 MHz ,DMSO-d6) δ = 174.1, 170.9, 155.6, 139.7, 133.0, 128.2, 123.9, 
113.8, 113.7, 77.4, 69.8, 69.6, 68.1, 51.3, 40.4, 37.3, 35.8, 34.0, 30.2, 29.8, 29.7, 29.4, 
28.9, 28.3, 26.1 ppm. 
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39) General method for peptide synthesis 
In a SPPS reaction vessel, Fmoc protected Wang resin (0.1 mmol) was swelled 
in a  DMF/DCM mixture (1:1, 5 mL) for 30 min and was then drained and rinsed with 
DMF (5 mL). Resin deprotection was done by addition of piperazine (0.58 M, 7 mL) 
and reacted for 30 sec at 75 ºC (∆5 ºC, 50 W), drained and piperazine was added (0.58 
M, 7 mL) and reacted for further 3 min at 75 ºC (∆5 ºC, 50 W). The deprotected was 
drained under vaccum and rinsed with DMF (5 mL x 3). Fmoc protected amino acid 
(2.5 eq., 0.25 mmol) dissolved in DMF (2.5 mL) was added to the deprotected resin 
with HBTU (0.474 M, 1 mL,) and DIEA in NMP (2.58 M, 500 µL). The reaction was 
performed under microwave irradiation using different temperature and coupling time 
depending on the amino acid used. Generally, all amino acids expect from arginine, 
histidine and cysteine, were reacted for 5 min at 75 ºC (∆5 ºC, 25 W). Arginine was 
reacted for 30 min at 25 ºC (∆5 ºC, 0 W). Histidine and cysteine were reacted for 10 
min at 50 ºC (∆5 ºC, 25 W), drained and more amino acid (2.5 eq., 0.25 mmol) was 
added and reacted for  further 10 min at 25 ºC (∆5 ºC, 0 W). 
Final deprotection was done by addition of piperazine (7 mL x 2). The reaction 
mixture was drained, washed with DMF (3 x 5 mL) and rinsed with DCM (3 x 5 mL) 
and left to dry under air for 15 min. The resin was then transferred into a cleavage mix 
solution containing H2O (0.25 mL), TIS (0.1 mL), DODT (500 µL) and TFA (9.4 mL) 
and stirred at room temperature for 3 hours. The peptide was filtered into a chilled 
solution of diethyl ether (100 mL) and the resin washed with DCM (2 x 2 mL). The 
ether solution was placed in the freezer for at least 1 hour, until the formation of a white 
precipitate. The mixture was centrifuged (10 min, 3000 rpm, <10 ºC), the supernatant 
removed and clean chilled diethyl ether (30 mL) was added. The process was repeated 
two more times. The recovered white waxy solid was left to dry overnight or dry-freeze. 
Peptide purity was analysed using HPLC using the gradient 95% H2O / 5% CH3CN / 
0.1% TFA to 5% H2O / 95% CH3CN / 0.1% TFA, over 60 min at a flow rate of 500 
µL.min-1, the UV detector was set at 215 nm. 
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40) C-3-Ala-Ala-Ala-Asp-propyl-resorcin[4]arene 50 
 
Asp-Ala-Ala-Ala (2 eq., 9.4 x 10-5 mol, 34 mg), DIC (2.7 eq., 1.27 x 10-4 mol, 20 µL), 
DIEA (2 eq., 9.2 x 10-5 mol, 16 µL) and C-3-aminopropyl-resorcin[4]arene 36 (1 eq., 
2.1 x10-5 mol 42 mg), were stirred in DCM/DMF mixture (1:1, 1 mL) for 24 hours. 
After filtration, the solvent was evaporated and the oil sonicated in water (1 mL), 
forming a white solid (5mg) that was used for analysis. The HPLC analysis revealed 3 
main peaks at 2.59 min (34%), 3.26 min (11%) and 3.61 min (12%). The MALDI-TOF 
MS m/z for C92H132N20O36 calcd. 2094.14, found: 2889, 1713 and 714 [RsC3NH2]+ 
respectively, did not allow the characterisation of the compound. 
41) AAA-p53(108-122)-A 51 
 
The following sequence AAAGFRLGFLHSGTAKSVA was synthesised using 
the general method for peptide synthesis resulting in a nearly quantitative yield. 
However the MS results indicated that 50% were still Fmoc protected. Cleaved AAA-
p53(108-122)-A unprotected peptide (2 eq., MW= 1873.01g.mol-1, 2.6 x 10-5, 50 mg) 
was dissolved in DMF/DCM mixture (1:1, 2 mL) with aminopropyl-pyrogallol[4]arene 
35 (1 eq., 5.2 x 10-5, 4.2 mg), PS-DCC (8 eq., 4.1 x 10-5, 31.5 mg) and PS-DIEA (6 eq., 
3.12 x 10-5, 8.5 mg). After pre-stirring (15 s), the mixture was heated (75ºC) by 
microwaves (25 W, PowerMax) for 10 min. The resin was then drained and washed 
with DMF (3 x 2 mL), the combined filtrate were evaporated under vacuum and 
triturated with cold diethyl ether (10 mL) resulting in a white solid that was used for 
analysis showing only possible trace of the compound. 
1H NMR (400 MHz , d6-DMSO) δ = 8.62 (br. s., 2 H), 8.27 - 8.10 (m, 3 H), 8.06 - 7.88 
(m, 4 H), 7.88 - 7.61 (m, 5 H), 7.38 - 7.11 (m, 4 H), 6.83 (br. s., 1 H), 5.16 - 4.96 (m, 2 
H), 4.96 - 4.83 (m, 1 H), 4.40 - 4.13 (m, 6 H), 3.97 (br. s., 1 H), 3.91 - 3.74 (m, 2 
H), 3.67 - 3.50 (m, 4 H), 3.39 (dt, J = 0.9, 7.0 Hz, 6 H), 3.15 - 2.97 (m, 2 H), 2.66 - 
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2.43 (m, 7 H), 2.39 - 2.13 (m, 3 H), 2.06 - 1.91 (m, 2 H), 1.89 - 1.72 (m, 2 H), 1.70 - 
1.64 (m, 1 H), 1.49 (quin, J = 6.1 Hz, 4 H), 1.36 - 1.16 (m, 6 H), 1.03 (d, J = 5.6 Hz, 2 
H), 0.84 (dd, J = 6.9, 15.7 Hz, 10 H) ppm. 13C NMR (101 MHz , d6-DMSO) δ = 226.3, 
217.3, 188.3, 153.7, 139.7, 129.0, 128.9, 120.2, 114.3, 82.6, 72.4, 64.9, 15.2. MALDI-
TOF m/z for C84H133N25O23  calcd. 1861.11, found: 1874.01 [M]+ and 1897.91 
[M+Na]+. 
 
42) HOOC-(CH2)3COO-p53 (108-122)-A 52 
 
The following sequence GFRLGFLHSGTAKSVA was synthesised using the 
method previously described (1 x 10-4 mol). To the Fmoc deprotected peptide was added 
glutaric anhydride (2.2 eq., 2.2 x 10-4 mol, 25 mg) with HBTU (0.474 M, 1 mL) and 
DIEA in NMP (2.58 M, 500 µL). The reaction mixture was heated to 75 ºC for 10 min 
under microwave irradiations (25 W). The resin was drained and washed with DMF (2 x 
5 mL) and a solution of aminopropyl pyrogallol[4]arene (1.4 x 10-5 mol, 11mg) was 
added with HBTU (0.474 M, 1 mL,) and DIEA in NMP (2.58 M, 500 µL). The reaction 
mixture was heated to 75 ºC for 10 min under microwave irradiations (25 W). The resin 
was drained, washed and cleaved using the general procedure. The white product 
collected after centrifugation (83 mg, 4.65 x 10-5 mol, 46%) was 74 % pure by HPLC. 
The MALDI-TOF m/z for C80H124N22O23 calcd. 1761.97, found 1785.68 [HOOC-
(CH2)3COO-p53 (108-122)-A +Na]+ 
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43) PS-PgC3OH 53 
 
Method 1: (53) Merrifield polymer Hertz resin 200 – 400 mesh (1 eq., 0.2 mmol, 
subst. 1.0 -1.5 mmol.g-1, 0.25 g) was swelled in a mixture a DMF / DCM mixture (1:1, 
5 mL) for 30 min and was then drained. A solution of C-3-hydroxypropyl-
pyrogallol[4]arene 25 (1.28 eq., 0.32 mmol, 0.25 g) in DMF (2 mL) and K2CO3 (12 eq., 
3.6 mmol, 0.50 g) was then added. The reaction mixture was subjected to microwave 
irradiation for 10 min at 100 ºC (100 W). The reaction mixture was drained, washed 
with DMF (3 x 5 mL) and rinsed with H2O (3 x 5 mL), MeOH (3 x 5 mL) resulting in a 
pink resin. (53) 
IR (ν): 3432.15, 3132.66, 2938.50, 1646.93, 1478.96, 1383.54, 1352.25, 1239.26, 
1265.84, 1235.27, 1094.14, 1057.24, 1005.04, 978.42, 778.67, 694.92, 663.23 cm-1. 
The resin was transferred to a cleavage mix solution containing H2O (500 µL) 
and TFA (9.5 mL) and stirred at room temperature for 3 hours. The mix was then 
transferred into H2O (50 mL), the solid that crashed out was then filtered and use for 
NMR analysis revealing the starting pyrogallol[4]arene 25.  
1H NMR (400 MHz, d6-DMSO) δ = 6.88 (s, 4 H, ArC1H), 4.15 (t, J = 7.8 Hz, 4 H, 
C7H), 2.17 (q, J = 7.3 Hz, 8 H, C11H2), 1.35 (m, 8 H, C10H2 ), 1.24 (m, 8 H, C9H2) ppm. 
Method 2: Merrifield polymer Hertz resin 200 – 400 mesh (1 eq., 0.2 mmol, 
subst 1.0 -1.5 mmol.g-1, 0.25g) was swelled in a mixture a DMF / DCM mixture (1:1, 5 
mL) for 30 min and was then drained. A solution of C-3-hydroxypropyl-
pyrogallol[4]arene 25 (0.25 g, 0.32 mmol, 1.28 eq.) in DMF (2 mL) and pyridine (32 
eq., 6.4 mmol, 500 µL) was then added. The reaction mixture was subjected to 
microwave irradiation for 30 min at 75 ºC (∆5 ºC, 50 W). The reaction mixture was 
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drained, washed with DMF (3 x 5 mL) and rinsed with MeOH (3 x 5 mL) resulting in a 
pink resin that was used as such. (54) 
IR (ν): 3311.15, 3024.66, 2923.50, 2829.56, 1601.93, 1492.96, 1451.54, 1420.92, 
1316.08, 1265.84, 1213.27, 1110.14, 1024.24.13 910.04, 824.42, 761.67, 699.92, 
674.23, 543.48 cm-1. 
The resin was transferred to a cleavage mix solution containing H2O (500 µL) 
and TFA (9.5 mL) and stirred at room temperature for 3 hours. The mix was then 
transferred into H2O (50 mL), the solid that crashed out was then filtered and use for 
NMR analysis.  
1H NMR (400 MHz, d6-DMSO) δ = 6.88 (s, 4 H, ArC1H), 4.15 (t, J = 7.8 Hz, 4 H, 
C7H), 2.17 (q, J = 7.3 Hz, 8 H, C11H2), 1.35 (m, 8 H, C10H2 ), 1.24 (m, 8 H, C9H2) ppm. 
IR cleaved resin (ν): 3026.24, 2917.25, 1731.33, 1685.00, 1600.96, 1492.09, 1451.60, 
1199.11, 1120.68, 1026.91, 799.12, 756.90, 696.97, 537.14, 412.71, 395.91 cm-1. 
44) PS-PgC3O-SO2CH3 55 
 
The resin was functionalised as previously described with C-hydroxypropyl-
pyrogallol[4]arene 25 (0.100 g, 0.4 mmol) and swelled in DMF (1 mL) for 15 min. 
After being washed and dried, methane sulfonyl chloride (17 eq., 1.7 mmol, 131 µL) 
and pyridine (17 eq., 1.7 mmol, 136 µL,) was added  and the mixture subjected to 
microwave irradiation for 10 min at 150 ºC (100 W). The resin was then drained and 
washed with DMF (2 x 5 mL) and MeOH (2 x 5 mL). The resin was used for SEM 
analysis, revealing the presence of sulphur.  
IR (ν ATR): 3023.60, 2919.88, 2157.34, 1600.59, 1178.50, 1027.82, 756.68, 697.03, 
534.08 cm-1 
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45) UV titration 
To the substituted resin (5 to 10 mg) was added piperazine (1 mL, 0.58M) and shaked 
for 15 min. After 10 min of centrifugation, a 100 µL of the mixture was added to 10 mL 
of DMF. Using the UV spectrometer, the absorption was then measured at 301 nm and 
corrected with the blank. The substitution was then assessed using the following 
equation : subst. (in meq.) = (A x dilution)/weigh. 
46) PS-PgC3NH-Fmoc 56 
 
Merrifield polymer Hertz resin (0.25 g, 0.8 mmol, 100- 200 mesh, subst. 1.0 - 
1.5 mmol.g-1) was swelled in a mixture a DMF/DCM mixture (1:1, 5 mL) for 30 min 
and was then drained. A solution of Fmoc-aminopropyl pyrogallol[4]arene (1 eq., 6.5 x 
10-5 mol, 0.11 g) in DMF (3 mL) and pyridine (10 eq., 6.4 mmol, 500 µL) was then 
added. The reaction mixture was subjected to microwave irradiation for 1 hour at 75 ºC 
(∆5 ºC, 50 W). The reaction mixture was drained, washed with DMF (3 x 5 mL), rinsed 
with MeOH (3 x 5 mL) and dried. The substitution was assessed by UV to be 1.06 meq. 
/g. 
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47) PS-PgC3OCys(Ac) 57  
 
The resin was functionalised as previously described (0.500 g, 1.52 mmol). To 
the washed resin, was added a solution of N-acetyl-L-cysteine (6.1 mmol, 1 g,) in DMF 
(2.5 mL), DIC (6.07 µmol, 941 µL,) and a catalytic amount of DMAP. The resin was 
transferred to a cleavage mix solution containing H2O (500 µL) and TFA (9.5 mL) and 
stirred at room temperature for 3 hours. The mix was then transferred into H2O (50 mL), 
the solid that precipitated was then filtered and used for IRanalysis. 
IR resin (ν): 3311.15, 3024.83, 2923.50, 2829.56, 2158.22, 1601.93, 1420.92, 1316.08, 
1265.84, 1110.14, 1024.13, 824.42, 761.67 cm-1. 
48) Butyl 2-(-2-(-2-aminopropanamido)-
propanamido)propanoate pyrogallol[4]arene 58 
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Merrifield polymer Hertz resin (0.49 mmol, 100-200 mesh, subst. 1.0 -1.5 
mmol.g-1, 0.499 g,) was swelled in a mixture a DMF/DCM mixture (1:1, 5 mL) for 30 
min and was then drained. A solution of C-hydroxypropyl pyrogallol[4]arene (1 eq., 1 
mmol, 0.781g) in DMF (3 mL) and pyridine (6.4 eq., 6.4 mmol, 500 µL,) was then 
added. The reaction mixture was subjected to microwave irradiation for 30 min at 75 ºC 
(∆5 ºC, 50 W). The resin was drained, washed with DMF (3 x 5 mL) and rinsed with 
MeOH (3 x 5 mL). The AAA sequence was synthesised on the resin as previously 
described (general method). After the final deprotection, the resin was drained, washed 
with DMF (3 x 5 mL) and DCM (3 x 5 mL), left to dry under air for 15 min. The resin 
was then transferred into a cleavage mix solution containing H2O (250 µL), TIS (100 
µL), DODT (500 µL) and TFA (9.4 mL) and stirred at room temperature for 3 hours. 
The peptide was filtrated into a chilled solution of diethyl ether (100 mL) and the resin 
washed with MeOH (2 x 2 mL). The ether solution was placed in the freezer for 24 
hours resulting in the formation of a white precipitate. NMR indicates trace of the 
expected compound but could not be purified.  
MALDI-TOF m/z for starting material found: 807.45, 913.507, 1015.758, 1073.778, 
1512.124.MALDI-TOF m/z for C76H108N12O28 calcd.: 1636.74, found: 945.16,  1015.57, 
1792.88 (indicate 11 alanine, which could be 3 x AAA and 1 x AA). 
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E. CHAPTER V: 
49) Haemolysis assay391 
Freshly drawn human blood (30 mL) were centrifuged in a polypropylene vial 
with physiological serum (NaCl 0.9%, 30 mL) for 5 min at 1200 g. The supernatant was 
removed and this operation was repeated twice. The volume of the washed erythrocytes 
was adjusted with PBS (72 mL). To the 10% DMSO / PBS buffered solution of 
calixarene derivatives(500 µL), was added the suspension of erythrocytes (500 µL). 
After moderate manual stirring, the mixture was incubated (30 min.) in a thermostated 
bath (37 ºC) and centrifuged (1200 × g for 5 min). An aliquot of the supernatant (20 µL) 
was added to the Drabkin reagent (2 mL). The quantity of haemoglobin was assayed 
spectrophotometrically at 540 nm. To ensure result reproducibility all assays were 
repeated three times. Positive and negative controls have been realised by replacing the 
sample with water (total haemolysis due to hypotonic stress), 10% DMSO / PBS and 
PBS. The percentage of haemolysis is expressed as the ratio between the absorbance of 
the sample (corrected using the value obtained for PBS) and the absorbance of the 
positive control. 
50) Culturing of Murine Bone Marrow Dendritic Cells 
BMDC were generated as described by Inaba and co-workers with 
modification.395 The hind limbs from immunologically naive mice were taken and all of 
the muscle and fat removed using forceps and scissors. After cutting the ends of the 
bones, bone marrow was flushed with BM-DC media (RPMI 1640 + 5% FCS + 10 mM 
HEPES Buffer + 50 µM 2-mercaptoethanol + 50 U/mL Penicillin/Streptomycin + 0.25 
µg/mL fungizone). The flushed cells and media were collected, centrifuged (1500 rpm, 
for 3 min at 4°C), resuspended in 4 mL of BM-DC media and then counted in acetic 
acid and trypan blue using a haemocytometer. The dendritic cells were plated at 1x106 
cells per mL/well with GM-CSF (1 ng/mL) and incubated (37°C, 5% CO2). On days 2 
and 4, non-adherent cells were washed gently by removing the media (700 µL) and 
replacing it by fresh BM-DC media (750 µL) of containing GM-CSF (100 ng/mL). 
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51) Maturing Bone Marrow Dendritic cells 
On day 7, BMDC were harvested, counted and supplemented with of 
LipoPolySaccharide (LPS, 1µg/mL) to induce maturation and then incubated at 37°C, 
5% CO2 overnight. On day 8, the cells were washed with fresh media supplemented 
with polyIC (12.5 µL) and incubated for 2 hour at 37°C, 5 % CO2.   
52) Fluorescent Activated Cell Sorting (FACS) 
The two colonies of DCs cultured either with the standard method (method A)395 
or the alternative one (method B)397 were collected. The DCs were fixed with 
paraformaldehyde and CD16/CD32 Fc blocker to minimise the non-specific binding 
and lower the background. The cells were then treated with the appropriate surface 
marker antibodies in order to characterise the various populations, i.e. MHC class II 
(HLA-DR-FITC, abcam), CD11c-RPE (Hamster antimouse, Serotec) and CD86-RPE 
(Rat antimouse, Serotec). All of these markers were tested using the monoclonal 
antibodies as well as their isotype controls in order to confirm the purity of the DCs 
population. In this experiment the dendritic cells have not been fixed with 
paraformaldehyde, but a CD16/CD32 Fc blocker as been used to minimise the non 
specific binding, which lowers the background. The results are presented by percentage 
of cells gated. 
53) Vialight® HS Assay 
The assay was performed according to the manufacturer instructions. BMDC 
were generated as previously described, on day 7 the cells were replated at 1 x 105 
cells/well/100 µL of media containing various concentrations of calixarene. After 24 
hours, the lysing reagent was added for 10 min, followed by the ATP monitoring 
reagent of the Vialight® HS Kit (Lonza). The plate was placed in the luminometer and 
the intensity of the light measured. The percentage of bioluminescence is expressed as 
the ratio between the reading of the sample and the reading of the untreated cells as the 
positive control.  
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54) Toxilight® BioAssay 
The assay was performed according to the manufacturer instructions. BMDC 
were generated as previously described, on day 7 the cells were replated at 2.5 x 105 
cells/well/mL of media containing various concentration of calixarene. After 24 hours, 
the ATP monitoring reagent from the Toxilight® BioAssay Kit (Lonza), was added. 
Finally, the plate was placed in the luminometer and the intensity of the light measured. 
The percentage of bioluminescence is expressed as the ratio between the reading of the 
sample and the reading of the untreated cells as the positive control. On day 4, non-
adherent cells were washed gently by removing the media (700 µL) and replacing it by 
fresh BM-DC media (750 µL) containing GM-CSF (100 ng/mL) of and various 
concentrations of calixarene. On day 7, the Toxilight assay was repeated. 
55) Propidium Iodide Assay 
BMDC were generated as previously described. On day 7 the cells were replated 
at 5000 cells/well/100µL of media containing various concentrations of calixarene. 
After 24 hours, the media was removed and the cells were washed three times with 
PBS. Ice cold ethanol (70 %) was added as a positive control and cells were incubated 
on ice for 15 min. After removal of the ethanol, propidium iodide solution (P484-10 
mL, 1 mg/L, Aldrich, 5 µL) was added to each well and incubated at 37 ºC for 30 min. 
The wells were then washed three times with PBS and dried. The cell count was 
performed using the ELISPOT, using the ImmunoSPot UV program. The scanning 
mode used was Fluorocell Configuration, using a red filter. The QC analysis was 
performed using an inverted method, large diffused spot, with gating set between 
0.00001 nm2 0.0153 nm2. The percentage of PI positive cells is expressed as the ratio 
between the cell count of (corrected by percentage of the well area covered) the sample 
of the sample and ethanol permeabilised cells. 
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